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and Health Literacy among Transgender and Gender Nonbinary People 
Anthony T. Pho 
BACKGROUND: Human Papillomavirus (HPV) is the most common sexually-transmitted 
infection in the U.S. and is associated with a number of cancers. A vaccine that can prevent 90% 
of HPV-associated cancers has been available since 2006, yet millions of young adults remain 
unvaccinated. Low vaccination uptake has been observed in cisgender sexual minority 
communities and less is known about HPV vaccination among transgender and gender nonbinary 
(TGNB) people. The aims of this dissertation were: (a) to identify facilitators for and barriers to 
HPV vaccination among gender minority people; (b) to compare HPV vaccination rates, HPV 
risk and situational factors like barriers to care, access to care, preventive care, HPV knowledge 
and Internet use in a sample of TGNB people and cisgender sexual minority people; and (c) to 
explore the association of online health information and HPV vaccination receipt among TGNB 
people compared to cisgender sexual minority people and determine if eHealth Literacy or 
general health literacy moderate this relationship.  
METHODS: The dissertation comprised three studies. First, an integrative review of the 
literature included searches of three electronic databases to identify and appraise studies that 
explore patient-, provider- and system-level HPV vaccination barriers among gender minority 
people. Second, guided by the Integrative Model of eHealth Use, a cross-sectional secondary 
analysis of The Population Research in Identities and Disparities for Equality (PRIDE) 
Study Annual Questionnaire 2018-19, compared the rate of HPV vaccination among TGNB and 
cisgender sexual minority people and described situation factors (e.g., barriers to care, access to 
 
 
care, preventive care), Internet use, HPV knowledge, HPV risk, and HPV vaccination among 
these communities. Third, a novel cross-sectional online survey of TGNB and cisgender sexual 
minority participants recruited from The PRIDE Study, also guided by the Integrative Model of 
eHealth Use, explored the association between online health information seeking and receipt of 
HPV vaccine, and whether eHealth literacy and/or general health literacy moderate this 
relationship. Statistical methods for the cross-sectional studies included prevalence ratios (PR) 
using robust Poisson statistics and multivariable logistic regression with post hoc Bonferroni-
Holm correction. 
RESULTS: The integrative review identified six cross-sectional studies and one qualitative study 
that explored HPV vaccine barriers and facilitators among gender minority people. The majority 
of the studies included <10% gender minority participants. Key barriers to vaccination identified 
were misperceptions of risk at patient-level, bias towards vaccinating female assigned 
individuals at the provider-level and population effects of recommendations for girls-only at the 
policy-level. The cross-sectional secondary analysis of The PRIDE Study 2018-19 Annual 
Questionnaire and included N = 5,500 responses and found that: (a) the prevalence of ever 
receiving HPV vaccine was 1.2 times greater among TGNB participants than cisgender 
participants (PR 1.2; 95% CI, 1.1-1.3); (b) the prevalence of ever receiving HPV vaccine was 2.4 
times greater among transgender men who were assigned female at birth compared to 
transgender women who were assigned male at birth (PR 2.4; 95% CI, 2.0-2.8); and (c) no 
differences in vaccination initiation and vaccination completion based on gender identity, sex 
assigned at birth, sex organs born with, or current sex organs. The cross-sectional novel online 
survey of PRIDE participants yielded N = 3,258 responses (response rate 19.6%). After 
controlling for covariates including age, race/ethnicity and educational attainment, we found that 
 
 
TGNB as compared to cisgender participants had increased odds (aOR=1.5=; 95% CI, 1.1-2.2) 
of reporting receipt of HPV vaccine ever and decreased odds (aOR=0.7; 95% CI, 0.5-0.9) of ever 
receiving of HPV vaccine when they looked for info on vaccines in the past year. Conversely, 
TGNB participants had over twice the odds (aOR=2.4; 95% CI, 1.1-5.6) of ever receiving HPV 
vaccine if they visited a social networking site like Facebook or Instagram in the past year. There 
were no moderating effects observed from eHealth or general health literacy. 
CONCLUSIONS: TGNB communities are understudied in terms of HPV vaccination and the 
existing literature shows misperceptions about the need of HPV vaccination among TGNB 
communities at both the patient and provider level. TGNB participants were more likely to have 
ever received HPV vaccine compared to cisgender sexual minority participants in the cross-
sectional secondary analysis of The PRIDE Study 2018-19 Annual Questionnaire which may be 
attributed to high primary engagement in the cohort. Finally, online health information seeking 
about vaccines was associated with decreased receipt of HPV vaccine (ever) whereas social 
media use increased HPV vaccine receipt (ever) among TGNB participants compared to 
cisgender sexual minority participants. These conflicting findings suggest that the quality of 
online health information relating HPV vaccines, how, when and why TGNB people search for 
health information online may affect health behaviors like HPV vaccination. More research is 
warranted to explore how online health information seeking may influence personal health 
decision-making among TGNB communities. 
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Chapter 1: Introduction 
Human papillomavirus (HPV) is the most common sexually-transmitted infection (STI) in adults 
in the United States with a prevalence of 79 million existing infections and incidence rate of 14 
million new infections per year (Dunne et al., 2014). High-risk strains of HPV (type 16 & 18) are 
associated with 79% of anal cancers, 66% of cervical cancers, 62% of oropharyngeal cancers, 
and 55% vaginal cancers (Centers for Disease Control and Prevention, 2013; Dunne et al., 2014). 
A vaccine to prevent HPV infection was introduced in 2006 and was initially recommended only 
for girls, with a 2-dose series from age 9 through 15 years, and a 3-dose catch-up series from age 
16 through 26 years. The recommendation was expanded to boys in 2009 and men who have sex 
with men (MSM) in 2011 (Markowitz et al., 2014; Petrosky et al., 2015). The national goal 
proposed in Healthy People 2020 targeted 80% vaccine completion for HPV (i.e., received the 
full vaccination series) (Markowitz et al., 2014). However, the Centers for Disease Control and 
Prevention (CDC) now estimates that only fifty-one percent of eligible adolescents have 
achieved vaccine completion and approximately 23 million young adults remain unvaccinated 
for HPV in the general population (Walker et al., 2017; Williams et al., 2017). In June 2019, the 
CDC Advisory Committee on Immunization Practices (ACIP) expanded the recommended age 
range from 9 through 26 years to 9 through 45 years for both women and men (Meites, 2019). 
Low HPV vaccine completion (13 to 32%) has been observed in adult sexual minority 
populations defined by their sexual orientation i.e., gay men, lesbian women, bisexual men and 
women (Agenor, Peitzmeier, et al., 2016; McRee et al., 2014; Reiter et al., 2015; Williams et al., 
2017). Studies have identified lack of knowledge or trust in vaccines, non-disclosure of sexual 
identity to providers, and fear of discrimination/stigma as barriers to HPV vaccination in sexual 
minority people (Barefoot et al., 2017; Cummings et al., 2015; Gerend, Madkins, Phillips, 
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Mustanski, et al., 2016; McRee et al., 2014; Youatt, 2017). Less is known about HPV 
vaccination among gender minorities known as transgender and gender nonbinary (TGNB) 
people, who are estimated to number at least 1.4 million in the U.S (Flores, 2016). Unlike 
cisgender sexual minority people whose gender identity matches their assigned sex at birth, 
TGNB people have gender identities/expressions that may not conform to their assigned sex at 
birth and may self-identify as transmen / transwomen, transgender men / transgender women or 
men / women (American Psychological Association, 2015; Institute of Medicine, 2011). Some 
TGNB people self-identify as nonbinary or genderqueer, terms used to describe people whose 
gender is not exclusively male or female, including those who identify with a gender other than 
male or female, as more than one gender, or as no gender (James, 2016). For the purposes of this 
dissertation, we use the terms transgender and gender nonbinary (TGNB) to encompass these 
communities, however we acknowledge that TGNB may not capture all that ways in which 
gender minority people express their identities. As gender identity and gender expression 
continue to evolve, we are committed to acknowledging and describing the gender-expansive 
diversity of gender minority people. Sexual and Gender Minorities (SGM) were designated a 
Health Disparities Population (HDP) for research purposes by the National Institutes of Health 
(NIH) in recognition of the health disparities and unique health challenges that face these 
communities (Pérez-Stable, 2016). 
Problem Statement 
The true proportion of adult TGNB and cisgender sexual minority people who have not 
received any doses of HPV vaccine is likely higher than the general population given studies to-
date (Agenor, McCauley, et al., 2016; Agenor et al., 2015; Agenor, Peitzmeier, et al., 2016; 
Charlton et al., 2017; McRee et al., 2014; Reiter et al., 2015). TGNB people report a higher 
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prevalence of poor health and experience stigma and discrimination with healthcare providers 
based on their gender identity, resulting in poor health outcomes from delaying or deferring 
necessary care (Bockting et al., 2013; Bradford et al., 2013; Jaffee et al., 2016; Macapagal et al., 
2016; Meyer et al., 2017; Safer et al., 2016; Winter et al., 2016). For example, TGNB people 
with a cervix and are sexually active are at risk of HPV infection, yet they have reduced rates of 
cervical cancer screening and increased time between recommended screening intervals 
compared to cisgender women (Peitzmeier, Khullar, et al., 2014; Peitzmeier, Reisner, et al., 
2014).  
There have been few studies that focus on HPV vaccination among TGNB people. A 
small study of rural-residing TGNB people noted a variation in HPV vaccination initiation (e.g., 
received at least one HPV shot); the greatest proportion 62.1% (n = 18) who initiated were 
transgender nonbinary people assigned female at birth, followed by transmen 36.6% (n = 15), 
nonbinary people assigned male at birth 20% (n = 1), and the smallest proportion initiating 
vaccination were transwomen 5.3% (n = 1) (Bednarczyk et al., 2017). Although this research 
also noted a significant association between healthcare provider recommendation and receipt of a 
HPV vaccine shot, the study’s small sample size limits its generalizability (Bednarczyk et al., 
2017). Studies among cisgender sexual minority people have similarly shown a positive 
association between provider recommendation and HPV vaccination (Gerend, Madkins, Phillips, 
Mustanski, et al., 2016; Gorbach et al., 2017; McRee et al., 2014). However, new research 
suggests that independent of healthcare providers, individuals who encounter cultural barriers to 
accessing care are more likely to seek health information online (Perez et al., 2016).  
Studies using data from the Health Information National Trends Survey (HINTS) found 
that sexual minority people are more likely to seek health information online, more likely to 
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watch health videos online, and less likely to first seek health information from a physician 
compared to heterosexual people (Jabson et al., 2017; Langston et al., 2019; Lee et al., 2017). 
TGNB people have particularly unique health information needs relating to their gender identity 
such as gender-affirming hormone management (Horvath et al., 2012; Perez et al., 2016). 
Although TGNB people have been shown to utilize the Internet for community building and 
information sharing, there is a paucity of research that explores online health information seeking 
among TGNB people and how this may be associated with personal health decision-making such 
as whether to receive preventative care like HPV vaccination (Shapiro, 2004). 
Purpose of Dissertation 
The purpose of this dissertation is to examine HPV vaccination in U.S.-based adult 
TGNB people (age ≥18 years). As part of the dissertation, we conducted a series of studies using 
participants in an online U.S.-based longitudinal study of SGM people, The Population Research 
in Identities and Disparities for Equality (PRIDE) Study. The PRIDE Study is a large national 
cohort composed of over 18,800 SGM people since its launch in May 2017 (Lunn, Capriotti, et 
al., 2019; Lunn, Lubensky, et al., 2019; The PRIDE Study, 2019).  




The proposed dissertation seeks to generate new knowledge about HPV vaccination among 
TGNB people. To achieve this goal, we propose three study aims described in Table 1.1. 
Significance 
HPV represents considerable cost and disease burden. HPV is estimated to have a direct 
medical cost in-excess of $1.7 billion in the U.S. HPV is a STI that is thought to be acquired 
soon after initiating sexual activity. HPV infection can cause genital warts but could also develop 
into cancer depending on the site of infection (Satterwhite et al., 2013). The average number of 
HPV-related cancers diagnosed annually is estimated to be >33,000 (Saraiya et al., 2015; Viens 
et al., 2016). Research on the burden of HPV infection has disproportionately focused on 
cervical cancer in women (Bowyer et al., 2014; Crosbie et al., 2013). However, incidence is now 
increasing for HPV-related oropharyngeal and anal cancers. Recent studies have shown that the 
incidence of HPV-related oropharyngeal cancer in men has increased dramatically, now 
surpassing the rate of cervical cancer in women, and the incidence of anal cancer has doubled 
over that past two decades (D'Souza et al., 2017; Machalek et al., 2012; Sonawane et al., 2017; 
Stier et al., 2016). 
SGM people are at risk of HPV infection and HPV-related cancers. Although HPV is 
thought to be a highly prevalent in the general population, studies have shown increased risk of 
HPV infection among SGM people including increased rates of oropharyngeal, cervical, and anal 
HPV infection (D'Souza et al., 2017; Forner et al., 2018; Machalek et al., 2012; Singh et al., 
2019). A recent study found that the prevalence of anal HPV infection was 1.3 times greater for 
transgender women than cisgender men who have sex with men, or MSM (PR 1.3; CI 95%,  
1.1 – 1.4) (Singh et al., 2019). Higher rates of anal HPV infection have been observed among 
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HIV-positive MSM compared to HIV-positive heterosexual cisgender men (Patel et al., 2018). 
Anal cancer rates have been shown to be 80 times higher in HIV-positive MSM compared to 
HIV-negative MSM (Silverberg et al., 2012). High rates of HIV-infection have been observed 
among TGNB people which is thought to increase their risk of HPV-associated cancer (Poteat et 
al., 2016; Quinn et al., 2015). 
Cisgender sexual minority people and TGNB people may experience unique barriers to 
vaccination. Studies to date that explore HPV vaccination barriers have focused primarily on 
cisgender minority individuals. Yet, TGNB people often experience similar barriers to healthcare 
as cisgender sexual minority people (Cruz, 2014; Edmiston et al., 2016). All SGM people may 
experience increased fear of discrimination and stigma from healthcare providers, and these pose 
a barrier to obtaining HPV vaccination (Barefoot et al., 2017; Cummings et al., 2015; Meyer, 
2003). Similarly, individuals who fear discrimination may not disclose their sexual identity to 
healthcare providers, which has also been observed to be a significant barrier to preventive 
vaccination (Gerend, Madkins, Phillips, Mustanski, et al., 2016; Wheldon et al., 2017; Youatt et 
al., 2017). Lack of HPV and vaccine knowledge is a known barrier to vaccination, and studies 
have shown that TGNB people and cisgender MSM may be unaware that HPV vaccination is 
recommended for both men and women (Apaydin, Fontenot, Shtasel, et al., 2018; Wheldon et 
al., 2017). 
HPV vaccination is effective when the recommended 3-dose vaccine series is completed; 
however, studies have not always assessed number of doses. The first HPV vaccine protected 
against four strains of HPV when it was introduced in 2006 and was updated in 2014 to protect 
against nine strains (McNamara et al., 2016). The vaccine has been shown to be highly effective, 
with one analysis of a national probability sample demonstrating a 61% reduction in prevalence 
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in HPV infection in adult females age 20-24 years within eight years of vaccine introduction 
(Oliver et al., 2017). Another analysis projects a 90% reduction of HPV-associated cancers 
through vaccination (Saraiya et al., 2015). Studies have shown that adults who receive only one 
dose of the vaccine are not fully protected from HPV infection, whereas three-doses provides 
immunity and prevents HPV-related cancers (Kang et al., 2018). Studying vaccination initiation 
versus completion is important for understanding HPV risk, yet previous studies often neglect to 
report number of doses, representing a critical gap in knowledge (Fuller & Hinyard, 2017; 
Oliver, 2017). 
Cisgender sexual minority people have decreased rates of HPV vaccination initiation and 
completion compared to the general population, but less is known about TGNB people. 
Disparities in HPV vaccination rates have been investigated among cisgender sexual minority 
people. A study using a national sample of gay and bisexual men (age 18-26 years) found that 
only 13% (n = 428) of the sample received at least one-dose of the HPV vaccine (Reiter et al., 
2015). Another study using a national sample of lesbian and bisexual women (age 18-26 years) 
found that 45% (n = 543) of subjects received at least one dose of the HPV vaccine (McRee et 
al., 2014). Others have investigated disparities in vaccination rates among cisgender sexual 
minority people that provide a more nuanced view. For example, a study found that bisexual 
women were significantly more likely than heterosexual women to have initiated the HPV 
vaccination series but were significantly less likely to complete the series, lesbian women were 
no more likely to initiate vaccination but were less likely to complete the series than heterosexual 
individuals (Agenor et al., 2015). These findings suggest the possibility that vaccination 
initiation/completion rates could also differ within TGNB sub-groups, e.g., transgender men, 
        
16 
 
transgender women, and transgender nonbinary people depending on assigned sex at birth 
(Bednarczyk et al., 2017). 
Theoretical Model 
The Integrative Model of eHealth Use (IMeHU) by Bodie & Dutta guides this 
dissertation (Bodie & Dutta, 2008). This model proposes a framework (Figure 1.1) to understand 
the relationship between electronic health use and health behavior outcomes. It posits that 
orientation to online health information is associated with health behavior outcomes, and that this 
relationship is influenced by individual factors such as situation, health knowledge and beliefs, 
general health literacy, and electronic health literacy (Bodie & Dutta, 2008). This theoretical 
framework is particularly useful for this dissertation because it considers individual factors such 
as demographics as well as individual situational factors such as barriers to care, access to care, 
preventive care, and health knowledge/beliefs. The IMeHU has not previously been applied to 
study health information seeking among TGNB people. 
  




Figure 1. 1 Integrative Model of eHealth Use (Bodie & Dutta, 2008) 
[Shaded areas denote constructs that were operationalized in the adapted model] 
We adapted the model (Figure 1.2) such that the model construct known as health 
information orientation, or motivation to seek health information and online health behavior are 
combined and operationalized as general and online health information seeking, and these 
become the primary predictors of interest. Health literacy, computer literacy and health 
information efficacy in the original model are operationalized in the adapted model as general 
health literacy and electronic health literacy (eHealth) literacy, and these are hypothesized to 
moderate the effect of health information orientation on the health behavior outcome; HPV 
vaccination initiation and completion. In addition to the main predictors, general and online 
health information seeking, the adapted model also proposes additional individual factors as 
predictors. These encompass health knowledge/beliefs (e.g., heard of HPV vaccine), 
demographics (e.g., gender identity), Internet use (e.g., social media use), and additional 
situation factors that broadly include barriers to healthcare (e.g., delayed/not received care, 
avoiding care anticipating of provider discrimination/stigma, level of disclosure of of sexual 
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orientation and/or gender identity to provider), preventive care (e.g., receipt of other preventive 
vaccinations, and access to care (e.g., having a primary care provider). The original constructs in 
the Integrative Model of eHealth Use and how they are operationalized in our adapted model are 
summarized in Table 1.2. The operationalization of the adapted model, including specific 
variables and instruments is described in further detail in Chapter 4 and Chapter 5. 
 
Figure 1. 2 Adapted Integrative Model of eHealth Use (IMeHU)  
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Online health information seeking has not been explored among TGNB people. Yet, 
online health information seeking has the potential to be an important individual factor for the 
study of health behavior, especially in today’s increasingly connected world. The Pew Center 
estimates that 77% of people in the U.S. now own a mobile smartphone making mobile Internet 
access nearly ubiquitous (Pew Research Center, 2018). Internet use has been described among 
TGNB people but not the relationship between online health information seeking and health 
behavior such as vaccination (Evans et al., 2017; Patel et al., 2016; Sun et al., 2016; Wigfall & 
Friedman, 2016). Health information seeking is generally understood as the ways in which 
individuals obtain information about their health, health promotion, risks, and illness (Lambert & 
Loiselle, 2007). Studies in MSM have shown increased likelihood of HPV vaccination in 
individuals who searched online for sexual health information and increased perceived benefits 
of vaccination in those with higher levels of motivation to seek heath information (Stupiansky et 
al., 2017; Wheldon, Daley, et al., 2018). Given the unique healthcare needs of TGNB people, 
these communities may be more likely seek health information online in order to make up for 
knowledge deficits in their health care providers, or simply to avoid discrimination related to 
their gender identity that they may encounter in health care (Mayer et al., 2008; Wylie et al., 
2016). 
Electronic health literacy is another individual factor that has not been studied among 
TGNB people. Health literacy is understood as a person’s ability to understand and process 
health information to make health decisions (Institute of Medicine, 2004). The National 
Assessment of Health Literacy reported that over 75 million adults combined had basic and 
below basic health literacy (Cutilli & Bennett, 2009). Low health literacy is associated with a 
wide range of poor health outcomes such as increased HIV risk, incorrect medication usage, and 
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decreased preventive cancer screening such as cervical Pap smears (Berkman et al., 2011). 
Complicating matters further, healthcare information is increasingly digital, requiring electronic 
health literacy (eHealth literacy) that encompasses a new set of knowledge, skills, and 
understanding of technology in order to make healthcare decisions (Norman & Skinner, 2006). 
To date, there has been no study of eHealth literacy specific to TGNB people although eHealth 
literacy has been studied among cisgender sexual minority people using the eHealth Literacy 
Scale (Blackstock et al., 2016; Horvath & Bauermeister, 2017; Norman & Skinner, 2006). 
Moreover, we apply the Integrative Model of eHealth Use as a novel approach to study of 
eHealth literacy as a moderator between health information orientation and a health behavior 
(HPV vaccination) among TGNB people. 
Summary 
A significant knowledge gap exists regarding HPV vaccination among TGNB people. 
Previous research of HPV vaccination has demonstrated decreased HPV vaccination among 
cisgender sexual minority people but with inconsistencies in the rigor of their approach, 
particularly the omission of number of vaccine doses which is critical for characterizing HPV 
risk (Agenor et al., 2015; Fuller & Hinyard, 2017; McRee et al., 2014; Oliver, 2017; Reiter et al., 
2015). Moreover, there has been limited research that explores vaccination among TGNB people 
(Bednarczyk et al., 2017). This dissertation proposes to address some of the deficiencies of the 
prior research and generate new knowledge about HPV vaccination among TGNB people with 
the goal of informing future interventions to improve HPV vaccine uptake among these 
communities. 
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Table 1. 1 Specific aims of dissertation 
Aim Description Hypotheses Method Chapter 
1 Conduct an integrative review of the literature to identify 







 a. Identify barriers and 
facilitators that influence 
HPV vaccination among 
adult gender minority 
people 
 
   
2 Describe HPV vaccination rates, HPV risk and situational 
factors (barriers to care, access to care, preventive care) in a 








 a. Compare HPV vaccination 
initiation / completion rates 
among adult TGNB and 
cisgender sexual minority 
people 
a. TGNB people have 
lower rates of HPV 
vaccination initiation and 
completion compared to 




 b. Compare prevalence of 
HPV risk activities in adult 
TGNB and cisgender sexual 
minority peoples 
b. TGNB people have 
similar rates of HPV risk 
activities as cisgender 
sexual minority people 
 
  
 c. Compare HPV knowledge, 
situation factors (barriers to 
care, access to care, 
preventive care) and Internet 
use among adult TGNB and 
cisgender sexual minority 
people 
 
c. TGNB people report 
similar knowledge of 
HPV, increased barriers 
to care, reduced access to 
care, reduced preventive 
care and similar Internet 
use compared to 
cisgender sexual minority 
people 
  
     
3 Explore factors associated with HPV vaccination 
initiation/completion among TGNB people, particularly 
online health information seeking and eHealth literacy, by an 
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Aim Description Hypotheses Method Chapter 
 a. Explore the association of 
online health information 
seeking, health knowledge/ 
beliefs, situation factors 
(barriers to care, access to 
care, preventive care), and 
Internet use with HPV 
vaccination 
 




situation, and Internet use 




 b. Determine if general and 
electronic health literacy 
moderate the association 
between online health 
information seeking and HPV 
vaccination 
b. Online health 
information seeking 
behavior is associated 
with vaccination and 
electronic health literacy 
and general health 
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Table 1. 2 IMeHU adapted constructs 





Online Health Behavior 










Predictor PRIDE Study items 
 
Situation Situation Predictor PRIDE Study items 
 
Demographics Demographics Predictor PRIDE Study items 
 
Internet Use 
Social Media Use 







Health Information Efficacy 
 
Moderator Chew, et al. adapted 
discrete items 
eHealth Literacy Health Literacy 
Health Information Efficacy 
Computer Literacy 
 





Health Behaviors Outcome HPV vaccination 
(ever) and number of 
doses 
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Chapter 2: Human papillomavirus vaccination among gender 
minority people: an integrative review of the literature 
The study in Chapter Two addresses the first aim of the dissertation in an integrative 
review to explore barriers to and facilitators for human papillomavirus (HPV) vaccination among 
transgender and gender nonbinary (TGNB) people. 
Introduction 
Human papillomavirus (HPV) is the most common sexually-transmitted infection (STI) 
in adults in the United States with a prevalence of 79 million existing infections and incidence 
rate of 14 million new infections per year (Dunne et al., 2014). High-risk strains of HPV (type 16 
& 18) are associated with the majority of oropharyngeal, vagino-cervical, and ano-rectal cancers 
(Centers for Disease Control and Prevention, 2013; Dunne et al., 2014). A preventive vaccine 
was introduced in 2006, initially only recommended for girls, with a 2-dose series from age 9 
through 14 years, and a 3-dose catch-up series from age 15 through 26 years. The 
recommendation was expanded to boys in 2009 and men who have sex with men in 2011 
(Markowitz et al., 2014; Petrosky et al., 2015). Healthy People 2020 set a national target goal for 
80% vaccination completion in adolescents (Markowitz et al., 2014). However, current vaccine 
completion is approximately 54.2% among eligible adolescents in the general population and the 
Centers for Disease Control and Prevention (CDC) estimates that as of 2015, approximately 23 
million young adults remain unvaccinated (Elam-Evans et al., 2020; Williams et al., 2017). In 
June 2019, the CDC Advisory Committee on Immunization Practices expanded the 
recommended age range from 9 through 26 years to 9 through 45 years for both women and men 
(Meites, 2019). 
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Low rates of 3-dose vaccine completion (range 13-32%) have been observed in adult sexual 
minority people defined by their sexual orientation (e.g., gay men, lesbian women, bisexual men 
and women) (McRee et al., 2014; Reiter et al., 2015; Williams et al., 2017). Studies have 
identified lack of knowledge or trust in vaccines, non-disclosure of sexual identity to providers, 
and fear of discrimination/stigma as barriers to vaccination in sexual minorities (Barefoot et al., 
2017; Cummings et al., 2015; Gerend, Madkins, Phillips, Mustanski, et al., 2016; McRee et al., 
2014; Youatt, 2017). Less is known about HPV vaccination in adult gender minority people that 
include transgender and gender-expansive people who are estimated to number 1.4 million in the 
U.S. (Flores, 2016). In contrast to cisgender people, whose gender identity is consistent with 
their sex at birth, gender minority people have a gender identity or gender expression that differs 
from that commonly associated with their sex assigned at birth (Institute of Medicine, 2011). 
Gender minority people report a higher prevalence of poor health and experience stigma and 
discrimination with healthcare providers based on their gender identity, resulting in poor health 
outcomes from delaying or deferring necessary care like vaccination (Bradford et al., 2013; 
Jaffee et al., 2016; Macapagal et al., 2016; Meyer et al., 2017; Safer et al., 2016; Winter et al., 
2016). Moreover, gender minority people who have a cervix and are sexually active are at risk of 
HPV and yet have reduced rates of cervical cancer screening and increased time between 
recommended screening intervals compared to cisgender women (Peitzmeier, Khullar, et al., 
2014; Peitzmeier, Reisner, et al., 2014). Sexual and gender minority (SGM) people were 
designated a health disparities population for research by the National Institutes of Health in 
recognition of poor health outcomes in these communities (National Institutes of Health, 2019). 
The true proportion of adult sexual and gender minority people who have not received 
any doses of HPV vaccine is likely higher than the general population (Agenor, McCauley, et al., 
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2016; Agenor et al., 2015; Agenor, Peitzmeier, et al., 2016; Charlton et al., 2017; McRee et al., 
2014; Reiter et al., 2015). We used the integrative review framework proposed by Whittemore & 
Knafl (2005) to organize our review which includes the following components: problem 
identification, literature search strategy, data evaluation, data analysis, and synthesis of findings. 
Problem Identification 
This integrative review seeks to describe barriers to and facilitators for HPV vaccination 
in adult gender minority people. We use the social ecological model to guide this review. This 
model has been adopted in numerous settings and is helpful for framing an investigation about 
vaccination because it considers how an individual’s health behavior may be influenced by 
intrapersonal, interpersonal, institutional, community, and policy-level factors (McLeroy et al., 
1988). We adapt this multi-level view of health behavior to three ecological levels: patient-level 
(intrapersonal); provider-level (interpersonal); and systems-level (institutional/ community/ 
policy).  
Methods 
Data Sources and Literature Search Strategy 
The literature search strategy included a computer search, review of reference lists from 
retrieved articles, and hand-searching using Google Scholar to identify additional articles. The 
computer search included three databases: PubMed/MEDLINE, Cumulative Index of Nursing 
and Allied Health Literature (CINAHL), and EMBASE. Searches were performed November 
through December 2019. Citations were organized and sorted using EndNote® version X8.2 
software (Clarivate Analytics, Inc, Philadelphia, PA). Keywords were explored from the 
following categories: sexual and gender minority communities, HPV vaccination, and keywords 
pertaining to vaccination barriers and facilitators. 
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We included both sexual and gender minority keywords to decrease the possibility of 
omitting a study that included gender minority people. Literature searches pertaining to sexual 
and gender minority populations are challenging because several terms can be used to describe 
lesbian, gay, bisexual and transgender (LGBT) people. Lee, et al. (2016) investigated this issue 
in a systematic review and identified eight search terms for transgender individuals alone. The 
query including keywords and Boolean logic suggested by Lee et al. (2016) informed our search 
strategy. The final query was formatted for PubMed/MEDLINE using medical subject headings 
(MeSH) terms and was simplified to comply with the controlled vocabularies for each database. 
A full description of the keywords and query for each database is described in Appendix A. 
Eligibility Criteria 
We included studies that examined factors associated with HPV vaccination in adult 
gender minority communities, both quantitative and qualitative study designs, abstracts and full-
text articles. Studies were included if the sample population included exclusively gender 
minority people, or both sexual minority people and gender minority people. We excluded 
studies that reported only HPV vaccine prevalence without mention of barriers or facilitators. 
Non-English language studies and non-U.S. based studies were excluded as we wished to focus 
on the experience of gender minority people in the U.S. We excluded studies that focused 
exclusively on adolescent/pediatric populations age <18 years because of the difference in 
healthcare decision-making agency involving a parent/guardian compared to an independent 
adult. 
Data Screening & Extraction 
First, the initial database query results were entered into EndNote and de-duplicated 
using the Bramer de-dupe method (Bramer et al., 2016). Two reviewers (AP and SM) then used 
        
28 
 
Covidence software (Covidence Ltd., Melbourne, Australia) to identify any additional duplicates 
and proceed with the screening. Reviewers independently screened citations by title and abstract 
using the inclusion/exclusion criteria. The same criteria were re-applied to the full-text review. 
Disagreements were discussed and resolved at each phase of screening. 
Methodological Quality Appraisal of Studies 
There exists no gold standard for quality appraisal in an integrative review and the 
process of evaluating quality is complex (Whittemore & Knafl, 2005). The quantitative studies 
were evaluated with an 8-item quality checklist published by the Joanna Briggs Institute (JBI) 
(Johanna Briggs Institute, 2018). The two reviewers performed quality appraisal for the 
quantitative studies independently and then met to discuss and resolve any differences. The 
single qualitative focus group study was evaluated by a single-reviewer (AP) for qualitative rigor 
with narrative criterion proposed by Wu et al (2016). 
Data Extraction and Synthesis 
The primary author reviewed and extracted key results from each study. The data extraction 
process approach included 1) data reduction, 2) data display 4) data comparison, 4) conclusion 
drawing and verification (Whittemore & Knafl, 2005). We used the social ecological model to 
organize the study results into patient-, provider-, and policy-level findings and synthesize these 
into barriers to and facilitators for HPV vaccination. This data extraction step was performed by 
one author (AP). 
Data Analysis 
The data analysis included all studies that met the inclusion/exclusion criteria regardless 
of methodological rigor. This enabled the incorporation of as many perspectives as possible on 
barriers to and facilitators for vaccination. The data for barriers to and facilitators for preventive 
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vaccination among SGM people were analyzed a priori according to the social ecological model 
categories: patient-level (intrapersonal), provider-level (interpersonal), and system-level 
(institutional/community/policy). Data analysis included the following steps suggested by 
Whittemore & Knafl (2005): first data were reduced according to sub-categories and then 
extracted into a matrix to organize them into a manageable framework; the extracted data was 
converted into data display in the form of tables; the display data was compared to identify 
meaningful patterns; findings synthesized into summary conclusions. 
Results 
Database Search Results 
Searches of the three databases returned 514 citations and hand-searching for citations 
using reference lists and yielded four citations. After removing duplicates (n = 191), the number 
of studies was reduced to 327. Articles were then screened by title and abstract and after the 
inclusion/exclusion criteria was applied, 278 articles were excluded from the following reasons: 
non-U.S. study (n = 134), described HPV disease/treatment only (n = 76), clinical or systematic 
review article (n = 26), described vaccine cost-effectiveness only (n = 22), described other 
testing and/or vaccine other than HPV (n = 13), no SGM people included in the sample (n = 6), 
and conference abstract with full-text unavailable for review (n = 1). The remaining 49 studies 
were screened by full-text review involving line-by-line reading of each study. After 
inclusion/exclusion criteria were applied again, 41 studies were excluded for the following 
reasons: no gender minorities included in the study sample (n = 39), study described vaccine 
prevalence rates only (n = 3). We retained seven studies for the integrative review. The Preferred 
Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines flow diagram 
that describes the article search and selection process is documented (Figure 1). 
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Of the retained studies, six were cross-sectional design (Apaydin, Fontenot, Borba, et al., 
2018; Bednarczyk et al., 2017; Fontenot et al., 2016; Gorbach et al., 2017; Halkitis et al., 2019; 
Singh et al., 2019), and one a qualitative focus group design (Apaydin, Fontenot, Shtasel, et al., 
2018). Two of the cross-sectional studies employed electronic health record (EHR) data 
(Apaydin, Fontenot, Borba, et al., 2018; Fontenot et al., 2016), three studies employed in-person 
computer assisted interview (CASI) (Gorbach et al., 2017; Halkitis et al., 2019; Singh et al., 
2019), and one study employed an Internet-based online survey (Bednarczyk et al., 2017). 
Inclusion of Sexual Minority People 
None of the studies included gender minorities exclusively and five of the seven studies 
had samples with < 10% gender minority people (Apaydin, Fontenot, Shtasel, et al., 2018; 
Fontenot et al., 2016; Gorbach et al., 2017; Halkitis et al., 2019; Singh et al., 2019). The two 
studies with the highest proportion of gender minorities, Apaydin et al. (2018) and Bednarzcyk et 
al. (2017) were the most gender-diverse, including participants that identified as gender non-
binary or genderqueer; gender identifications used by gender minority people whose gender 
expression is not exclusively masculine or feminine (Institute of Medicine, 2011). The cross-
sectional study by Apaydin et al. (2018) had the highest gender minority total (n = 77, 26.9%), 
transmasculine / transman (n = 41, 14.9%), transfeminine/transwoman (n = 33, 12%), and of 
these some also identified as genderqueer (n = 17, 6.2%). Bednarcyzk et al. (2017) had gender 
minority total (n = 106, 16.1%), transwoman (n= 23, 3.5%), and transman (n = 46, 7.0%), and 
non-binary identified (n = 37, 5.7%). Four studies had both transgender men and women, 
including the qualitative and cross-sectional studies by Apaydin et al. (Apaydin, Fontenot, 
Borba, et al., 2018; Apaydin, Fontenot, Shtasel, et al., 2018), and the studies by Bednarczyk et al. 
(2017) and Fontenot et al. (2016). The studies by Gorbach et al. (2017) and Singh et al. (2019) 
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included only transgender women. The study by Halkitis et al. (2019) included transgender 
people (n = 33, 6.8%) but did not further specify their gender identity. With the exceptions of 
Bednarczyk et al. (2017), the qualitative study by Apaydin et al. (2018), and the study by Singh 
et al. (2019), the other studies did not distinguish between gender minorities and sexual 
minorities in their results. 
Quality Appraisal 
To add further rigor to the review, we performed a two-reviewer quality appraisal of the 
evidence using a standardized instrument (Johanna Briggs Institute, 2018). The quality of the 
cross-sectional studies was high with a mean score of 7.2 out of 8. All studies met at least six of 
the eight JBI quality criteria. The most common methodological deficit was lack of consideration 
for confounders. The quality appraisal for the cross-sectional studies is summarized on Table 2.2. 
One reviewer (AP-only) appraised the quality of the single qualitative focus group study by 
Apaydin et al. (2018) using a using narrative criterion for qualitative rigor proposed by Wu et al. 
(2016), including credibility, dependability, confirmability, transferability, trustworthiness and 
transparency. The study had no major quality concerns, but rigor would have been improved 
with additional description of the theoretical basis for the thematic content analysis. 
Trustworthiness and transparency would have been improved with more description of audit 
trails during and after the focus groups and whether-or-not member checks with participants 
were performed. 
Vaccination Barriers. 
Patient-level. The most frequently cited patient-level barrier to vaccination was lack of 
knowledge of HPV, HPV risk and the HPV vaccine. Apaydin et al. explored this in a focus group 
of SGM people (Apaydin, Fontenot, Shtasel, et al., 2018). Transgender women were unaware of 
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the risks associated HPV-infection in the context of transfeminine bodies and some had the 
misconception that HPV vaccine was not relevant depending upon sexual activity before or after 
gender affirmation surgery. Singh et al. (2019) also found that less than half (n = 23, 46.9%) of 
transgender women in their study were aware that there is a vaccine that can protect against 
certain types of HPV and only one in four (n = 12, 24.5%) transgender women were aware that 
HPV can cause throat and oral cancer. Gorbach et al. (2017) found that lack of knowledge 
extended to not knowing where to get the vaccine and concerns over safety of vaccines, but these 
patient-level barriers were not specific to transgender participants. Apaydin et al. (2018) noted a 
unique personal-level barrier expressed by a transgender woman who had to weigh their anxiety 
about being in public as a transgender person with the need for multiple visits for the shots. All 
SGM participants viewed long time intervals between doses, multiple doses, and inconvenience 
of work conflicting with appointment hours as additional barriers to vaccination. Fontenot et al. 
(2016) found that transgender males had 62% lower odds of HPV vaccination compared with 
cisgender females, however specific barriers related to trans men in the study were not identified. 
Additional patient-level barriers to vaccination included lower education attainment and presence 
of substance use disorders in a mixed SGM sample (Apaydin, Fontenot, Shtasel, et al., 2018). 
Provider-level. Bednarczyk et al. (2017), examined the association between provider 
recommendation and vaccination and found that providers recommended HPV vaccination less 
to individuals with male sex assigned at birth (n= 53, 17%), regardless of their gender identity 
and these individuals received at least one-dose of the vaccine (n= 40, 13.7%), less frequently 
than individuals with female sex assigned at birth who were recommended to get the HPV 
vaccine more frequently (n= 146, 47.2%), and subsequently initiated at least one-dose more 
frequently (n= 130, 43.9%). Gorbach et al. (2017), also noted over one-fourth (n= 217, 26.9%) 
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of their study participants cited lack of provider recommendation as a barrier to vaccination, 
however the sample was predominantly cisgender male with only (n= 39, 4.8%) identifying as 
transgender women. Apaydin et al. (2018) also found that SGM people cited negative 
interactions with primary care providers (PCPs) when discussing their care, especially sexual 
behavior, as a provider-level barrier to vaccination. 
System-level. Singh et al. (2019) identified a lag in HPV vaccination among cisgender 
women may be associated with the fact that their study was conducted within a few years of the 
CDC ACIP change in recommendation to include men, women and transgender persons. 
Apaydin et al. (2018) cited a system-level bias in historical trends in HPV vaccine marketing that 
targets cisgender straight women whereas transgender women expressed such marketing made 
them question whether they needed the vaccine or if it would be effective on them. Gorbach et 
al. (2017) noted the system-level barriers of cost of vaccine and whether insurance would cover 
the vaccine. Although Halkitis et al. (2019) explored system-level constructs such as residential 
neighborhood poverty and HIV prevalence, they did not find any association between these 
system-level factors as HPV vaccination in the cisgender sexual minority males and transgender 
individuals in their sample. 
Vaccination Facilitators. 
Patient-level. Fear of disease, specifically genital warts and HIV-coinfection and health 
concerns related to being HIV-positive, were a motivator for cisgender gay men to receive HPV 
vaccination in the qualitative study by Aapaydin et al. (2018) In their related study they also 
observed that participants had over two and half times the odds (OR=2.59; CI 95%, 1.2 - 5.59) of 
having received HPV vaccination if they had received Hepatitis A/B vaccination and had 1.2 
times the odds (OR=1.22; 95% CI, 1.03 - 1.43) of receiving HPV vaccination if they had 
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received STI screening, however transgender status was not significantly associated with 3-dose 
vaccine completion. 
Provider-level. The single most important provider-level facilitator for HPV vaccination 
was health care provider recommendation. Gorbach et al. (2017) found that in a predominantly 
cisgender male sample, individuals who received a provider recommendation for HPV 
vaccination had nearly twelve times increased odds (aOR=11.85; 95% 6.70-20.98) of 
vaccinating. Bednarczyk et al. (2017) also noted the profound effect of provider recommendation 
on vaccination in gender minority participants; nearly all of the transmen who received a 
recommendation (n= 17, 47.2%) also received at least one dose of HPV vaccine (n= 14, 41.2%), 
all of the transwomen (n= 1, 6.7%) also received at least one dose of HPV vaccine. Nearly all 
(n= 6, 42.9%) of the non-binary identified participants who received a recommendation also 
received at least one dose of HPV vaccine (n= 7, 50%). Apaydin et al. (2018) found that 
transgender men expressed that the gender-affirming care they received resulted in comfort 
levels and trust in their primary care provider which facilitated their receiving a full 3-dose adult 
vaccine series.  
System-level. The most prominent system-level facilitator of vaccination was access to 
SGM-affirming care and engagement with primary care. Apaydin et al. (2018) found that the 
percentage of completed primary care appointments among SGM participants was associated 
with increased odds (OR=1.03, 95% CI 1.01 – 1.05, p = .018) of 3-dose HPV vaccination 
completion. This study also noted that for all SGM focus group participants regardless of HIV 
status, gender identity, and/or sexual orientation, having access to an SGM identity-affirming 
healthcare system was a major facilitator for vaccination. Singh et al. (2019) highlighted that the 
latest CDC ACIP recommended groups for HPV vaccination do include transgender people and 
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MSM which would in theory be a policy system-level facilitator. However, the authors point out 
the HPV vaccination recommendations have not led to significant vaccine uptake in MSM.  
Discussion 
Synthesis of Findings 
This integrative review summarizes existing evidence that explores barriers to and 
facilitators for HPV vaccination in gender minority people. We identified seven studies that 
included gender minority people. However, studies rarely treated gender minority participants 
separately from sexual minority participants when reporting results. This limited our ability to 
distinguish barriers and facilitators that could be considered specific to gender minority people. 
Vaccination barriers and facilitators according to the levels of the social ecological model were 
also explored variably. The studies in our review focused primarily on patient-level and 
provider-level factors with less attention to system-level factors. The small number of studies 
that included gender minority people and relatively small proportions of gender minority 
participants recruited for each study suggests a gap in the literature regarding HPV vaccination 
among gender minority people. This dearth of knowledge is concerning as evidence suggests that 
gender minority people have increased risk for HPV infection and HPV-associated cancer than 
cisgender people (Gatos, 2018; Kobayashi et al., 2017; Peitzmeier, Khullar, et al., 2014; Singh et 
al., 2019). 
Many of the findings for vaccination barriers and facilitators in this review are not unique 
to gender minority people. For example, facilitators like vaccine knowledge and perceived threat 
of disease are all also known to be key facilitators for preventive vaccination in the general 
population (Nowak et al., 2015). However, some facilitators and barriers may be more relevant 
        
36 
 
and impactful in the context of the gender minority experience. We offer discussion of some of 
these results through this lens. 
The patient-level finding that lack of HPV knowledge is a profound barrier to 
vaccination, especially for gender minority people who are not aware of their risk for HPV 
disease and may additional misconceptions about HPV vaccination appropriateness related to 
gender affirmation surgery. These findings support the notion that gender minority people may 
complex health information needs related to their gender identity (Horvath et al., 2012; 
MacCarthy et al., 2015). Moreover, anxiety expressed by a transgender participant regarding the 
need to attend multiple visits for HPV shots may suggest a proxy for anxiety related to engaging 
with the health care system. This would be consistent with studies that show that gender minority 
people are more likely to delay care or not receive care due to fear of discrimination and stigma 
(Bradford et al., 2013; Jaffee et al., 2016) 
The provider-level finding that provider recommendation is a key facilitator of 
vaccination is consistent with studies that examined provider recommendation in preventive 
vaccination in sexual minority communities that is likely also applicable to gender minority 
communities. A study of MSM found that participants who had received a provider 
recommendation had over 42 times the odds (OR = 42.23; 95% CI, 14.90 - 19.68) of HPV 
vaccination initiation than those who did not receive a recommendation (Gerend, Madkins, 
Phillips, & Mustanski, 2016). The findings from our review reinforce the profound ability of 
providers to increase HPV vaccination. However, providers who are not culturally competent 
with respect to gender minority people and their bodies may not recommend HPV vaccination 
appropriately. Studies have shown that when health care providers lack competence in SGM 
care, this is a barrier to vaccination (Blackwell, 2016; Wheldon, Sutton, et al., 2018).  
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Of the system-level findings, vaccine cost/insurance coverage is consistent with previous 
research on cost as a barrier to care among SGM populations (Dahlhamer et al., 2016). Access to 
care is a well understood facilitator of healthcare and in the case of gender minority 
communities, access to care from transgender health competent providers is a potential facilitator 
for preventive care like HPV vaccination (Apaydin, Fontenot, Shtasel, et al., 2018). Research has 
shown that gender minority people and cisgender sexual minority people who are less ‘out’ to 
their medical providers and others in general are also less likely to engage in primary care 
services like preventive vaccination (Whitehead et al., 2016). 
From a policy perspective, national recommendations are another system-level barrier to 
vaccination for gender minority people. Prior to 2016, MSM were the only SGM group that was 
mentioned in adult vaccination recommendations, yet gender minority people shared risk factors 
with MSM especially those relating to sexual health (Castillo et al., 2015). Transgender people 
were added to the CDC ACIP updated recommendation in December, 2016 (Meites, 2016). Even 
after the addition of MSM to the vaccine guidelines for HPV, the rates of vaccination in this 
group continue to lag the general population and there is emerging evidence that gender minority 
people will also continue to lag the general population despite being added to the national 
recommendation (Oliver, 2017). Moreover, many national health surveys omit gender identity in 
their data collection and this limits the ability to describe vaccination trends and determine 
whether disparities exist for gender minority people. 
When considered in gestalt, the findings of this review begin to outline an integrated 
perspective of HPV vaccination in gender minority people that emphasizes a set of key 
facilitators including patient knowledge of HPV risk, compelling recommendations from health 
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care providers who are attuned to their needs and national vaccination recommendations that 
establish gender minority people as a priority at-risk population to offer vaccination. 
Limitations 
This review addresses a gap in the literature regarding barriers to and facilitators for HPV 
vaccination in gender minority people but is not without several limitations. First, although we 
conducted a thorough search of the literature from three major databases, it is possible that we 
missed studies that were indexed in other databases. We did not include grey literature in our 
search which may have further excluded relevant citations, especially non-quantitative studies. 
We restricted our inclusion criteria to U.S.-based studies only which may have excluded studies 
that had larger proportions of gender minority people or studies focused solely on this group. 
Because of the limited number of studies that included gender minority people in the sample, this 
necessitated considering study results that mixed SGM people together. Although SGM people 
may experience similar challenges relating to dear of discrimination and stigma in healthcare, 
there is growing evidence that gender minority people have unique healthcare needs and may 
engage in preventive care differently than cisgender sexual minority people (Edmiston et al., 
2016). 
Conclusion 
This study identifies the current evidence that describes barriers to and facilitators for 
HPV vaccination in gender minority people. Few studies were identified that included gender 
minority people and the low proportion of gender minority participants in each study sample 
points to a significant gap in knowledge about this population that warrants further research. Our 
review highlights some of the factors that contribute to disparities HPV vaccination among SGM 
people overall and that gender minority people may have additional patient-level, provider-level 
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and system-level factors that influence HPV vaccine uptake. Future avenues for research should 





Table 2. 1 Studies included in the literature review with summary features 
Author  
(Year) 
Study design Select sample 
characteristics 






















Age (M = 26.3,  






attainment lower than 
some college / post-
secondary school 
Patient: education 
attainment 4-college or 
higher, attended 
primary care visits, 
received vaccination 
for hepatitis A/B, 






















Age (M = 25,  
SD = 1)  







Provider: lack of 
awareness about HPV 
and relevance to 
SGM; lack of SGM 
care competency 
System: 3-dose 
vaccine schedule  
Patient: proactive 
health-seeking 
behaviors, fear of 
genital warts, fear of 






System: access to 
health care affirming 
















Study design Select sample 
characteristics 









N = 660 
 





Age (range 18 to 34) 
 
 




Provider: bias against 
vaccinating male sex 




Provider: bias towards 
vaccinating female sex 
assigned at birth 
7/8 
Fontenot 


















Age (M = 21-22,  









cervical Pap test, 
received STI test, 
engaged in oral sex 
6/8 





Study design Select sample 
characteristics 
Barriers Facilitators Quality 
Criteria 
Gorbach  









N = 1,033 
 
Los Angeles, 









Age (M = 23,  
SD = 2) 
  
Patient: not knowing 























System: private clinic 









N = 486 
 





Age (M = 23.7,  
SD = 0.7) 
 
 
System: no significant 
difference in HPV 
vaccination by 
neighborhood poverty 
or HIV prevalence, 
age, education, sexual 
orientation, gender 
identity, or income  
None identified 8/8 





Study design Select sample 
characteristics 
Barriers Facilitators Quality 
Criteria 
























Age (range 18 to 26) 
 
 
Patient: Lack of 
knowledge of HPV 
risk, HPV vaccine, 
unsure whether could 














Table 2. 2 Methodological appraisal of cross-sectional studies 
Cross-sectional study  













1. Criteria for inclusion in 
the sample clearly defined? 
 
Y Y Y Y Y Y 
2. Study subjects and the 
setting described in detail? 
Y Y Y Y Y Y 
 
3. Exposure measured in a 
valid and reliable way? 
Y Y Y Y Y Y 
 
4. Objective/standard criteria 
used for measurement? 
Y Y Y Y Y Y 
 
5. Confounding factors 
identified? 
N Y N Y Y Y 
 
6. Strategies to deal with 
confounding factors stated? 
N N N Y Y Y 
 
7. Outcomes measured in a 
valid and reliable way? 
Y Y Y Y Y Y 
 
8. Appropriate statistical 
analysis used? 
 
Y Y Y Y Y Y 
Score 6 7 6 8 8 8 
Y=yes, N=no 
 





Figure 2. 1 PRISMA Flow Diagram for Literature Search 
Records identified through 
database searching 



































Additional records identified through 
other sources 
(n = 4) 
Records after duplicates removed 
(n = 327) 
Title & abstract screened 
(n = 327) 
Records excluded 
(n = 278) 
 
Non-U.S. study: 134 
Disease/treatment: 76 
Review article: 26 
Cost effectiveness: 22 
Other test/vaccine: 13 
No SGM sample: 6 
Abstract / full text not avail: 1 
Full-text articles assessed 
for eligibility 
(n = 49) Full-text articles excluded 
(n = 42) 
 
No gender minorities: 39 
Vaccine prevalence only: 3 
Studies meeting inclusion 
criteria 
(n = 7) 
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Chapter 3: The PRIDE Study Dataset 
Dataset Selection 
The PRIDE Study (The PRIDE Study, 2019), is a large-scale, longitudinal, U.S.-based, national, 
cohort study of adult sexual and gender minority (SGM) people that includes lesbian, gay, 
bisexual, transgender, gender expansive, and queer (LGBTQ) identified people. The overarching 
goal of the study is to improve the health of LGBTQ people and better understand how does 
being LGBTQ influence physical, mental or social health over time. The PRIDE Study is 
participant- and community-centric, engaging SGM communities who are involved in health 
advocacy and research through its national network called PRIDEnet. As of June 2020, 
PRIDEnet includes a 32-member Community Partner Consortium composed of health clinics 
that serve SGM communities, community centers and professional/advocacy organizations for 
SGM people; an 11-member Participant Advisory Committee composed of members from the 
SGM community to provide study oversight and guidance, and eight PRIDEnet ambassadors 
who facilitate communication and representation of SGM communities nation-wide.  
The PRIDE Study recruits participants through PRIDEnet partners using multiple 
strategies including snowball, word-of-mouth, and Internet social media campaigns. The study 
has enrolled more than 18,800 people since launching in May 2017. As of April 2019, over one-
third (32.8%) of the cohort identified as a gender minority and nearly all (98.7%) identified as a 
sexual minority. In terms of sexual orientation, over one-third of the sample identified as queer 
(35.7%) or gay (34.4%) and just under one-third identified as bisexual (27.5%). The cohort was 
majority (91.7%) white race. The next largest racial / ethnic group represented in the cohort 
include includes individuals of Hispanic/Latino/Spanish ancestry (8.4%), followed by Asian 
(4.3%), African-American (4.1%), and American-Indian/Alaska Native individuals (3.5%). Most 
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of the cohort (91.3%) reported having some college of more educational attainment. Considering 
the disproportionate representation of white and college-educated participants, The PRIDE Study 
is not necessarily representative of the SGM people in the U.S. However, participants reside in 
all major census regions (Lunn, Lubensky, et al., 2019).  
 The PRIDE Study maintains an online Web portal for participants at pridestudy.org. The 
portal provides a site for online enrollment and hosting online survey questionnaires. The PRIDE 
Study collects data via both its online novel Web portal platform and Qualtrics. The PRIDE 
Study Annual Questionnaire (AQ) is an online survey and is meant to capture a comprehensive 
view of a participant’s physical, mental, and social health. The AQ is launched every June and 
typically takes 45-75 minutes to complete. The survey is organized into five blocks 
(Introduction, Mental Health, Physical Health, Social Health, and Miscellaneous). The AQ also 
collects information about past medical history, past surgical history, receipt of vaccines, and 
receipt of other preventative care such as cancer screening. The AQ captures information about 
social history, substance use, sexual behavior and satisfaction, and behavioral health. Finally, the 
AQ includes items relating to SGM identity, including experiences of stigma and discrimination, 
identity formation, acceptance from self and others like health care providers about SGM status, 
social supports, family formation and structure and others. (Lunn, Capriotti, et al., 2019; Lunn, 
Lubensky, et al., 2019; The PRIDE Study, 2019). In addition to the yearly follow-up AQ, The 
PRIDE Study hosts additional questionnaires throughout the year for topics that are not covered 
in the AQ. For example, in March 2020, the study launched a survey related to the effects of 
Coronavirus Disease 2019, or COVID-19 on the health and well-being of SGM people. 
We established an ancillary study agreement with The PRIDE Study (The PRIDE Study, 
2019) to obtain data for this dissertation using both existing survey items and adding new survey 
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items. Approval for our ancillary study was obtained by two rigorous study applications and 
research proposal reviews by The PRIDE Study Research Advisory Committee and Participant 
Advisory Committee. We performed a detailed review of the codebook of the dataset to 
determine available items and potential gaps. Through a collaborative process it was determined 
that responses from The PRIDE Study Annual Questionnaire 2018-19 would be used for Study 
Aim Two because this version of the survey included key outcome variables: receipt of HPV-
vaccine (ever) and number of HPV-doses received. 
Use of The PRIDE Study cohort data set overcomes limitations of previous studies to 
explore factors associated with HPV vaccination among TGNB people. Previous studies using 
large samples of TGNB people have emphasized describing TGNB population demographics, 
and those that have examined preventive behaviors have not described HPV vaccination 
(Crissman et al., 2017; Herman et al., 2017; Meyer et al., 2017). TGNB people have been 
included in studies that focus on sexual health but not as the primary population of interest, 
frequently representing <10% of study sample (Cao et al., 2017; Choi et al., 2017). This has 
limited the generalizability of previous studies. The PRIDE Study cohort is a national 
convenience sample of SGM that includes diverse identity information, including less commonly 
described sexual orientations such as queer (i.e. other than bisexual, gay, heterosexual, lesbian) 
and less commonly described gender identities such as genderqueer (i.e. other than man, 
transgender man, transgender woman, woman) which enables more accurate categorization of 
individuals and more meaningful comparisons for this dissertation. 
The PRIDE Study collects patient-reported data including individual health behavior 
related to sexual identity such as non-disclosure of sexual identity to healthcare providers. 
Consequently, the use of this rich dataset enables the investigation of potential factors related to 
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vaccination that are specific to TGNB people such as whether individuals delayed or did not 
receive care due to concern that they would be discriminated against because of their gender 
identity. 
Identification of Additional Survey Items.  
We operationalized an adapted version of the Integrative Model for eHealth Use as part 
of our comprehensive review of The PRIDE Study codebook and identified gaps in the following 
three areas: 1) health information-seeking behavior, 2) general health literacy, and 3) eHealth 
literacy. These constructs are explored in Study Aim Three. We were informed by our sponsor’s 
previous research regarding health information-seeking and general health literacy that adapted 
items from the national Health Information National Trends Survey also knowns as HINTS 
(National Cancer Institute, 2018), and used general health literacy items proposed by Chew et al. 
(2004). Health information seeking items were informed by a previous study of online health 
information-seeking behavior as part of the Washington Heights Inwood Informatics 
Infrastructure for Comparative Effectiveness Research (WICER) Study (Lee et al., 2014). We 
propose to use a more extensive set of the HINTS items in our study that was informed by 
previous studies of health information seeking among sexual minority people (Jabson et al., 
2017; Langston et al., 2019; Lee et al., 2017). Online health information seeking can be assessed 
by various means, but the straight-forward approach used by HINTS is simply to ask if an 
individual goes online to seek information about a specific health issue such as HPV vaccination 
(Anker et al., 2011). 
To determine how to measure eHealth literacy, we also undertook a detailed item review 
of the only validated electronic health literacy measure available to-date, the eHealth Literacy 
Scale also known as eHEALS (Appendix B), which has been used in numerous settings and 
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populations including sexual minority people such as MSM (Horvath & Bauermeister, 2017; 
Norman & Skinner, 2006). To ensure completeness of data collection, the items used for primary 
data collection (Study Aim Three) included existing PRIDE Study survey items that reflect our 
adapted Integrated Model of eHealth Use. 
The remaining constructs in the new survey include health knowledge/beliefs, situation, 
Internet use, and demographics. Although The PRIDE Study annual survey includes items that 
represent these constructs, we did not rely on previous Annual Questionnaire survey responses 
for the new survey. To ensure completeness of prospectively collected data, the new survey 
included novel items (i.e., health information seeking, general and eHealth literacy), as well as 
items of interest that previously appear in The PRIDE Study AQ (e.g., health knowledge/beliefs, 
situation, Internet use, and demographics). The variables proposed for the new primary data 
collection survey (Study Aim Three) are described in Chapter 5. 
Comparison Groups 
 The PRIDE Study collects gender identity information in the two-step manner 
recommended by Office of the National Coordinator for Health Information Technology, 
including sex assigned at birth and gender identity (Cahill et al., 2016; Deutsch et al., 2013). The 
dataset also includes information on lived gender. Having responses to these three gender 
identity items was critical to the formation of our comparison groups. The primary comparison 
groups for Study Aim Two and Study Aim Three are described in Table 3.1. We include the 
Boolean logic and variables used for each group. 
Our prospective survey is assembled from valid and reliable instruments (Appendix 
B,C,D,E). The health information seeking items are drawn from HINTS 5 Cycle 3 (National 
Cancer Institute, 2018) and the electronic health literacy from the latest version of the eHEALS 
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scale (Norman & Skinner, 2006) that has been validated for use in multiple languages and 
settings (Aponte & Nokes, 2017; Chung & Nahm, 2015). The three discrete subjective general 
health literacy items have also been validated as an alternative to longer format health literacy 
instruments (Chew et al., 2004). Finally, we leverage the existing PRIDE Study AQ items to 
assess demographics, barriers to care, access to care and preventive care that have undergone 
rigorous review and revision by The PRIDE Study/PRIDEnet Participant Advisory Committee 
and Research Advisory Committee year over year since the launch of the study in 2017. Our 
secondary analysis leverages existing survey items in the AQ 2018-19 to provide the necessary 
data to achieve our study aims. 
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Table 3. 1 Comparison groups 
Comparison Group Reference 
A1. TGNB all  




Administrative identification / 
stratified by gender identity  
(A2 ALL and A3 ALL) 
 
CISGENDER (ALL) 
Administrative identification / 
stratified by gender identity  
(A2 ALL and A3 ALL) 
 





SAAB (Female2) AND GENDERID 
(Genderqueer1 OR Transgender man3 




SAAB (Male1) AND GENDERID 
(Genderqueer1 OR Transgender 
woman4 OR Woman5 OR Another 
gender identity6) 
 
A3. Cisgender female 
compared to:  
Cisgender male 
Cisgender Female 




SAAB (Male1) AND GENDERID 
(Man2) 
 
B1. TGNB organs born female 
compared to:  
Cisgender female 
 
GENDERID (Genderqueer1 OR 
Transgender man3 OR Transgender 
woman4 OR Man2 OR Another 
gender identity6) AND 
ORGANS_BORN (cervix1 OR 
ovaries2 OR uterus OR vagina7) 
 
GENDERID (Woman5) AND 
ORGANS_BORN (cervix1 OR 
ovaries2 OR uterus6 OR vagina7) 
B2. TGNB organs born male 
compared to: 
Cisgender male 
GENDERID (Genderqueer1 OR 
Transgender man3 OR Transgender 
woman4 OR Woman5 OR Another 
gender identity6) AND 
ORGANS_BORN (penis3 OR 
prostate4 OR testicles5) 
 
GENDERID (Man2) AND 
ORGANS_BORN (penis3 OR 
prostate4 OR testicles5) 
 
C1. Organs born male + organs 
now female compared to: 
Organs born male + organs now 
male 
ORGANS_BORN  
(penis3 OR prostate4 OR testicles5) 




(cervix1 OR ovaries2 OR uterus6 OR 
vagina7) AND ORGANS_NOW 
(cervix2 OR ovaries3 OR uterus7, 
vagina8) 
   
C2. Organs born female + 
organs now male compared to: 
Organs born male + organs now 
male 
ORGANS_BORN 
(cervix1 OR ovaries2 OR uterus6 OR 
vagina7) AND ORGANS_NOW 
(penis4 OR testicles6) 
 
ORGANS_BORN  
(penis3 OR prostate4 OR testicles5) 
AND ORGANS_NOW  
(penis4 OR prostate5 OR testicles6) 
 
   
D1. TGNB + Organs Now 
Female + AFAB compared to: 
Cisgender + Organs now 
female +AFAB 
GENDERID (Genderqueer1 OR 
Transgender Man3 OR Transgender 
Woman4 OR Another gender 
identity6) AND ORGANS_NOW  
(cervix2 OR ovaries3 OR uterus7 OR 
vagina8) AND SAAB (Female2) 
 
GENDERID (Woman5) AND 
ORGANSNOW (cervix2 OR ovaries3 
OR uterus7 OR vagina8) AND SAAB 
(Female2) 
   
   
   
        
53 
 
Comparison Group Reference 
   
D2. TGNB + Organs Now + 
Assigned Male at Birth 
(AMAB) compared to: 
 
 
GENDERID (Genderqueer1 OR 
Transgender Man3 OR Transgender 
Woman4 OR Another gender 
identity6) AND ORGANS_NOW 
(vagina8) AND SAAB (Male1) 
 
GENDERID (Man2) AND 
ORGANS_NOW (penis4 OR 
prostate5 OR testicles6) AND SAAB 
(Male1) 
E1. Binary Identity 
Transmasculine ALL compared 
to: 
Transfeminine ALL 
GENDERID (Genderqueer1 OR 
Transgender Man3 OR Another 





GENDERID (Man3) AND SAAB 
(Female2) AND LIVEGEN (Man1) 
 
GENDERID (Genderqueer1 OR 
Transgender Man3 OR Another 





GENDERID (Woman5) AND SAAB 
(Male1) AND LIVEGEN (Woman2) 
 
F1. Nonbinary Identity 
Nonbinary + AFAB compared 
to: 
Nonbinary + AMAB 
GENDERID (Genderqueer1 OR 
Another Gender Identity6) OR 
LIVEGEN (Sometimes man / 
sometimes woman3 OR Third gender 
other than man or woman4) AND 
SAAB (Female2) 
 
GENDERID (Genderqueer1 OR 
Another Gender Identity6) OR 
LIVEGEN (Sometimes man / 
sometimes woman3 OR Third gender 




F2. Transgender Nonbinary 
ALL compared to: 
Transgender Binary ALL 
(F1 ALL) (E1 ALL) 
   
AFAB (Assigned Female at Birth) 
AMAB (Assigned Male at Birth) 
SAAB (Sex Assigned at Birth) 
TGNB (Transgender and Gender Nonbinary) 
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Chapter 4: Human papillomavirus vaccination among transgender 
and gender nonbinary people: a cross-sectional secondary analysis 
of The PRIDE Study 2018-19 annual questionnaire 
The study in Chapter Four addresses the second aim of the dissertation to compare rates of HPV 
vaccination initiation and completion among TGNB and cisgender sexual minority people, 
compare HPV knowledge, situation factors (e.g., barriers to care, access to care, preventive care), 
Internet use, and HPV risk activities among these groups. The study is a cross-sectional 
secondary analysis of responses from participants in The PRIDE Study Annual Questionnaire 
2018-19. 
Background 
Human papillomavirus (HPV) is the most common sexually-transmitted infection (STI) 
in adults in the United States with a prevalence of 79 million existing infections and incidence 
rate of 14 million new infections per year (Dunne et al., 2014). High-risk strains of HPV are 
associated with the majority of recto-anal, vagino-cervical, and oropharyngeal cancers (Centers 
for Disease Control and Prevention, 2013; Dunne et al., 2014). A vaccine to prevent HPV-
infection was introduced in 2006. The Advisory Committee on Immunization Practices (ACIP) 
recommends two doses of vaccine starting at age 9-11 years and three adult “catch-up” doses for 
those who have not had received any vaccine doses by age 15-years. The national goal proposed 
in Healthy People 2020 was 80% vaccine completion for HPV (e.g., received the full vaccination 
series, or all recommended doses based on age group) (Markowitz et al., 2014). The Centers for 
Disease Control and Prevention (CDC) estimates that approximately fifty-four percent of eligible 
adolescents have achieved vaccine completion and approximately 23 million young adults 
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remain unvaccinated for HPV in the general population (Elam-Evans et al., 2020; Walker et al., 
2017; Williams et al., 2017). In June 2019, ACIP expanded the recommended age range from 9 
through 26 years to 9 through 45 years for both women and men (Meites, 2019). 
Low HPV vaccine completion (13 to 32%) has been observed in adult sexual minority 
populations defined by their sexual orientation i.e., gay men, lesbian women, bisexual men and 
women (Agenor, Peitzmeier, et al., 2016; McRee et al., 2014; Reiter et al., 2015; Williams et al., 
2017). Studies have identified lack of knowledge or trust in vaccines, non-disclosure of sexual 
identity to providers, and fear of discrimination/stigma as barriers to vaccination in sexual 
minority people (Barefoot et al., 2017; Cummings et al., 2015; Gerend, Madkins, Phillips, 
Mustanski, et al., 2016; McRee et al., 2014; Youatt, 2017). Less is known about HPV 
vaccination among gender minorities known as transgender and gender nonbinary (TGNB) 
people, who are estimated to number at least 1.4 million in the U.S. (Flores, 2016). Unlike 
cisgender sexual minority people whose gender identity matches their assigned sex at birth, 
TGNB people have gender identities/expressions that may not conform to their assigned sex at 
birth and may self-identify as transmen/women, transgender men/women or men/women 
(American Psychological Association, 2015; Institute of Medicine, 2011). Some TGNB people 
self-identify as nonbinary or genderqueer, terms used to describe people whose gender is not 
exclusively male or female, including those who identify with a gender other than male or 
female, as more than one gender, or as no gender (James, 2016). For the purposes of this study, 
we use the terms transgender and gender nonbinary (TGNB) to encompass these communities, 
however we acknowledge that TGNB may not capture all that ways in which gender minority 
people express their identities. Sexual and Gender Minorities (SGM) were designated a Health 
Disparities Population (HDP) for research purposes by the National Institutes of Health (NIH) in 
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recognition of the health disparities and unique health challenges that face these communities 
(Pérez-Stable, 2016). 
Problem Statement 
The true proportion of adult TGNB and cisgender sexual minority people who have not 
received any doses of HPV vaccine is likely higher than the general population given studies to-
date (Agenor, McCauley, et al., 2016; Agenor et al., 2015; Agenor, Peitzmeier, et al., 2016; 
Charlton et al., 2017; McRee et al., 2014; Reiter et al., 2015). TGNB people report a higher 
prevalence of poor health and experience stigma and discrimination with healthcare providers 
based on their gender identity, resulting in poor health outcomes from delaying or deferring 
necessary care (Bradford et al., 2013; Jaffee et al., 2016; Macapagal et al., 2016; Meyer et al., 
2017; Safer et al., 2016; Winter et al., 2016). For example, TGNB people with a cervix who are 
sexually active are at risk of HPV and yet have reduced rates of cervical cancer screening and 
increased time between recommended screening intervals compared to cisgender women 
(Peitzmeier, Khullar, et al., 2014; Peitzmeier, Reisner, et al., 2014). There have been few studies 
that focus on receipt of HPV vaccination among TGNB people. A small study of rural-residing 
TGNB people noted variation in HPV vaccination initiation (e.g., received at least one HPV 
shot); the greatest proportion who initiated were nonbinary people assigned female at birth (n = 
18, 62.1%), followed by transmen (n = 15, 36.6%), nonbinary people assigned male at birth (n = 
1, 20%), and the smallest proportion initiating vaccination transwomen (n = 1, 5.3%) 
(Bednarczyk et al., 2017). Although this research also noted a significant association between 
healthcare provider recommendation and receipt of a HPV vaccine shot, the study’s small sample 
limits its generalizability (Bednarczyk et al., 2017). Studies among cisgender sexual minority 
people have similarly shown a positive association between provider recommendation and HPV 
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vaccination (Gerend, Madkins, Phillips, Mustanski, et al., 2016; Gorbach et al., 2017; McRee et 
al., 2014). 
SGM people have demonstrated increased risk of HPV infection and HPV-related 
cancers. Although HPV is thought to be a highly prevalent in the general population, studies 
have shown increased risk of HPV infection among SGM people including increased rates of 
oropharyngeal, cervical, and anal HPV infection (D'Souza et al., 2017; Forner et al., 2018; 
Machalek et al., 2012; Singh et al., 2019). A recent study found that the prevalence (PR 1.3; CI 
95%, 1.1 – 1.4) of anal HPV infection was 1.3 times greater for transgender women than 
cisgender men who have sex with men, or MSM (Singh et al., 2019). Higher rates of HIV-
infection have been observed among TGNB people compared to the general population which is 
thought to increase their risk of HPV-associated cancer (Poteat et al., 2016; Quinn et al., 2015). 
Cisgender sexual minority people and TGNB people may experience unique barriers to 
vaccination. Studies to date that explore HPV vaccination barriers have focused mostly on 
cisgender minority individuals. Yet, TGNB people often experience similar barriers to healthcare 
as cisgender sexual minority people (Cruz, 2014; Edmiston et al., 2016). All SGM people may 
experience increased fear of discrimination and stigma from healthcare providers, and these pose 
a barrier to obtaining HPV vaccination (Barefoot et al., 2017; Cummings et al., 2015; Meyer, 
2003). Similarly, individuals who fear discrimination may not disclose their sexual identity to 
healthcare providers, which has also been observed to be a significant barrier to preventive 
vaccination (Gerend, Madkins, Phillips, Mustanski, et al., 2016; Wheldon et al., 2017; Youatt et 
al., 2017). Lack of HPV and vaccine knowledge is a known barrier to vaccination, and studies 
have shown that TGNB people and cisgender MSM may be unaware that HPV vaccination is 
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recommended for both men and women (Apaydin, Fontenot, Shtasel, et al., 2018; Wheldon et 
al., 2017). 
HPV vaccination is effective when the recommended 3-dose vaccine series is completed; 
however, studies have not always assessed number of doses. The vaccine has been shown to be 
highly effective, with one analysis of a national probability sample demonstrating a 61% 
reduction in prevalence in HPV infection in adult females age 20-24 years within eight years of 
vaccine introduction (Oliver et al., 2017). Another analysis projects a 90% reduction of HPV-
related cancers through vaccination (Saraiya et al., 2015). Although there is emerging evidence 
that even one-dose of HPV vaccine may be beneficial (Sonawane et al., 2019), previous studies 
have shown that adults who receive only one-dose of the vaccine are not completely protected 
from HPV infection, whereas three-doses provides immunity and more adequately prevents 
HPV-related cancers (Kang et al., 2018). Studying vaccination initiation versus completion is 
important for understanding HPV risk, yet previous studies often neglected report number of 
doses, representing a critical gap in knowledge (Fuller & Hinyard, 2017; Oliver, 2017). 
Methods 
The Integrative Model of eHealth Use or IMeHU (Bodie & Dutta, 2008) guided our 
study. The model posits that online health information seeking is associated with health behavior 
outcomes and that this relationship is influenced by situational factors like barriers to care, 
access to care, preventive care and Internet use (Figure 4.1). We explore the role of online health 
information seeking and the role of moderators like eHealth literacy and general literacy on the 
receipt of HPV vaccine in a separate study (Chapter 5). For the current study, we focus on 
describing individual situational factors (other than health information seeking) that may 
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influence the receipt of HPV vaccination. We compare HPV risk among TGNB people and 
cisgender sexual minority people. 
To achieve our study aims, we performed a secondary cross-sectional analysis of 
participants in The Population Research in Identities and Disparities for Equality (PRIDE) Study 
(pridestudy.org), a large-scale long-term U.S.-based national health study of SGM people (The 
PRIDE Study, 2019). The PRIDE Study launched in 2017 and recruits only adults age 18-years 
and older. The current cohort is estimated to be more than 18,800 participants. The PRIDE Study 
launches an Annual Questionnaire (AQ) to its participants in the months of May or June. For the 
purposes of our cross-sectional analysis, we used the follow-up period from May 2018 to May 
2019 as it included questions about receipt of HPV vaccine, number of doses, and HPV 
knowledge. Additional details of The PRIDE Study longitudinal cohort and dataset are described 
elsewhere (Lunn, Capriotti, et al., 2019; Lunn, Lubensky, et al., 2019). This study was approved 
by the Institutional Review Boards at Columbia Irving University Medical Center (IRB-
AAAS6719) and Stanford University Medical School. 




Figure 4. 1 Adapted Integrative Model of eHealth Use (IMeHU) 
[Shaded areas denote areas of focus in this study] 
All participants in The PRIDE Study cohort 2018-19 were deemed eligible for the online 
survey with no age restrictions and no restrictions to participant sexual or gender identity 
demographic information. The PRIDE Study collects participant survey data online using 
Qualtrics (Qualtrics, Provo, UT). Participants can skip any item and start and stop the survey as 
much as they like during survey periods by logging into their existing PRIDE Study Web portal 
accounts. 
We conducted review of the 2018-19 Annual Questionnaire codebook to determine 
variables to include in the analysis using the IMeHU a priori to categorize situational factors. 
The survey item categories and number of items in each category were distributed as follows: 
HPV and vaccine knowledge (3-items), barriers to care (12-items), access to care (6-items), 
preventive care (10-items), and demographic (16-items), Internet-use (2-items), HPV Risk (9-
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items). Survey responses from TGNB participants were compared with cisgender sexual 
minority participants as the reference group.  
Comparison Groups 
 We used the responses from multiple demographic questions (e.g., gender identity, lived 
gender day-to-day, assigned sex at birth, organs born with, organs now) to identify TGNB 
participants and distinguish them from cisgender participants. We used Boolean logic to account 
for both gender identity and biological sex. Table 4.1 summarizes the comparison groups and our 
inclusion logic. 
Statistical Analysis 
The dataset was cleaned, and all analysis performed in SAS 9.4 (SAS Institute Inc., Cary, 
NC). Descriptive statistics for demographics were calculated and means and standard deviations 
established. Chi-square and paired t-tests were employed to examine differences in categorical 
and continuous variables. The distribution of continuous variables and potential outlier values for 
age and age at sexual debut were identified using boxplots in SAS. To determine if 
multicollinearity was present, we used variance inflation factor (VIF) statistics. A VIF value less 
than five suggested no multicollinearity (Akinwande et al., 2015). We calculated point 
prevalence for receipt of HPV vaccine (ever), vaccine initiation (e.g., 1-dose) vaccine completion 
(e.g., 3-doses). We calculated prevalence ratios (PR) and confidence intervals (CI) using robust 
Poisson statistics (Petersen & Deddens, 2008). The prevalences of receipt of HPV vaccination 
ever, vaccine initiation and vaccine completion were stratified by gender identity, sex organs 
born with, sex organs now, and sex assigned at birth. Alpha was set at .001 for level of 
significance to control for galloping alpha due to the large number of comparisons between 
groups. 




We combined responses from the primary AQ 2018-19 survey that included 7,325 
responses and a one-time supplemental survey that captured Internet-use items during the same 
survey timeframe with 5,619 responses. The combined surveys had 7,535 responses and 5,733 of 
these completed the entire survey (e.g., viewed every page of the survey). We further excluded 
233 (4.1%) of the completed surveys that were missing gender identity, lived gender and/or sex 
assigned at birth information that were necessary for our comparison groups. The final dataset 
included 5,500 survey responses. 
Of the remaining 5,500 survey responses, a total of 1,691 (31%) were completed by 
TGNB participants, and 3,859 (69.5%) completed by cisgender sexual minority participants 
(Table 4.2). A greater proportion of TGNB participants were assigned female at birth (AFAB) 
(78.2%) compared to cisgender AFAB (58.6%) (p < .0001). Conversely, the proportion of 
TGNB participants who were assigned male at birth (AMAB) (21.8%) participants was about 
half of cisgender AMAB (41.4%) (p < .0001). Greater than one-third (39.8%) of TGNB 
participants said their lived gender day-to-day was sometimes man/woman or a third gender or 
something other than a man or woman. Over half (58.1%) of TGNB participants identified as 
queer sexual orientation compared to one-third (29.1%) of cisgender sexual minority participants 
(p < .0001). The majority of TGNB and participants were white race (80.8%) and had more than 
a high school education (90.0%), cisgender participants were similarly majority white (82.1%) 
and a greater proportion had more than a high school education (93.4%) (p < .0001). Although 
majority of both groups reported they worked one or more paid jobs, TGNB participants reported 
lower annual income than cisgender participants with more than three-quarters (80.9%) of 
TGNB participants with an income less than $50,000 per year compared to cisgender participants 
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(61.8%) (p < .0001). More cisgender participants rated their health as fair/poor (47.9%) 
compared to TGNB participants (34.7%) ( p< .0001). The median age of participants was 31 
(interquartile range [IQR], 25-41). Cisgender participants were slightly older than TGNB 
participants, mean age 36.3 SD 13.9 and mean age 31.3 SD 11.4, respectively (p < .0001). Of 
note, for all demographic variables we report participant responses as discrete categories, 
multiple responses options were not analyzed. 
Barriers to Care 
The proportion of TGNB participants who reported ever being denied or given lower 
quality medical care was two times (30.9%) that of cisgender participants (15.6%) (p < .0001). 
The reasons for being denied or given lower quality care differed between the groups. TGNB 
people reported race/ethnicity most frequently (16.7%) compared to cisgender participants 
(3.1%), but cisgender participants most frequently reported gender identity (12.2%) as the reason 
for being denied or given lower quality care compared to TGNB participants (3.2%) (p < .0001). 
One-third (31.9%) of TGNB participants reported they delayed necessary medical care in 
the past year compared to cisgender participants (16.8%) (p < .0001). Both groups similarly 
reported that their insurance company would not cover the care as the most frequently mentioned 
reason for delaying care, TGNB (14.5%) and cisgender (14.6%), but a greater proportion 
(12.4%) of cisgender participants reported that they delayed care because they could not afford it 
compared to TGNB participants (5.5%) (p = .0003). The proportion of TGNB participants who 
reported putting off seeing a health care provider because of concern that they would be 
disrespected or mistreated in the past year was three-times (34.5%) the proportion of cisgender 
participants (10.9%) (p < .0001). Over half (55.3%) of TGNB participants cited age as the reason 
they put off seeing a health care provider compared to (7.3%) cisgender participants whereas a 
        
64 
 
greater proportion (19.7%) of cisgender participants reported gender identity as the reason for 
putting off seeing a health care provider compared to (3.7%) TGNB participants (p < .0001). 
Lastly, the proportion of TGNB participants who reported they were unable to obtain necessary 
medical care, tests or treatments in the past year was two-times (21.4%) that of cisgender 
participants (9.8%) (p < .0001). Both groups reported the most frequent reason they were unable 
to obtain care was their insurance company would not cover their care, (33.4%) TGNB and 
(36.3%) cisgender (p = .0009). The groups were also similar in reporting not being able to afford 
the care as the second most reported reason for being unable to get medical care, tests, or 
treatment, (26.8%) TGNB and (27.3%) cisgender (p = .0009).  
Access to Care 
Nearly all participants in both groups reported having a primary care provider (PCP), 
having seen their PCP in the past year, and nearly all reported having insurance. Majority of both 
groups reported having private insurance but a greater proportion (14.3%) of TGNB participants 
had Medicaid or Medicare compared to (10.5%) cisgender (p < .0001). Over half (55.8%) of 
TGNB participants reported having gone to a provider/clinic for transgender care in the past year 
and over half (56.2%) reported having ever taken hormones for gender affirmation. 
Preventive Care 
Nearly half (47.9%) of cisgender participants reported their health was fair or poor 
compared to about one-third (34.7%) of TGNB participants (p < .0001). Both cisgender and 
TGNB participants reported receiving vaccines other than HPV. Hepatitis-B was the most 
frequently reported vaccine other than HPV and majority of both groups reported receipt of 
Hepatitis-B vaccine. 
  




A greater proportion (73.3%) of TGNB participants reported using dating apps than 
(65.9%) cisgender participants (p < .0001). The most popular dating apps for both groups were 
Adam4Adam, Tinder and OK Cupid. Both groups were similar in terms of the time spent on 
apps, with over half of each group reporting less than one hour spent using the app per week. 
One-third (32.2%) of cisgender participants reported one to six hours per week compared to one-
fourth (24.9%) of TGNB participants (p < .0001). 
HPV Risk 
The median age of sexual debut for all participants was 18 (interquartile range [IQR], 15-
25). The mean age of sexual debut did not differ between the groups; mean 17.3 SD 4.8 for 
TGNB participants and 17.8 SD 5.2 for cisgender participants (p = .2224). The median number 
of lifetime sexual partners for all participants was 6 (interquartile range [IQR], 2-15). Cisgender 
participants averaged two times the number of lifetime sexual partners mean = 16.1 SD 18.3 
compared to TGNB participants mean = 8.6 SD 12.1 (p < .0001). Both TGNB participants and 
cisgender sexual minority participants reported receptive sexual activities that would put them at 
risk of exposure to HPV. The most frequently reported activity in either group was receptive 
penis to vagina sex but there was no difference between the groups in the proportion reporting 
receptive penis to vagina sex (p = .0204). The proportion of cisgender participants who reported 
receptive mouth to penis sex was two times (40.1%) the proportion of TGNB participants 
(20.1%) (p < .0001). Similarly, the proportion of cisgender participants who reported receptive 
mouth to vagina sex was two times (32.6%) the proportion of TGNB participants (16.1%) and 
the proportion of cisgender participants who reported receptive mouth to anus sex was two times 
(35.0%) the proportion of TGNB participants (15.5%) (p < .0001). 
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HPV Vaccination Rates 
More TGNB participants reported ever receiving HPV vaccine (46.2%) compared to 
cisgender (38.8%) (p < .0001) (Table 4.3). A small proportion of TGNB participants (1.4%) and 
cisgender participants (0.5%) reported that the doctor refused to give them the HPV vaccine 
when they requested it (p < .0001). There were 2,213 participants who reported ever receiving 
HPV vaccine (39.9%). TGNB and cisgender participants did not differ in the proportion of each 
group that initiated HPV vaccine (e.g., received 1-dose) versus completed HPV vaccine (e.g., 
received 3-doses). Greater than 90% of both groups had heard of HPV (Table 4.4) 
Prevalence of Receipt of HPV Vaccine 
The prevalence (PR 1.2; 95% CI, 1.1-1.3) of receiving HPV vaccine ever was 1.2 times 
greater among TGNB participants than cisgender participants (Table 4.5). The prevalence (PR 
1.1; 95% CI, 1.1-1.2) of receiving HPV vaccine ever was also 1.1 times greater among TGNB 
participants who were born with female organs compared to cisgender females who were born 
with female organs. The prevalence (PR 2.4; 95% CI, 2.0-2.8) of ever receiving HPV vaccine 
was 2.4 times greater among transgender men who were assigned female at birth (AFAB) 
compared to transgender women who were assigned male at birth (AMAB). Similarly, the 
prevalence (PR 2.1; 95% CI, 1.9-2.3) of receiving HPV vaccine ever was 2.1 times greater 
among cisgender sexual minority females compared to cisgender sexual minority males. The 
prevalence (PR 1.1; 95% CI, 1.1-1.2) of ever receiving HPV vaccine was 1.1 times greater 
among TGNB participants with female organs now and assigned female at birth compared to 
cisgender participants with female organs now and assigned female at birth. 
Across all comparison groups we observed no difference in vaccine initiation (e.g, 
received 1-dose) and no difference in vaccine completion (e.g., received 3-doses). The only 
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remaining notable difference in vaccination receipt was observed among transgender nonbinary 
AFAB, for whom the prevalence (PR 2.0; 95% CI, 1.6-2.5) of receiving HPV vaccine ever was 
two times greater than transgender nonbinary AMAB. However, we observed no differences in 
HPV vaccine receipt comparing transgender nonbinary participants with transgender binary 
participants; and no differences in vaccine receipt when comparing transmasculine participants 
with transfeminine participants. 
Discussion 
Our study found that in a sample of 5,500 SGM people participating in a large national 
online cohort, 2,213 (41.1%) participants ever received any doses of the HPV vaccine and of the 
participants who received the HPV vaccine, 121 (5.5%) initiated (e.g., received 1-dose) and 
1,561 (70.5%) completed (e.g., received 3-doses). Our finding that transgender men assigned 
female (AFAB) at birth were more likely to have received HPV vaccine than transgender women 
assigned male at birth (AMAB) is consistent with gender disparities that date back to the 
introduction of the HPV vaccine in 2006 and this was mirrored in cisgender participants. In the 
general population, males continue to lag females in HPV vaccination rates and this lag is 
thought to be related to population effects from the original recommendation that limited 
vaccination to girls (Daley et al., 2017; Williams et al., 2017). Moreover, our observed difference 
in vaccination between transgender AFAB and AMAB is similar studies of HPV vaccination in 
sexual minority people such as gay men who have been shown to have vaccination initiation 
rates as low as 13% compared to 47% in studies of sexual minority women (Agenor, Peitzmeier, 
et al., 2016; Reiter et al., 2015). 
Although we did not find any differences in vaccine initiation and vaccine completion, 
we did find that across all groups that greater than 80% of participants completed 3-doses of 
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vaccine. This runs counter to studies that show decreased vaccine completion in both the general 
population and in sexual minority communities alike (Agenor, Peitzmeier, et al., 2016; Apaydin, 
Fontenot, Borba, et al., 2018; Williams et al., 2017). Both TGNB and cisgender sexual minority 
participants in our sample demonstrated other health-promoting behaviors that may have 
contributed to their high rates of HPV vaccine completion. The majority had a PCP and saw 
them in the last year. The majority had also received at least two vaccines other than HPV with 
high proportions of both groups reporting that had received a vaccine for influenza and Hepatitis-
B. The latter is notable because, like HPV vaccine, Hepatitis-B requires a similar 3-dose 
schedule. Studies among SGM communities have shown an increase in HPV vaccination when 
individuals receive other vaccines like Hepatitis A/B (Apaydin, Fontenot, Borba, et al., 2018). 
Although both cisgender sexual minority and TGNB participants demonstrated increased 
engagement with health care and this may have contributed to their receipt of HPV vaccine, 
TGNB participants reported greater barriers to care overall. Our findings are consistent with 
studies that show that both TGNB and cisgender sexual minority people have been known to 
delay or not receive necessary care (Jaffee et al., 2016; Macapagal et al., 2016). However our 
finding that a greater proportion of TGNB participants put off seeing a health care provider 
because of concern they would be disrespected or mistreated compared to cisgender participants 
because of the considerably different primary reason given for putting off seeing health care 
providers. TGNB participants reported age as the main reason for putting off seeing their 
providers whereas cisgender participants reported gender identity as the main reason. TGNB 
people have been shown to experience discrimination and stigma which affects their engagement 
in health care (Grant et al., 2011). There is emerging evidence that TGNB older adults 
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experience increased barriers to care but this is an understudied area (Fredriksen-Goldsen et al., 
2017; Fredriksen-Goldsen et al., 2014; Porter et al., 2016). 
Limited conclusions can be drawn from the higher use of dating apps we observed among 
TGNB participants compared to cisgender participants and over half of both groups spent less 
than an hour using the apps. Studies have shown that use of dating apps in MSM has been 
associated with STIs (Beymer et al., 2014). However, dating apps and amount of time spent on 
apps has not been investigated in relation to vaccination. 
Lastly, our findings regarding HPV risk activities establishes that both TGNB and 
cisgender participants in our sample engage in activities that increase risk for exposure to HPV-
infection. HPV vaccine is ideally administered before sexual debut. The age mean of 17 years for 
both groups is the age when initiating the 3-dose ‘catch-up’ adult series is recommended if an 
adolescent has not received any doses. Our finding that cisgender participants in our sample 
reported twice the number lifetime sexual partners than TGNB may represent increased risk of 
exposure for cisgender people. However, a recent study that examined prevalence of HPV 
infection found that unvaccinated transgender women had a higher prevalence of anal HPV 
infection than cisgender MSM (Singh et al., 2019). Although our results showed that TGNB and 
cisgender participants reported similar prevalence of engaging in anal receptive sex, TGNB 
people had decreased prevalence of any type of anal/rectal cancer screening compared to 
cisgender participants. HIV-infection has been observed among TGNB people, especially 
transgender women, and co-infection with HIV is thought to increase the risk of HPV-associated 
rectal/anal cancer (Poteat et al., 2016; Quinn et al., 2015). 




 This study has several strengths. It is one of the first studies to investigate HPV 
vaccination initiation and completion in a large sample of TGNB people. It leverages an online 
national cohort of SGM people are being followed longitudinally. However, the study is not 
without its limitations. The descriptive nature of the study limits conclusions. Self-reporting of 
receipt of HPV vaccine is subject to recall bias. Although national, The PRIDE Study is an 
online convenience sample. The participants in the sample are not representative of TGNB and 
cisgender sexual minority people, especially given that almost all were White race and had 
greater than high school education attainment. Finally, the cross-sectional nature of the study 
limits our ability to derive any causal relationships. 
Conclusion 
In summary, in our cross-sectional study of participants in the 2018-19 PRIDE Study 
Annual Questionnaire, we found TGNB people had higher prevalence of ever receiving HPV 
vaccine compared with cisgender sexual minority people. Transgender men who were assigned 
female at birth had two times the prevalence of ever receiving HPV vaccine compared to 
transgender women who were assigned male sex at birth and this was also reflected among 
cisgender sexual minority females had over two times the prevalence of ever receiving HPV 
vaccine compared to cisgender sexual minority males. These findings suggest that independent 
of gender identity, HPV vaccine disparities based on assigned sex at birth continue to exist 
among SGM communities. However, our finding that the prevalence of ever receiving HPV 
vaccine was greater among TGNB participants who were born with female organs compared to 
cisgender sexual minority females suggests TGNB people who are born with female organs may 
engage differently in preventative services like HPV vaccination than sexual minority women. 
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We found no differences in HPV vaccination initiation and completion between TGNB and 
cisgender participants, but that majority of participants had achieved vaccine completion, which 
suggests a high degree of primary care engagement in The PRIDE Study sample. Future studies 
should consider a national probability sampling to improve knowledge of HPV vaccination 
receipt among TGNB communities. 
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Table 4. 1 Comparison groups 
Comparison Group Reference 
A1. TGNB all  




Administrative identification / 
stratified by gender identity  
(A2 ALL and A3 ALL) 
 
CISGENDER (ALL) 
Administrative identification / 
stratified by gender identity  
(A2 ALL and A3 ALL) 
 





SAAB (Female2) AND GENDERID 
(Genderqueer1 OR Transgender man3 




SAAB (Male1) AND GENDERID 
(Genderqueer1 OR Transgender 
woman4 OR Woman5 OR Another 
gender identity6) 
 
A3. Cisgender female 
compared to:  
Cisgender male 
Cisgender Female 




SAAB (Male1) AND GENDERID 
(Man2) 
 
B1. TGNB organs born female 
compared to:  
Cisgender female 
 
GENDERID (Genderqueer1 OR 
Transgender man3 OR Transgender 
woman4 OR Man2 OR Another 
gender identity6) AND 
ORGANS_BORN (cervix1 OR 
ovaries2 OR uterus OR vagina7) 
 
GENDERID (Woman5) AND 
ORGANS_BORN (cervix1 OR 
ovaries2 OR uterus6 OR vagina7) 
B2. TGNB organs born male 
compared to: 
Cisgender male 
GENDERID (Genderqueer1 OR 
Transgender man3 OR Transgender 
woman4 OR Woman5 OR Another 
gender identity6) AND 
ORGANS_BORN (penis3 OR 
prostate4 OR testicles5) 
 
GENDERID (Man2) AND 
ORGANS_BORN (penis3 OR 
prostate4 OR testicles5) 
 
C1. Organs born male + organs 
now female compared to: 
Organs born male + organs now 
male 
ORGANS_BORN  
(penis3 OR prostate4 OR testicles5) 




(cervix1 OR ovaries2 OR uterus6 OR 
vagina7) AND ORGANS_NOW 
(cervix2 OR ovaries3 OR uterus7, 
vagina8) 
   
C2. Organs born female + 
organs now male compared to: 
Organs born male + organs now 
male 
ORGANS_BORN 
(cervix1 OR ovaries2 OR uterus6 OR 
vagina7) AND ORGANS_NOW 
(penis4 OR testicles6) 
 
ORGANS_BORN  
(penis3 OR prostate4 OR testicles5) 
AND ORGANS_NOW  
(penis4 OR prostate5 OR testicles6) 
 
   
D1. TGNB + Organs Now 
Female + AFAB compared to: 
Cisgender + Organs now 
female +AFAB 
GENDERID (Genderqueer1 OR 
Transgender Man3 OR Transgender 
Woman4 OR Another gender 
identity6) AND ORGANS_NOW  
(cervix2 OR ovaries3 OR uterus7 OR 
vagina8) AND SAAB (Female2) 
 
GENDERID (Woman5) AND 
ORGANSNOW (cervix2 OR ovaries3 
OR uterus7 OR vagina8) AND SAAB 
(Female2) 
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Comparison Group Reference 
   
D2. TGNB + Organs Now + 
Assigned Male at Birth 
(AMAB) compared to: 
 
 
GENDERID (Genderqueer1 OR 
Transgender Man3 OR Transgender 
Woman4 OR Another gender 
identity6) AND ORGANS_NOW 
(vagina8) AND SAAB (Male1) 
 
GENDERID (Man2) AND 
ORGANS_NOW (penis4 OR 
prostate5 OR testicles6) AND SAAB 
(Male1) 
E1. Binary Identity 
Transmasculine ALL compared 
to: 
Transfeminine ALL 
GENDERID (Genderqueer1 OR 
Transgender Man3 OR Another 





GENDERID (Man3) AND SAAB 
(Female2) AND LIVEGEN (Man1) 
 
GENDERID (Genderqueer1 OR 
Transgender Man3 OR Another 





GENDERID (Woman5) AND SAAB 
(Male1) AND LIVEGEN (Woman2) 
 
F1. Nonbinary Identity 
Nonbinary + AFAB compared 
to: 
Nonbinary + AMAB 
GENDERID (Genderqueer1 OR 
Another Gender Identity6) OR 
LIVEGEN (Sometimes man / 
sometimes woman3 OR Third gender 
other than man or woman4) AND 
SAAB (Female2) 
 
GENDERID (Genderqueer1 OR 
Another Gender Identity6) OR 
LIVEGEN (Sometimes man / 
sometimes woman3 OR Third gender 




F2. Transgender Nonbinary 
ALL compared to: 
Transgender Binary ALL 
(F1 ALL) (E1 ALL) 
   
AFAB (Assigned Female at Birth) 
AMAB (Assigned Male at Birth) 
SAAB (Sex Assigned at Birth) 
TGNB (Transgender and Gender Nonbinary) 
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Characteristic n (%) n (%) n (%) Χ2 p-value 
         
DEMOGRAPHIC         
 5,500 (100) 1,691 (31.0) 3,859 (69.5) 846.9 <.0001 
Sexual Orientation         
Asexual 548 (9.9) 319 (18.9) 229 (5.9) 220.9 <.0001 
Bisexual 1,596 (28.8) 496 (29.3) 1,100 (28.5) 0.4 .5310 
Gay 1,951 (35.2) 284 (16.8) 1,667 (43.2) 359.6 <.0001 
Lesbian 1,227 (22.1) 227 (13.4) 1,000 (25.9) 106.5 <.0001 
Pansexual 880 (15.9) 426 (25.2) 454 (11.8) 158.9 <.0001 
Queer 2,136 (38.5) 982 (58.1) 1,154 (29.9) 394.1 <.0001 
Questioning 154 (2.8) 77 (4.6) 77 (2.0) 28.6 <.0001 
Same-gender loving 278 (5.0) 105 (6.2) 173 (4.5) 7.4 .0067 
Straight/Heterosexual 99 (1.8) 83 (4.9) 16 (16.2) 135.5 <.0001 
Another sexual orientation 197 (3.6) 124 (7.3) 73 (1.9) 101.7 <.0001 
Multiple categories selected         
         
Gender Identity         
Genderqueer 945 (17.0) 674 (39.9) 271 (7.0) 897.3 <.0001 
Man 1,873 (33.8) 269 (15.9) 1,604 (41.6) 346.2 <.0001 
Transgender man 573 (10.3) 566 (33.5) 7 (0.2) 1,407.3 <.0001 
Transgender woman 275 (5.0) 271 (16.0) 4 (0.1) 633.0 <.0001 
Woman 2,385 (43.0) 121 (7.2) 2,264 (58.7) 1,273.1 <.0001 
Another gender identity 676 (12.2) 577 (34.1) 99 (2.6) 1,094.6 <.0001 
         
Lived gender day-to-day (missing=142)         
Man 2,115 (39.1) 569 (34.3) 1,546 (41.2)  <.0001* 
Woman 2,581 (47.7) 429 (25.9) 2,152 (57.4)   
Sometimes man/woman* 135 (2.5) 123 (7.4) 12 (0.3)   
Third gender or something other than man or woman 577 (10.7) 538 (32.4) 39 (1.0)   
         
Assigned sex at birth         
Male 1,967 (35.4) 369 (21.8) 1,598 (41.4) 197.2 <.0001 
Female 3,583 (64.6) 1,322 (78.2) 2,261 (58.6)   
         
Intersex 56 (1.0) 48 (0.9) 8 (0.2)  <.0001* 










Characteristic n (%) n (%) n (%) Χ2 p-value 
         
Organs born with         
Cervix 3,483 (62.8) 1,286 (76.1) 2,197 (56.9) 183.9 <.0001 
Ovaries 3,487 (62.8) 1,288 (76.2) 2,199 (57.0) 185.3 <.0001 
Penis/Phallus (not prosthetic) 1,852 (33.4) 353 (20.9) 1,499 (38.9) 170.9 <.0001 
Prostate 1,859 (33.5) 355 (21.0) 1,504 (39.0) 170.6 <.0001 
Testicles 1,903 (34.3) 363 (21.5) 1,540 (39.0) 177.4 <.0001 
Uterus/Womb 3,481 (62.7) 1,290 (76.3) 2,191 (56.8) 191.4 <.0001 
Vagina/Frontal genital opening 3,483 (62.8) 1,288 (76.2) 2,195 (56.9) 187.1 <.0001 
         
Organs now         
Breasts or breast tissue1 3,390 (61.1) 1,181 (69.8) 2,209 (57.2) 79.0 <.0001 
Cervix2 3,253 (58.6) 1,139 (67.4) 2,114 (54.8) 77.1 <.0001 
Ovaries3 3,290 (59.3) 1,158 (68.5) 2,132 (55.3) 85.8 <.0001 
Penis/Phallus (not prosthetic)4 1,884 (34.0) 330 (19.5) 1,554 (40.3) 225.5 <.0001 
Prostate 5 1,819 (32.8) 322 (19.1) 1,497 (38.8) 207.8 <.0001 
Testicles6 1,826 (32.9) 288 (17.0) 1,538 (39.9) 277.1 <.0001 
Uterus/Womb7 3,223 (58.1) 1,133 (67.0) 2,090 (54.2) 80.1 <.0001 
Vagina/Frontal genital opening8 3,486 (62.8) 1,299 (76.9) 2,187 (56.7) 205.2 <.0001 
         
Race/ethnicity (missing=1)         
American Indian/Alaska Native 8 (0.1) 3 (0.2) 5 (0.1)  .0002* 
Asian 157 (2.8) 41 (2.4) 116 (3.0)   
Black, African American, African 99 (1.8) 23 (1.4) 76 (2.0)   
Hispanic, Latino, Spanish 132 (2.4) 27 (1.6) 105 (2.7)   
Middle Eastern, North African 16 (0.2) 4 (0.2) 12 (0.3)   
Native Hawaiian, Pacific Islander 2 (0.04) 0 (0) 2 (0.1)   
White 4,536 (81.7) 1,367 (80.8) 3,169 (82.1)   
Other (None fully describe me) 35 (0.6) 18 (1.1) 17 (0.4)   
Mixed (>1 race/ethnicity selected) 564 (10.2) 208 (12.3) 356 (9.2)   
         
In a Relationship (missing=5)         
Yes 3,357 (62.1) 975 (58.7) 2,382 (63.6) 11.5 .0007 
No 2,052 (37.9) 686 (41.3) 1,366 (36.5)   
         
Legal marital status (missing=5)         
Married 1,465 (27.1) 371 (22.3) 1,094 (29.2)  <.0001* 










Characteristic n (%) n (%) n (%) Χ2 p-value 
Legally recognized civil union 7 (0.1) 2 (0.1) 5 (0.1)   
Registered domestic partnership 83 (1.5) 16 (1.0) 67 (1.8)   
Widowed 49 (0.9) 12 (0.7) 37 (1.0)   
Divorced 336 (6.2) 126 (7.6) 210 (5.6)   
Separated 56 (1.0) 23 (1.4) 33 (0.9)   
Single, never married 3,413 (63.1) 1,112 (66.9) 2,301 (61.4)   
         
Work in one or more paid jobs?         
Yes 4,119 (75.9) 1,159 (69.7) 2,960 (78.6) 50.7 <.0001 
No 1,310 (24.1) 505 (30.4) 805 (21.4)   
         
Occupation (missing=1,449)         
Employed >=40 hr/week 2,231 (54.4) 519 (44.9) 1,712 (58.1)  <.0001* 
Employed 1-39 hr/week 529 (12.9) 190 (16.4) 339 (11.5)   
Temporarily employed 17 (0.4) 9 (0.8) 8 (0.3)   
Self-employed 112 (2.7) 24 (2.1) 88 (3.0)   
Not employed, looking 56 (1.4) 9 (0.8) 47 (1.6)   
Not employed, not looking 5 (0.1) 1 (0.1) 4 (0.1)   
Homemaker 0 (0) 0 (0) 0 (0)   
Student full time  2 (0.1) 0 (0.) 2 (0.1)   
Student part time 5 (0.1) 1 (0.1) 4 (0.1)   
Disabled, not able to work 2 (0.1) 0 (0) 2 (0.1)   
Retired 1 (0.02) 0 (0) 1 (0.03)   
>1 Occupation 1,148 (28.0) 404 (35.0) 744 (25.3)   
         
Income 2019 tax year (missing=242)         
$0 374 (7.1) 184 (11.3) 190 (5.2) 299.1 <.0001 
$1 – 10,000 967 (18.2) 418 (25.6) 549 (15.0)   
$10,001 – 20,000 672 (12.7) 261 (16.0) 411 (11.2)   
$20,001 – 30,000 573 (10.8) 184 (11.3) 389 (10.6)   
$30,001 – 40,000 558 (10.5) 171 (10.5) 387 (10.5)   
$40,001 – 50,000 442 (8.3) 101 (6.2) 341 (9.3)   
$50,001 – 60,000 398 (7.5) 87 (5.3) 311 (5.3)   
$60,001 – 70,000 266 (5.0) 58 (3.6) 208 (3.6)   
$70,001 – 80,000 186 (3.5) 41 (2.5) 145 (2.5)   
$80,001 – 90,000 161 (3.0) 28 (1.7) 133 (1.7)   
$90,001 – 100,000 139 (2.6) 21 (1.3) 118 (1.3)   










Characteristic n (%) n (%) n (%) Χ2 p-value 
$100,000+ 572 (10.8) 81 (5.0) 491 (5.0)   
         
Education attainment         
High school or less 426 (7.7) 170 (10.1) 256 (6.6) 19.4 <.0001 
More than high school 5,214 (92.3) 1,521 (90.0) 3,603 (93.4)   
         
Census region resides in (missing=62)         
Region 1 – Northeast 1,094 (19.9) 360 (21.7) 734 (19.2) 10.0 .0184 
Region 2 – Midwest 1,115 (20.3) 357 (21.5) 758 (19.8)   
Region 3 – South 1,473 (26.8) 408 (24.5) 1,065 (27.8)   
Region 4 - West 1,806 (32.9) 538 (32.4) 1,268 (33.2)   
         
         
SITUATION – BARRIERS TO CARE         
% Health Care Providers aware of your Sexual 
Orientation (missing=443) 
        
0 – None 690 (13.5) 200 (13.8) 490 (13.4) 69.9 <.0001 
50% 492 (9.63) 144 (9.9) 348 (9.5)   
100% 2,022 (39.6) 474 (32.7) 1,548 (42.3)   
         
% Health care providers aware of your Gender Identity 
(missing 3,625) 
        
0 – None 468 (24.3) 298 (18.5) 170 (54.1) 225.0 <.0001 
50% 153 (8.0) 125 (7.8) 28 (8.9)   
100% 679 (35.3) 642 (39.9) 37 (11.8)   
         
Denied or given lower quality medical care EVER 
(missing = 174) 
1,173 (21.8) 593 (35.9) 580 (15.6) 276.4 <.0001 
         
Reason why denied/given lower quality medical care 
EVER (N=1,172) missing=1 
        
0 None of these 26 (2.2) 13 (2.2) 13 (2.2) 271.7 <.0001 
1 Sexual orientation 10 (0.9) 5 (0.8) 5 (0.9)   
2 Gender identity 90 (7.7) 19 (3.2) 71 (12.2)   
3 Gender expression 9 (0.8) 8 (1.4) 1 (0.2)   
4 Race and/or ethnicity 117 (10.0) 99 (16.7) 18 (3.1)   
5 Age 6 (0.5) 1 (0.2) 5 (0.2)   










Characteristic n (%) n (%) n (%) Χ2 p-value 
6 Ability/disability status 190 (16.2) 19 (3.2) 171 (3.2)   
7 Something else 86 (7.3) 28 (4.7) 58 (4.7)   
8 Body size, weight or shape 22 (1.9) 9 (1.5) 13 (1.5)   
9 >1 reason selected 616 (53.0) 391 (66.1) 225 (66.1)   
         
Delayed medical care in past year (missing=147) 1,157 (21.4) 525 (31.9) 632 (16.8) 155.0 <.0001 
         
Reason delayed care in past year (N=1,154) missing=3         
0 Couldn’t afford care 107 (9.3) 29 (5.5) 78 (12.4) 35.9 .0003 
1 Insurance company wouldn’t cover 168 (14.6) 76 (14.5) 92 (14.6)   
2 Health care provider refused insurance plan 10 (0.9) 4 (0.8) 6 (1.0)   
3 Problems getting to provider’s office 4 (0.4) 1 (0.2) 3 (0.5)   
4 Speak a different language 116 (10.1) 41 (7.8) 75 (11.9)   
5 Couldn’t get time off work or school 0 (0) 0 (0) 0 (0)   
6 Don’t know where to go to get care 11 (1.0) 4 (0.8) 7 (1.1)   
7 Was refused services 4 (0.4) 3 (0.6) 1 (0.2)   
8 Couldn’t get childcare 7 (0.6) 4 (0.8) 3 (0.5)   
9 Didn’t have time or took too long 2 (0.2) 0 (0) 2 (0.3)   
10 Other 3 (0.3) 3 (0.6) 0 (0)   
11 Thought would be mistreated/disrespected on basis 
of sexual orientation 
0 (0) 0 (0) 0 (0)   
12 Thought would be mistreated/disrespected on basis 
of gender identity 
22 (1.9) 7 (1.3) 15 (2.4)   
13 Provider could not schedule in a timely fashion 114 (9.9) 56 (10.7) 58 (9.2)   
14 >1 reason selected 586 (50.8) 296 (56.5) 290 (46.0)   
         
Did not see provider because thought would be 
disrespected / mistreated in past year (missing=157) 
980 (18.2) 572 (34.5) 408 (10.9) 429.9 <.0001 
         
Reason put off seeing health care provider because 
concerned would be disrespected/mistreated (N=980) 
missing=23 
        
Sexual orientation 33 (3.5) 12 (2.1) 21 (5.3) 265.4 <.0001 
Gender Identity 3 (0.3) 2 (0.4) 1 (0.3)   
Gender Expression 99 (10.3) 21 (3.7) 78 (19.7)   
Race and/or ethnicity 24 (2.5) 18 (3.2) 6 (1.5)   
Age 339 (35.4) 310 (55.3) 29 (7.3)   










Characteristic n (%) n (%) n (%) Χ2 p-value 
Ability/disability status 15 (1.6) 8 (1.4) 7 (1.8)   
Something else 340 (35.5) 152 (27.1) 188 (47.5)   
Body size, weight, or shape 104 (10.9) 38 (6.8) 66 (16.7)   
         
Unable to obtain medical care, test or treatments you or 
a health care provider deemed necessary in the past year 
(missing=143) 
719 (13.3) 352 (21.4) 367 (9.8) 133.6 <.0001 
         
Main reason why unable to get medical care, tests, or 
treatments? (N=713) missing=6 
        
0 Couldn’t afford 193 (27.1) 93 (26.8) 100 (27.3) 33.1 .0009 
1 Insurance company wouldn’t cover care 249 (34.9) 116 (33.4) 133 (36.3)   
2 Doctor refused to accept insurance plan 24 (3.4) 8 (2.3) 16 (4.4)   
3 Problems getting to doctor’s office 16 (2.2) 8 (2.3) 8 (2.2)   
4 I speak a different language         
5 Couldn’t get time off work or school 26 (3.7) 12 (3.5) 14 (3.8)   
6 Don’t know where to go to get care 25 (3.5) 18 (5.2) 7 (1.9)   
7 Was refused services 34 (4.8) 17 (4.9) 17 (4.6)   
8 Couldn’t get child care 1 (0.1) 0 (0) 1 (0)   
9 Didn’t have time or took too long 20 (2.8) 7 (2.0) 13 (2.0)   
10 Other 68 (9.5) 35 (10.1) 33 (9.0)   
11 Thought would be mistreated/disrespected on basis 
of sexual orientation 
3 (0.4) 0 (0) 3 (0.8)   
12 Thought would be mistreated/disrespected on basis 
of gender identity 
21 (3.0) 20 (5.8) 1 (0.3)   
13 Provider could not schedule in timely fashion 33 (4.6) 13 (3.8) 20 (5.5)   
         
How often avoid talking about topics related to or 
indicating your sexual orientation with health care 
providers (missing=441) 
        
0 Never  2,772 (54.3) 737 (50.8) 2,035 (55.6) 32.1 .0004 
5 Half the time 559 (10.9) 163 (11.2) 396 (10.8)   
10 Always 250 (4.9) 80 (5.5) 170 (4.7)   
         
How often avoid talking about topics relating to 
gender/gender identity with health care providers (%) 
(missing=3,628) 
        










Characteristic n (%) n (%) n (%) Χ2 p-value 
0 Never  683 (35.5) 599 (37.2) 84 (26.8) 73.6 <.0001 
5 Half the time 269 (14.0) 234 (14.5 35 (11.2)   
10 Always 342 (17.8) 239 (14.9) 103 (32.9)   
         
SITUATION – ACCESS TO CARE         
Have Primary Care Provider (PCP) (missing=282) 4,345 (82.5) 1,297 (82.0) 3,048 (82.7) .3060 .5802 
         
Saw PCP in past year (missing=1,251) 3,874 (90.1) 1,186 (92.3) 2,688 (89.2) 9.8 .0018 
         
Went to provider/clinic for transgender care in past year 
(missing=150) 
929 (17.2) 918 (55.8) 11 (1.2) 2,476.9 <.0001 
         
Have ever taken hormones for gender affirmation 
(missing=132) 
941 (17.4) 927 (56.2) 14 (0.3) 2,490.5 <.0001 
         
Have health insurance (missing=213) 5,124 (96.0) 1,531 (94.3) 3,593 (96.8) 18.4 <.0001 
         
Type of health insurance          
Medicaid/Medicare 645 (11.6) 241 (14.3) 404 (10.5) 21.6 <.0001 
Private Insurance 4,612 (83.1) 1,346 (79.6) 3,266 (84.6)   
Other 293 (5.3) 104 (6.2) 189 (4.9)   
         
SITUATION – PREVENTIVE CARE         
Health in general (PROMIS-1) (missing=129)         
Excellent 204 (3.8) 104 (6.3) 100 (2.7) 136.2 <.0001 
Very good 896 (16.5) 361 (21.8) 535 (14.2)   
Good 1,943 (35.8) 616 (37.3) 1,327 (35.2)   
Fair 1,880 (34.7) 477 (28.9) 1,403 (37.2)   
Poor 498 (9.2) 95 (5.8) 403 (10.7)   
         
HIV test ever (missing=341)         
Yes 3,317 (63.7) 946 (57.7) 2,371 (66.4) 43.3 <.0001 
No 1,660 (31.9) 591 (36.1) 1,069 (29.9)   
Don’t know 232 (4.5) 102 (6.2) 130 (3.6)   
         
Ever had influenza vaccine (missing=161)         
Yes 3,753 (69.6) 1,035 (62.9) 2,718 (72.6) 53.3 <.0001 










Characteristic n (%) n (%) n (%) Χ2 p-value 
No 1,603 (29.8) 595 (36.2) 1,008 (26.9)   
Don’t know 33 (0.6) 16 (1.0) 17 (0.5)   
         
Ever had Hepatitis A vaccine (missing=164)         
Yes 3,006 (55.8) 844 (51.2) 2,162 (57.8) 39.5 <.0001 
No 898 (16.7) 255 (15.5) 643 (17.2)   
Don’t know 1,482 (27.5) 548 (33.3) 934 (25.0)   
         
Ever had Hepatitis B vaccine (missing=165)         
Yes 4,039 (75.0) 1,187 (72.2) 2,852 (76.3) 28.1 <.0001 
No 577 (10.7) 161 (9.8) 416 (11.1)   
Don’t know 769 (14.3) 297 (18.1) 472 (12.6)   
         
         
Ever had pneumococcal vaccine (missing=159)         
Yes 2,140 (39.7) 1,515 (40.5) 625 (38.0) 36.5 <.0001 
No 2,071 (38.4) 578 (35.1) 1,493 (39.9)   
Don’t know 1,180 (21.9) 444 (27.0) 736 (19.7)   
         
Ever had shingles vaccine (missing=164)         
Yes 865 (16.1) 241 (14.6) 624 (16.7) 26.3 <.0001 
No 3,473 (64.5) 1,017 (61.8) 2,456 (65.7)   
Don’t know  1,048 (19.5) 388 (23.6) 660 (17.7)   
         
Ever had a cervical Pap? (missing=2,019)         
Yes 2,661 (75.4) 874 (65.3) 1,787 (81.5) 117.9 <.0001 
No 841 (23.8) 451 (33.7) 390 (17.8)   
Don’t know 29 0.8) 13 (1.0) 16 (0.7)   
         
HPV test with recent Pap (missing=189)         
Yes 471 (8.8) 91 (5.6) 380 (10.2) 30.8 <.0001 
No 4,890 (91.2) 1,548 (94.5) 3,342 (89.8)   
         
Ever had anal/rectal cancer screening (missing=228)         
Digital anal rectal exam 761 (14.3) 147 (9.0) 614 (16.6) 113.5 <.0001 
Anal HPV test 74 (1.4) 21 (1.3) 53 (1.4)   
Anal Pap smear 28 (0.5) 8 (0.5) 20 (0.5)   










Characteristic n (%) n (%) n (%) Χ2 p-value 
High-Resolution Anoscopy (HRA) 21 (0.4) 7 (0.4) 14 (0.4)   
Had multiple types of anal cancer screening 374 (7.0) 56 (3.4) 318 (8.6)   
None of these 3,962 (74.5) 1,354 (83.2) 2,608 (70.6)   
Don’t know 102 (1.9) 35 (2.2) 67 (1.8)   
         
INTERNET USE         
App Use (missing=644)         
Use 1 dating app (e.g., Adam4Adam, Tinder, etc.) 3,344 (68.2) 1,106 (73.3) 2,238 (65.9) 226.0 <.0001 
Use multiple dating apps 1,562 (31.8) 404 (26.8) 1,158 (34.1)   
Average Time Spent on dating apps for those that use 
them (missing=2,706) 
        
Less than 1 hour per week 1,268 (57.6) 427 (57.6) 841 (53.7) 37.3 <.0001 
1-6 hours per per week 662 (30.1) 158 (24.9) 504 (32.2)   
1 hour per day 161 (7.3) 32 (5.0) 129 (8.2)   
2 hours per day 76 (3.5) 11 (1.7) 65 (4.2)   
3 or more hours per day 33 (1.5) 7 (1.1) 26 (1.7)   
         
SITUATION –RISK FOR HPV         
         
HPV history of genital warts (ever)(missing=226) 314 (5.9) 44 (2.7) 270 (7.3) 43.1 <.0001 
         
Sexual activity (ever)(N=1,235) 836 (67.7) 339 (66.6) 794 (68.5) 0.5 .4924 
         
Receptive oral sex (N=833)         
Mouth to penis 267 (32.1) 68 (20.1) 199 (40.1) 51.4 <.0001 
Mouth to vagina 190 (22.8) 110 (32.6) 80 (16.1)   
Both mouth to penis and vagina 281 (33.7) 113 (33.5) 168 (33.9)   
Never receptive penis/vagina oral sex 95 (11.4) 46 (13.7) 49 (9.9)   
         
Receptive oral sex – mouth to anus (N=829) 225 (27.1) 52 (15.5) 173 (35.0) 38.4 <.0001 
         
Receptive vaginal - penis to vagina (N=559) 341 (61.0) 138 (55.7) 203 (65.3) 5.4 .0204 
         
Receptive vaginal – vagina to vagina (N=826) 284 (34.4) 103 (30.5) 181 (37.1) 3.9 .0490 
         
Receptive anal sex – penis to anus (N=556) 162 (29.1) 67 (27.4) 95 (30.6) 0.7 .4098 
         










Characteristic n (%) n (%) n (%) Χ2 p-value 
Age at Sexual Debut & Lifetime Sexual Partners (see below)        
 
         





 Range Mean (SD) Mean (SD) Mean (SD) t-test  p-value 
SITUATION - HPV RISK          
Age at sexual debut+ 2-35 17.6 5.0 17.3 4.8 17.8 5.2 814 .2224 
Lifetime sexual partners++ 1-54 13.1 16.5 8.6 12.1 16.1 18.3 822 <.0001 
DEMOGRAPHICS          
Age+++ 18 – 81 34.8 13.4 31.3 11.4 36.3 13.9 3,856 <.0001 
*Fishers Exact Test for cells <30 
+Age at sexual debut median 18 (interquartile range [IQR], 15-20) 
++Lifetime sexual partners media 6 (interquartile range [IQR], 2-15) 
+++Age median 31 (interquartile range [IQR], 25-41) 
Outliers greater than or less than 1.5*[IQR] were removed prior to calculating mean and median 
 












Item n (%) n (%) n (%) Χ2 p-value 
         
Ever received HPV vaccine? 
(missing=161) 
        
Yes 2,213 (41.1) 761 (46.2) 1,452 (38.8) 66.4 <.0001 
No 2,631 (48.8) 676 (41.0) 1,955 (52.2)   
Doctor refused when asked 126 (2.3) 38 (2.3) 88 (2.4)   
I don’t know 419 (7.8) 172 (10.4) 247 (6.6)   
         
Reported doses ever received 
HPV vaccine (N=2,209) 
(missing=4) 
        
HPV Vaccine [1-dose] 121 (5.5) 44 (5.8) 77 (5.3) 13.2 .0042 
HPV Vaccine [2-doses] 219 (9.9) 83 (10.9) 136 (9.4)   
HPV Vaccine [3-doses] 1,561 (70.7) 502 (66.1) 1,059 (73.0)   
Don’t know / cannot recall 308 (13.9) 130 (17.1) 178 (12.3)   
         
 








Item n (%) n (%) n (%) Χ2 p-value 
         
Ever heard of HPV? 
(missing=2,232) 
        
Yes 3,044 (91.7) 1,066 (90.9) 1,978 (92.2)  .0317 
No 247 (7.4) 91 (7.8) 156 (7.3)   
I don’t know 27 (0.8) 16 (1.4) 11 (0.5)   
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Table 4. 5 Receipt of HPV Vaccine 
 Total Group Ref   
Group / Receipt of Vaccine n (%) n (%) n (%) PR 95% CI 
A1. Transgender ALL vs Cisgender ALL   TGNB Cisgender   
Received HPV vaccine (ever) (n=4,970) 2,213 (44.5) 2,213 (44.5) 1,452 (41.6) 1.2 1.2-1.3 
         
Initiated/Completed (n=2,213)         
  Initiated (1-dose) 121 (5.5) 44 (5.8) 77 (5.3) 1.1 0.8-1.6 
  Completed (3-doses) 1,561 (70.5) 502 (66.0) 1,059 (72.9) 0.9 0.9-1.0 
         





Received HPV vaccine (n=1,779) 926 (52.1) 836 (58.9) 90 (25.0) 2.4 2.0-2.8 
         
Initiated/Completed (n=771)         
  Initiated (1-dose) 57 (7.8) 49 (7.1) 8 (10.5) 0.7 0.3-1.3 
 Completed (3-doses)  615 (80.0) 566 (81.4) 49 (64.5) 1.2 1.0-1.5 
         





Received HPV vaccine (ever) (n=3,495) 1,452 (41.6) 1,098 (52.6) 354 (25.2) 2.1 1.9-2.3 
         
Initiated/Completed (n=1,272)         
  Initiated (1-dose) 77 (6.1) 51 (5.3) 26 (8.4) 0.6 0.4-1.0 
  Completed (3-doses) 1,059 (83.3) 815 (84.7) 244 (78.7) 1.0 1.1-1.2 
         
B1. Gender Identity + Organs Born With   TGNB 
Organs Born Female 
Cisgender Female 
Organs Born Female 
  
Received HPV vaccine (ever) (n=3,261) 1,783 (54.7) 687 (58.6) 1,096 (52.5) 1.1 1.1-1.2 
         
Initiated/Completed (n=1,528)         
  Initiated (1-dose) 89 (5.8) 28 (6.7) 51 (5.3) 1.2 0.8-1.8 
  Completed (3-doses) 1,274 (83.4) 461 (81.2) 813 (84.7) 0.9 0.9-1.0 
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 Total Group Ref   
Group / Receipt of Vaccine n (%) n (%) n (%) PR 95% CI 
B2. Gender Identity + Organs Born With 
 
  TGNB 
Organs Born Male 
Cisgender Male 
Organs Born Male 
  
Received HPV vaccine (ever)(n=1,717) 432 (25.2) 76 (24.4) 356 (25.3) 1.0 0.8-1.2 
         
Initiated/Completed (n=375)         
  Initiated (1-dose) 32 (8.5) 6 (9.5) 26 (8.3) 1.1 0.5-2.5 
  Completed (3-doses) 289 (77.1) 43 (68.3) 246 (78.9) 0.8 0.7-1.0 
         
C1. Organs Born With 
 
  Organs Born Female 
Organs Now Male 
Organs Born Female 
Organs Now Female 
  
Received HPV vaccine (ever)(n=3,245)  1,777 (54.8) 7 (43.8) 1,770 (54.8) 0.8 0.5-1.4 
         
Initiated/Completed (n=1,523)         
  Initiated (1-dose) 89 (5.8) 0 (0) 89 (5.9) - - 
  Completed (3-doses) 1,270 (83.4) 6 (85.7) 1,264 (83.4) 1.2 0.9-1.6 
         
C2. Organs Born With   Organs Born Male 
Organs Now Female 
Organs Born Male 
Organs Now Male 
  
Received HPV vaccine (ever)(n=1,709) 428 (24.0) 5 (19.2) 423 (25.1) 0.8 0.4-1.7 
         
Initiated/Completed (n=374)         
  Initiated (1-dose) 32 (8.6) 1 (20.0) 31 (8.4) 2.7 0.5-16.3 
  Completed (3-doses) 288 (77.0) 2 (40.0) 286 (77.5) 0.6 0.2-1.7 
         
D1. Gender Identity + Organs Now + SAAB   TGNB 
Organs Now Female 
AFAB 
Cisgender 
Organs Now Female 
AFAB 
  
Received HPV vaccine (ever)(n=3,195) 1,751 (54.8) 656 (58.9) 1,095 (52.6) 1.1 1.1-1.2 
         
Initiated/Completed (n=1,501)         
  Initiated (1-dose) 89 (5.9) 38 (7.0) 51 (5.3) 1.2 0.8-1.9 
  Completed (3-doses) 1,253 (83.5) 440 (81.2) 813 (84.8) 0.9 0.8-1.0 
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 Total Group Ref   
Group / Receipt of Vaccine n (%) n (%) n (%) PR 95% CI 
D2. Gender Identity + Organs Now + SAAB   TGNB 
Organs Now Male 
AMAB 
Cisgender 
Organs Now Male 
AMAB 
  
Received HPV vaccine (ever)(N=1,443) 357 (24.7) 4 (10.0) 353 (25.2) 0.4 0.2-1.0 
         
Initiated/Completed (n=313)         
  Initiated (1-dose) 27 (8.6) 1 (25.0) 26 (8.4) 3.4 0.6-19.3 
  Completed (3-doses) 243 (77.6) 0 (0) 243 (78.6) - - 
         
E1. Transgender Binary Identity 
 
  Transmasculine Transfeminine   
Received HPV vaccine (ever)(n=987) 513 (52.0) 264 (53.8) 249 (50.2) 1.1 1.0-1.2 
         
Initiated/Completed (n=432)         
  Initiated (1-dose) 37 (8.6) 21 (9.5) 16 (7.6) 1.2 0.7-2.3 
  Completed (3-doses) 347 (80.3) 173 (77.9) 174 (82.9 0.9 0.8-1.1 
         





Received HPV vaccine (ever)(n=1,249) 706 (56.5) 652 (60.8) 54 (30.7) 2.0 1.6-2.5 
         
Initiated/Completed (n =594)         
  Initiated (1-dose) 49 (8.3) 42 (7.7) 7 (14.3) 0.5 0.2-1.1 
  Completed (3-doses) 474 (79.8) 441 (80.9) 33 (67.4) 1.1 0.9-1.4 
         
F2. Trans Nonbinary Identity ALL vs Trans 
Binary Identity ALL 





Received HPV vaccine (ever)(N=1,638) 883 (53.9) 370 (56.8) 513 (52.0) 1.1 1.0-1.2 
         
Initiated/Completed (n=740)         
  Initiated (1-dose) 57 (7.7) 20 (6.5) 37 (8.6) 0.8 0.4-1.3 
  Completed (3-doses) 594 (80.3) 247 (80.2) 347 (80.3) 1.0 0.9-1.1 
         
AFAB (Assigned Female at Birth), AMAB (Assigned Male at Birth), SM (Sexual Minority) 
Robust Poisson method used to calculate PR (Prevalence Ratio) 
        
88 
 
Chapter 5: Human papillomavirus vaccination, online health 
information seeking, and health literacy among transgender and 
gender nonbinary people 
The study in Chapter Five addresses the third aim of the dissertation to explore factors associated 
with HPV vaccination initiation and completion among TGNB people; particularly online health 
information seeking and eHealth literacy. The study is a cross-sectional analysis of a novel online 
survey of participants recruited from The PRIDE Study cohort. 
Background 
Sexual and gender minority (SGM) people are an understudied population who are 
vulnerable to poor health and include sexual minorities based on sexual orientation (e.g., lesbian 
women, gay men, bisexual men and women) and gender minorities based on gender identity 
(e.g., transgender, nonbinary and other gender-expansive people) (National Institutes of Health, 
2019). The National Institutes of Health designated SGM people a health disparities population 
in acknowledgement of poor health outcomes and research gaps in these communities (Perez-
Stable, 2016). Studies using data from the Health Information National Trends Survey found that 
sexual minority people are more likely to seek and be exposed to incidental health information 
online, more likely to watch online health videos on YouTube, and less likely to first seek health 
information from a physician compared to their heterosexual peers (Jabson et al., 2017; Langston 
et al., 2019; Lee et al., 2017). Although research about health information seeking and eHealth 
literacy (the ability to use electronic health information to make health decisions) has been 
explored in sexual minority people, these topics have not been explored among transgender and 
gender nonbinary (TGNB) people, who are estimated to number at least 1.4 million in the U.S 
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(Flores, 2016). Unlike cisgender sexual minority people whose gender identity matches their 
assigned sex at birth, TGNB people have gender identities/expressions that may not conform to 
their assigned sex at birth and may self-identify as transmen/women, transgender men/women or 
men/women (American Psychological Association, 2015; Institute of Medicine, 2011). Some 
TGNB people self-identify as nonbinary or genderqueer, terms used to describe people whose 
gender is not exclusively male or female, including those who identify with a gender other than 
male or female, as more than one gender, or as no gender (James, 2016). 
For the purposes of this study, we use the terms transgender and gender nonbinary 
(TGNB) to encompass these communities, however we acknowledge that TGNB may not 
capture all that ways in which gender minority people express their identities. TGNB people 
have unique health information needs relating to their gender identity such as gender-affirming 
hormone management (Horvath et al., 2012). TGNB people report a higher prevalence of poor 
health and experience stigma and discrimination with healthcare providers based on their gender 
identity, resulting in poor health outcomes from delaying or deferring necessary care (Bradford 
et al., 2013; Jaffee et al., 2016; Macapagal et al., 2016; Meyer et al., 2017; Safer et al., 2016; 
Winter et al., 2016). For example, TGNB people with a cervix who are sexually active are at risk 
of HPV and yet have reduced rates of cervical cancer screening and increased time between 
recommended screening intervals compared to cisgender women (Peitzmeier, Khullar, et al., 
2014; Peitzmeier, Reisner, et al., 2014). Although TGNB people have been shown to utilize the 
Internet for community building and information sharing (Shapiro, 2004), there is a paucity of 
research that explores online health information seeking among TGNB people and how this may 
be associated with health decision-making. The purpose of this study is to describe health 
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information seeking among a sample of TGNB people to explore how this may be associated 
with a preventative health behavior, human papillomavirus (HPV) vaccination. 
Human papillomavirus (HPV) is the most common sexually-transmitted infection (STI) 
in adults in the United States with a prevalence of 79 million existing infections and incidence 
rate of 14 million new infections per year (Dunne et al., 2014). High-risk strains of HPV are 
associated with the majority of recto-anal, vagino-cervical, and oropharyngeal cancers (Centers 
for Disease Control and Prevention, 2013; Dunne et al., 2014). A vaccine to prevent HPV-
infection was introduced in 2006. The Advisory Committee on Immunization Practices (ACIP) 
recommends two doses of vaccine starting at age 9-11 years and three adult “catch-up” doses for 
those who have not had received any vaccine doses by age 15-years. The national goal proposed 
in Healthy People 2020 was 80% vaccine completion for HPV (e.g., received the full vaccination 
series, or all recommended doses based on age group) (Markowitz et al., 2014). The Centers for 
Disease Control and Prevention (CDC) estimates that only fifty-four percent of eligible 
adolescents have achieved vaccine completion and approximately 23 million young adults 
remain unvaccinated for HPV in the general population (Elam-Evans et al., 2020; Walker et al., 
2017; Williams et al., 2017). In June 2019, ACIP expanded the recommended age range from 9 
through 26 years to 9 through 45 years for both women and men (Meites, 2019). 
Low HPV vaccine completion (13 to 32%) has been observed in adult sexual minority 
people (Agenor, Peitzmeier, et al., 2016; McRee et al., 2014; Reiter et al., 2015; Williams et al., 
2017). Studies have identified lack of knowledge or trust in vaccines, non-disclosure of sexual 
identity to providers, and fear of discrimination/stigma as barriers to vaccination in sexual 
minority people (Barefoot et al., 2017; Cummings et al., 2015; Gerend, Madkins, Phillips, 
Mustanski, et al., 2016; McRee et al., 2014; Youatt, 2017). The true proportion of adult TGNB 
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and cisgender sexual minority people who have not received any doses of HPV vaccine is likely 
higher than the general population given studies to-date (Agenor, McCauley, et al., 2016; Agenor 
et al., 2015; Agenor, Peitzmeier, et al., 2016; Charlton et al., 2017; McRee et al., 2014; Reiter et 
al., 2015). There have been few studies that focus on HPV vaccination among TGNB people that 
similarly demonstrate low vaccine uptake (Bednarczyk et al., 2017; Singh et al., 2019). 
Methods 
We adapted the Integrative Model of eHealth Use or IMeHU (Bodie & Dutta, 2008) to 
guide our study. The IMeHU posits that online health information seeking is associated with 
health behavior outcomes and that this relationship is influenced by individual factors such as 
eHealth literacy (Figure 5.1). We employed a cross-sectional study design to explore the 
association of health information seeking and eHealth literacy and HPV vaccination among SGM 
people. Between February and May 2020, we launched an online survey to explore our study 
questions. An e-mail and text message invitation to participate in the survey was sent to over 
17,000 current participants in The Population Research in Identities and Disparities for Equality 
(PRIDE) Study (pridestudy.org), a large-scale long-term U.S.-based national health study of 
SGM people (The PRIDE Study, 2019). The PRIDE Study launched in 2017 and recruits only 
adults age 18-years and older. Details of The PRIDE Study longitudinal cohort and dataset are 
described elsewhere (Lunn, Capriotti, et al., 2019; Lunn, Lubensky, et al., 2019). This study was 
approved by the Institutional Review Boards at Columbia Irving University Medical Center 
(IRB-AAAS6733) and Stanford University Medical School. 




Figure 5. 1 Adapted Integrative Model of eHealth Use (IMeHU) 
All participants in The PRIDE Study cohort were deemed eligible for the online survey 
with no age restrictions and no restrictions to participant sexual or gender identity demographic 
information. Survey data were collected using Qualtrics (Qualtrics, Provo, UT) and the survey 
was hosted on The PRIDE Study Web portal. We used a modified Dillman method for survey 
reminders that were issued by The PRIDE Study Web portal via email and opt-in text message 
(Dillman et al., 2014). 
We used 23-items from the Health Information National Trends Survey (HINTS 5 Cycle 
3) (Appendix D) to assess preferences for online health information seeking (National Cancer 
Institute, 2018). By using HINTS items, we sought to better understand preferences for 
information seeking, especially among TGNB people as these communities were omitted in 
previous versions of HINTS. We assessed the health information seeking primary independent 
variables of interest using two HINTS items: 




HINTS_B3) In the PAST 12 MONTHS, have you used the Internet  
to look for information about vaccines for yourself? 
 
HINTS_B5a) In the PAST 12 MONTHS, have you used a computer,  
smartphone, or other electronic means to do any of the following?  
Looked for health or medical information for yourself. 
 
We assessed eHealth literacy using the electronic Health Literacy Scale (eHEALS), an 
eight-item scale that uses Likert responses and yields a score 8-40 (low-to-high), corresponding 
with self-perceived eHealth literacy (Appendix B) (Norman & Skinner, 2006). We assessed 
general health literacy using three discrete subjective items that address reading and 
understanding written health information (e.g., confidence in filling out forms, difficulty 
understanding written communication, and needing help to read written material from a 
doctor/pharmacy). These items were also constructed with Likert responses (Chew et al., 2004). 
We assessed barriers to care, access to care and preventive care, and demographic 
characteristics, and whether participants had ever received HPV vaccine and number of doses 
received using items taken from the PRIDE Study annual follow-up questionnaire that is sent 
annually during the month of June. Although these items were previously posed to participants, 
the questions were posed again to ensure the completeness of our cross-sectional survey. The 
final survey included 74 items (Appendix E) and could be completed in 15-20 minutes. The 
survey item categories and number of items in each category were distributed as follows: HPV 
and vaccine knowledge (3-items), health information seeking (23-items), general health literacy 
(3-items), eHealth literacy (10-items), barriers to care (5-items), access to care (7-items), 
preventive care (8-items), and demographics (15-items). Survey responses from TGNB 
participants were compared with cisgender sexual minority participants as the reference group. 
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Participants could skip any item and start and stop the survey as much as they liked during the 
survey period by logging into their existing PRIDE Study Web portal accounts. 
Comparison Groups 
 We used the responses from multiple demographic questions (e.g., gender identity, lived 
gender day-to-day, assigned sex at birth, organs born with, organs now) to identify TGNB 
participants and distinguish them from cisgender participants. We used Boolean logic to account 
for both gender identity and biological sex. Table 5.1 summarizes the comparison groups and our 
inclusion logic. 
Statistical Analysis 
The dataset was cleaned and all analysis performed in SAS 9.4 (SAS Institute Inc., Cary, 
NC). Descriptive statistics for demographics were calculated and means and standard deviations 
established. Chi-square and paired t-tests were employed to examine differences in categorical 
and continuous variables. Alpha was set at .001 for level of significance for bivariate 
comparisons to control for multiple comparisons. The distribution of continuous variables and 
potential outlier values for age and eHEALS scores were identified using boxplots in SAS. To 
determine if multicollinearity was present, we used variance inflation factor (VIF) statistics. A 
VIF value less than five suggested no multicollinearity (Akinwande et al., 2015). We calculated 
point prevalence for receipt of HPV vaccine ever, vaccine initiation (e.g., 1-dose) vaccine 
completion (e.g., 3-doses). We calculated prevalence ratios (PR) and confidence intervals (CI) 
using robust Poisson statistics (Petersen & Deddens, 2008). We used multivariable logistic 
regression to model the association of health information seeking on the dependent vaccination 
outcomes. The prevalences of receipt of HPV vaccination ever, vaccine initiation, and vaccine 
completion were stratified by gender identity, sex organs born with, sex organs now, and sex 
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assigned at birth. The multivariable logistic regression was conducted for all TGNB compared to 
all cisgender participants for the three dependent outcomes (i.e., receipt of HPV vaccination 
ever, vaccination initiation, and vaccination completion). We performed post hoc testing using 
the Bonferroni-Holm sequential procedure for adjusted alphas (Eichstaedt et al., 2013). To test 
for any moderating effects, we assessed for interaction between general and eHealth literacy 
online health information seeking. For each dependent outcome, we ran two models adding in 
the interaction terms, eHEALS score and each of the categorical general health literacy variables 
one at a time. We evaluated the effect of the interaction variables on the logistic regression 
models using Likelihood Ratio tests.  
Results 
At the close of the survey, there were 3,339 completed responses (e.g., viewed every 
question and arrived at survey completion page), and a response rate of 19.6%. We excluded 81 
(2.4%) of the responses due to missing sex and gender identity or age information. Of the 
remaining 3,258 participants, a total of 1,172 (36%) were classified as TGNB and 2,086 (64%) 
as cisgender (Table 5.2). A greater proportion of TGNB participants were assigned female at 
birth (AFAB) (79.4%) compared to cisgender AFAB (56.1%) (p < .0001). Conversely, the 
proportion of TGNB participants who were assigned male at birth (AMAB) (20.6%) was half 
that of cisgender AMAB participants (43.9%) (p < .0001). One-third of TGNB participants 
(35.8%) said their lived gender day-to-day was sometimes man/woman or a third gender or 
something other than a man or woman. The proportion of cisgender participants that identified as 
gay sexual orientation was over twice (44.6%) that of TGNB participants (15.9%) (p < .0001). 
Over half (57.3%) of TGNB participants identified as queer sexual orientation compared to 
cisgender participants (29.6%) (p < .0001). The majority of TGNB and participants were White 
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(81.6%) and had more than a high school education (93.7%) (Table5.2). Cisgender participants 
were also majority White (82.5%) and nearly all (96.6%) had more than a high school education. 
TGNB participants reported lower annual income than cisgender participants with more than 
three-quarters of TGNB participants (76.7%) with an income less than $50,000 per year 
compared to cisgender participants (55.1%) (p < .0001). Slightly more TGNB participants rated 
their health as fair/poor (43%) compared with cisgender (40.1%) (p < .0001). The median age of 
participants was 31 (interquartile range [IQR] 25-43). Cisgender participants were slightly older 
than TGNB participants, age mean 38.2 SD 14.9 and age mean 31.7 SD 11.6 respectively  
(p < .0001). 
Barriers to Care, Access to Care, Preventive Care 
Over forty-three percent of TGNB participants (43.3%) delayed necessary medical care 
in the past year compared to cisgender (24.5%) (p < .0001). Nearly one-third of TGNB 
participants reported not seeing a health care provider because they thought they would be 
disrespected or mistreated in the past year compared to one-tenth of cisgender participants 
(9.9%) (p < .0001). In terms of access to care, majority of both groups reported having a primary 
care provider (PCP), seeing them in the past year. Nearly all participants reported having health 
insurance. With regards to preventive care, nearly all TGNB and cisgender participants reported 
having received a vaccine other than HPV and majority of both groups had received three-or-
more vaccines since 18-years age. 
Health Literacy 
Both groups reported a high level of eHealth literacy with similar eHEALS scores (range 
8-40); TGNB participants score mean 32.9 SD 4.8 and cisgender participants score mean 33.9 
SD 4.8 (p < .0001). The groups were also similar in how they rated their general health literacy 
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with majority of participants in either group reporting high confidence filling out forms, and 
occasional/never difficulty understanding written communication or needing help to read written 
material from a doctor or pharmacy. 
Health Information Seeking 
The groups were similar in terms of health information seeking (Table 5.3). Majority of 
both groups indicated they would use the Internet first when looking for health information and 
next a doctor or health care provider. Nearly all reported using a computer, smartphone or other 
electronic means to look for health or medical information in the past year. The groups did not 
differ in terms of having a smartphone and did not differ in terms of Internet use such as visiting 
social media sites like Facebook or watching a health-related videos on YouTube or other 
streaming services. 
HPV Vaccination Rates 
More TGNB participants (55.8%) reported ever receiving HPV vaccine compared to 
cisgender (41.9%) (p < .0001) (Table 5.4). Of the participants who reported receiving HPV 
vaccine ever, the groups were similar in number of doses received with a greater proportion of 
cisgender participants reporting receipt of 3-doses (69.1%) compared to TGNB participants 
(61.3%) (p = .0009). Nearly all had heard of HPV (Table 5.5). Small proportions of TGNB 
participants (2.8%) and cisgender participants (3.7%) reported that a doctor refused to give them 
HPV vaccine when they requested it (p = .0009). 
The prevalence (PR 1.3; 95% CI, 1.3-1.4) of ever receiving HPV vaccine was 1.3 times 
greater among TGNB participants than cisgender participants (Table 5.6). However, of the 
aggregate TGNB and cisgender participants who reported ever receiving an HPV vaccine, there 
was no difference in vaccine initiation (e.g, received 1-dose) or vaccine completion (e.g., 
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received 3-doses). There were notable differences when comparing groups based on gender 
identity and sex organs born with. TGNB identity and organs born female had 1.2 times 
prevalence (PR 1.2; 95% CI, 1.1-1.2) of ever receiving HPV vaccine compared to cisgender 
females. However, they were 0.9 times as likely (PR 0.9; 95% CI, 0.8-0.9) complete 3-doses of 
vaccine. When considering gender identity, organs now and sex assigned at birth, the groups 
with the greatest difference in vaccination prevalence was TGNB participants with organs now 
male and AMAB whose prevalence (PR 3.2; 95% CI, 1.2-9.1) of vaccination initiation was 3.2 
times greater than cisgender participants with male organs now and AMAB. There was no 
difference in prevalence of vaccination among TGNB participants who were categorized as 
transmasculine (e.g., self-identified as a man or transgender man) and transfeminine. However, 
transgender nonbinary AFAB had 1.6 times prevalence (PR 1.6; 95% CI, 1.3-2.0) of ever 
receiving HPV vaccine compared to nonbinary AMAB. Nonbinary transgender participants had 
1.2 times the prevalence of ever receiving HPV vaccine compared to binary transgender 
participants (e.g., transgender people who identified as transmasculine or transfeminine). The 
prevalence (PR 4.6; 95% CI, 1.1-19.1) of vaccine initiation was 4.6 times higher in participants 
who were born with male organs and now have female organs compared to participants who 
were born with male organs and now have male organs. However, the large effect size is likely 
over-estimated given the small number (n=2) of participants who were born with male organs 
and now have female organs. 
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Dependent Outcomes: HPV Vaccination Ever, HPV initiation, HPV completion 
 To explore the relationship between health information seeking and each dependent 
outcome of interest, we performed multivariable logistic regression. In our sample of 3,258 
participants 1,528 (46.9%) people had ever received any HPV vaccine doses. First, we 
performed a bivariate analysis of 30 independent variables on each of the three dependent 
outcomes (i.e., HPV vaccine ever, HPV initiation, HPV completion). Variables that did not meet 
our entry criterion of p < .25 and were removed and not proposed in the preliminary main effects 
model. Independent variables of interest were selected based on the IMeHU categories (e.g., 
gender identity, health information seeking, knowledge/beliefs, Internet use, barriers to care, 
access to care, preventive care, demographics). We include the detailed bivariate analysis 
including Chi-square values for the dependent outcome receipt of HPV vaccine ever (Table 5.7) 
but do not display the detailed Chi-square distribution for the other two dependent variables (e.g. 
vaccine initiation / completion). We include a summary of the bivariate analysis, preliminary 
main effects model, and final reduced model are for each of the three dependent outcomes 
(Tables 5.8-5.10). Of note, some variables were kept in the model even though they did not meet 
the entry or retain alpha criteria because they were main factors under investigation and as such 
important variables of interest (e.g., gender identity and/or online information seeking). 
Dependent Outcome: HPV Vaccine Ever 
After controlling for covariates including age, race/ethnicity and education attainment, 
we found that TGNB participants had increased odds (aOR=1.5=; 95% CI, 1.1-2.2) of reporting 
receipt of HPV vaccine ever compared to cisgender participants (Table 5.8). TGNB participants 
compared to cisgender participants had decreased odds (aOR=0.7; 95% CI, 0.5-0.9) of receipt of 
HPV vaccine when they looked for info on vaccines in the past year. TGNB participants had 
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over twice the odds (aOR=2.4; 95% CI, 1.1-5.6) of ever receiving HPV vaccine if they visited a 
social networking site like Facebook in the past year; and also had over twice the odds 
(aOR=2.1; 1.1-4.1) of ever receiving vaccine if they reported having heard of HPV. TGNB 
participants had 1.5 odds (aOR=1.5; 95% CI, 1.1-2.0) of receiving HPV vaccine ever compared 
to cisgender participants when they reported having delayed medical care in the past year. 
Having less than 50% of health care providers be aware of sexual orientation or gender identity 
was significant in preliminary modeling but ultimately not associated with the HPV vaccine 
receipt in the reduced model. TGNB participants had decreased odds of ever receiving HPV 
vaccine compared to cisgender participants if they reported tracking healthcare charges and costs 
(aOR=0.6; 95% CI, 0.5-0.9), or if they reported have made appointments with their providers 
online (aOR=0.5, 95% CI, 0.4-0.9). Medicaid was also associated with decreased odds of ever 
receiving HPV vaccination (aOR=0.3; 95% CI 0.1-0.7). In terms of preventive care, TGNB 
participants compared to cisgender participants had two times the odds (aOR=2.0; 95% CI, 1.5-
2.8) of ever receiving HPV vaccine when they reported having had an HIV test in the past year. 
The greatest effect size was observed when participants reported receipt of vaccines other than 
HPV, TGNB participants who reported receipt three-or-more vaccines since they were 18-years 
old had 3.5 times the odds (aOR=3.5; 95% CI, 1.5-8.2) of ever receiving HPV vaccine compared 
to cisgender participants. TGNB participants who reported having had any anorectal cancer 
screening had decreased odds (aOR=0.6; 0.4-0.8) of receiving vaccine ever compared to 
cisgender participants. In terms of covariates, TGNC participants who were age younger than 27-
years decreased odds (aOR=0.08; 95% CI, 0.05-0.11) of receiving HPV vaccine ever compared 
to cisgender participants younger than 27-years age. However, the remaining covariates race and 
education attainment were not significant in the reduced model. 
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Dependent Outcome: HPV Vaccine Initiation (1-dose) 
 Of the individuals who reported HPV vaccine ever (N=1,528) we performed logistic 
regression modeling on vaccine initiation (e.g., received 1-dose). After bivariate analysis (Table 
5.8) we proposed a preliminary main effects model. Most of the independent variables were 
ultimately removed from the reduced model, failing to meet the p<.05 retain criteria. In the final 
reduced model, we found no association between TGNB identity and vaccine initiation. 
However, we did find an association with health information seeking, number of vaccines other 
than HPV received, and age. Looking for vaccine info online in the past year was associated with 
2.7 times the odds of vaccine receipt (aOR=2.7; 95% CI, 1.8-4.1). Receipt of three-or-more 
vaccines other than HPV was associated with decreased odds (aOR=0.3; 0.1-0.9) of vaccine 
initiation. In terms of covariates, Age <27-years was associated with 1.8 times the odds 
(aOR=1.8; 95% CI, 1.2-2.8) of vaccination initiation. The other two covariates, race/ethnicity 
and education attainment were not significant in the reduced model. 
Dependent Outcome: HPV Vaccination Completion (3-doses) 
 We re-ran the bivariate analysis for the dependent outcome vaccine completion or receipt 
of 3-doses of HPV vaccine (Table 5.10). After proposing a preliminary model, the reduced 
model retained eight independent variables at the p<.05 level. After controlling for covariates 
age, race/ethnicity and education attainment, TGNB participants had decreased odds (aOR=0.7; 
95% CI, 0.5-0.9) of vaccine completion compared to cisgender participants. TGNB participants 
that looking for any health information online had nearly four times the odds (aOR=3.8; 95% CI, 
1.4-10.5) of vaccine completion compared to cisgender participants but there was no association 
with vaccine completion if they searched for information about vaccines online in the past year 
(aOR=0.7; 95% CI, 0.6-1.0). TGNB participants had decreased odds (aOR=0.5; 95% CI, 0.3-0.8) 
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of vaccine completion if they saw their PCP in the last year. TGNB participants had nearly five 
times the odds (aOR=4.8; 95% CI, 1.9-12.2) of vaccine completion if they reported having 
received one-to-two vaccines since 18-years old and nearly seven times the odds (aOR=6.7; 95% 
CI, 2.8-16.1) of vaccine completion if they received three-or-more vaccines since age 18-years. 
In terms of covariates, age, race/ethnicity and education attainment were not significant in the 
reduced model. 
Interaction of Health Literacy 
 To test for the moderating effect, we assessed for interaction between online health 
inforamation seeking and eHealth/general health literacy. After adding interaction terms for the 
eHEALS score and each of the general health literacy variables to the three reduced logistic 
regression models, we found no interaction between general and eHealth literacy and online 
health information seeking using the LR method. 
Discussion 
Our study found that in a sample of 3,258 SGM people participating in a large national 
online cohort, 1,528 (46.9%) people received the HPV vaccine (ever) and of the people who 
received the HPV vaccine ever, 121 (7.9%) received 1-dose and 1,004 received 3-doses (65.7%). 
In general, TGNB people were more likely to have ever received HPV vaccine. Our finding that 
TGNB participants with female organs were more like to ever receive vaccination and complete 
3-dose vaccination series compared to cisgender participants with female organs is worth 
consideration. Both TGNB and cisgender sexual minority people have been known to delay or 
not receive necessary care and TGNB people may experience increased rates of discrimination in 
healthcare (Jaffee et al., 2016; Macapagal et al., 2016). Higher receipt of HPV vaccine among 
TGNB people compared to cisgender sexual minority people in our sample may be related to 
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how they engage with health care. Both groups reported having a PCP and saw them in the last 
year and over half TGNB people also reported going to a provider/clinic for transgender care in 
the past year. Increased engagement in healthcare for gender affirmation may increase their 
contact with primary care providers who would suggest vaccination (Edmiston et al., 2016). 
Moreover, majority of both groups reported receiving three of more vaccines other than HPV 
since 18-years age, this likely reflects high primary care engagement in our sample.  
Our findings that individuals who are born with female organs born have increased rates 
of HPV vaccination regardless of gender identity is consistent with what is known in the 
literature about HPV vaccination in sexual minority people such as gay men who have been 
shown to have vaccination initiation rates as low as 13% compared to 47% in studies of sexual 
minority women (Agenor, Peitzmeier, et al., 2016; Reiter et al., 2015). A study of rural residing 
LGBT people found that on the basis of sex assigned at birth HPV vaccine initiation was 42% 
for females and 14% for males (Bednarczyk et al., 2017). Vaccination rates have not been 
described with large samples of TGNB people. To our knowledge this is the first study to 
describe HPV vaccination rates in a larger national sample of TGNB people. 
Because ACIP guidelines recommended that only girls to be vaccinated when the vaccine 
was first introduced and boys were added 3 years later, this gender-based lag in policy likely 
decreased uptake in boys which is further compounded with decreased knowledge that the 
vaccine is recommended for all. In our sample, most of the participants had heard of HPV. 
However, studies have shown that SGM people have knowledge deficits regarding HPV 
infection and prevention and the common misconception among sexual minority people and 
transgender people alike is that HPV vaccination is only for women or people with female sex 
organs (Apaydin, Fontenot, Shtasel, et al., 2018). 
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Eight months prior to the launch of our survey, ACIP still recommended a maximum age 
of 26 years for receiving the HPV vaccine and it should be noted that ACIP explicitly added 
transgender people to its recommendation for HPV vaccination for the first time in December 
2016 (Meites, 2019). We performed a sub-analysis of this group and found that they were not at 
increased odds of receipt of vaccination compared to the rest of the sample. We also controlled 
for age in our logistic regression model and found that age less than 27-years old decreased odds 
of vaccination ever and increased odds of vaccine initiation but had no effect on vaccine 
completion among TGNB people compared with cisgender sexual minority people. There may 
also be individuals who received the HPV vaccine who are older than the recommendation. 
Special populations deemed at higher risk of HPV-infection and HPV-associated cancer may 
receive HPV vaccines through shared decision-making with their health care providers like 
people living with HIV and others (Lacey, 2019). 
Our logistic regression modeling showed decreased odds of ever receiving HPV vaccine 
when they searched for information about vaccines in the past year. This is a curious finding 
with multiple possible explanations. This may reflect concerns about the safety or necessity of 
vaccines that is manifested as vaccine hesitancy (Siddiqui et al., 2013). It is possible that the 
individuals that searched for vaccine information are more likely to have vaccine hesitancy. It is 
also possible that the quality of information that individuals encounter when searching for health 
information in general in contrast to vaccine-specific information could affect personal health 
decision-making and receipt of HPV vaccine, especially if the quality of the vaccine information 
is poor or increases anxiety through misinformation. Anti-vaccine Web content, even some 
specific to HPV vaccine have proliferated in recent years and research has shown that pro-HPV 
vaccine online videos on YouTube were 4 times more likely to report accurate information than 
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anti-vaccine videos (Ekram et al., 2019). Conversely, our finding that visiting social networking 
sites like Facebook increased the odds of ever receiving vaccine for TGNB participants is 
notable given the ubiquity and widespread use of social media today. Peer norms have been 
found to be a facilitator for preventative vaccination in sexual minority people and this could 
have implications for vaccination information sharing through social media platforms that have 
growing use among TGNB and SGM communities more broadly (Dahlhamer et al., 2017). 
There have been a limited number of studies that investigate the association of health 
information seeking and vaccination in sexual minority people. A study of men who have sex 
with men (MSM) showed an increase in receipt of HPV vaccine in those who searched online for 
sexual health (Stupiansky et al., 2017). Additional research found that MSM had higher 
perceived benefits of vaccination when they had higher levels of health information orientation 
(Wheldon, Daley, et al., 2018). These findings suggest that online health information seeking 
may represent an avenue for interventions to address HPV vaccine uptake among SGM 
communities. Moreover, an association between health information seeking and vaccination is 
further supported by recent findings that individuals who encounter cultural barriers to access 
care are more likely to seek health information online (Perez et al., 2016). 
Having heard of HPV increased the odds of ever receiving a vaccine which is consistent 
with the literature that has examined knowledge of HPV and vaccination among SGM 
communities (Apaydin, Fontenot, Shtasel, et al., 2018; Gerend, Madkins, Phillips, & Mustanski, 
2016; McRee et al., 2014). The decreased odds of ever receiving vaccine observed when TGNB 
people tracked healthcare charges/costs electronically or made appointments with health care 
providers online are Internet use behaviors would benefit from further investigation. Out-of-
pocket costs for care may be a perceived barrier to individuals who track costs closely. Research 
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has shown that cost of other vaccines is a barrier in sexual minority people (Wheldon et al., 
2017). This would especially be true with lower income individuals who have Medicaid which is 
consistent with our findings of decreased odds of ever receiving HPV vaccine when TGNB 
participants had reported having Medicaid compared to cisgender participants. The association of 
decreased vaccine receipt and online appointment making may be associated with a perceived 
barrier to obtaining care if preventative care appointments are not readily available. Having had 
an HIV test in the past year was associated with increase in ever receiving vaccination, which is 
also consistent with studies that have shown an increase in preventative vaccination in sexual 
minority people when HIV and STI testing was bundled together with vaccination (Cummings et 
al., 2015; Fontenot et al., 2016; Gorbach et al., 2017). 
Comparing TGNB participants and cisgender participants, there were conflicting results 
in vaccine initiation and vaccine completion. Having looked for information on vaccines in the 
past year was associated with an increase in vaccine initiation but not associated with vaccine 
completion. This could possibly be explained by the timing of online searching for vaccine 
information. Individuals that search for vaccine information before they initiate the HPV vaccine 
series may have increased intention to receive the HPV vaccine. However, searching for vaccine 
information may not have been associated with HPV series completion because the information 
received was more critical to the decision to start the series versus continuing to receive it. 
Conversely, searching for general health information was associated with vaccine completion but 
not vaccine initiation which might suggest that the type of information that is received from 
general health information online reinforces the need to complete the HPV vaccine series, or that 
TGNB individuals who regularly search for health information online are more likely to be 
engaged in their care. Having received three-or-more vaccines other than HPV was associated 
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with increased odds of vaccine completion but decreased vaccine initiation among TGNB 
participants compared to cisgender participants. This difference might be reconciled by closer 
examination primary care engagement. On the one hand an individual that received three-or-
more vaccines other than HPV may be highly engaged in their care and reminded to complete all 
doses. However, they might also experience confusion in the dosing schedule if they are also 
receiving other multi-dose vaccinations like hepatitis A/B. Moreover, concerns about multiple 
doses as a barrier to vaccination have been expressed by SGM people in qualitative studies 
exploring HPV vaccination (Apaydin, Fontenot, Shtasel, et al., 2018). Finally, being age 27-
years or younger was associated with an increase in vaccine initiation and a decrease in vaccine 
completion. It is possible that this is related to parent/caregiver deciding to initiate the vaccine 
for an adolescent but difficulty following-through to the second and third dose of the series, 
possibly also from confusion about the schedule, simply forgetting the need to return for 
additional doses, or are in the middle of completing the vaccine series. More study is warranted. 
The greatest effect sizes for increased odds of ever receiving HPV vaccine were observed 
if an individual received three-or-more vaccines other than HPV since they were 18-years old. 
This is consistent with the literature that has demonstrated that when services like HIV testing, or 
other vaccines such as hepatitis A/B are bundled together it can increase vaccine uptake among 
SGM communities (Apaydin, Fontenot, Borba, et al., 2018). 
Although we found no moderating effects of eHealth literacy or general health literacy, 
this is consistent with the high health literacy sample that had generally high eHEALS scores and 
reported little challenges understanding health information. It is likely that the lack of variability 
in health literacy further limited any moderating effects. 




 This study has several strengths. It is the first study to investigate HPV vaccination in a 
large national sample of TGNB people. It leverages an online national cohort of SGM people are 
being followed longitudinally. It is the first study to describe health information seeking and 
health literacy among TGNB people using items from validated instruments and survey items. 
However, the study is not without its limitations. The logistic regression model we investigated 
was informed by theory which was helpful in proposing independent variables of interest. The 
PRIDE Study is a convenience sample and given majority of participants were white and had 
greater than a high school education, our sample is not necessarily representative of TGNB and 
cisgender sexual minority people. Moreover, our primary dependent outcomes receipt of HPV 
vaccination and number of doses received is subject to recall bias which may worsen over time. 
Finally, the cross-sectional nature of the study limits our ability to derive any causal 
relationships. 
Conclusion 
In summary, in our cross-sectional study of online health information seeking and HPV 
vaccination, we found TGNB people had higher prevalence of receipt of HPV vaccine ever 
compared with cisgender sexual minority people. TGNB people who were born with female 
organs or were assigned female at birth, or female sex organs now also reported higher 
prevalence of receipt of vaccine ever and receipt of vaccine completion but not vaccine initiation 
regardless of their current gender identity. These findings suggest disparities in HPV vaccine 
receipt among SGM that mirror the general population with a bias towards people born with 
female organs. We also found seeking online information about vaccines was associated with a 
decreased in receipt of HPV vaccine ever, was associated with vaccine initiation, and but not 
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associated with vaccine completion among TGNB people compared with cisgender sexual 
minority people. We also found that seeking general health information in the past year was 
associated with an increase in vaccine completion but not vaccine initiation or ever receiving 
HPV vaccine. Factors most associated with HPV receipt were having received three-or-more 
vaccines since 18-years old, having heard of HPV, and having visited a social networking site 
like Facebook. We found no moderating effects of general or eHealth literacy. Future studies 
should focus on further exploration of preferences for online health information seeking and 
online social media use as a potential to develop interventions for TGNB and cisgender sexual 
minority people, especially those born with male sex organs to potentially improve the uptake of 
HPV and other vaccines, especially those that require multiple doses over time. 
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Table 5. 1 Comparison groups 
Comparison Group Reference 
A1. TGNB all  




Administrative identification / 
stratified by gender identity  
(A2 ALL and A3 ALL) 
 
CISGENDER (ALL) 
Administrative identification / 
stratified by gender identity  
(A2 ALL and A3 ALL) 
 





SAAB (Female2) AND GENDERID 
(Genderqueer1 OR Transgender man3 




SAAB (Male1) AND GENDERID 
(Genderqueer1 OR Transgender 
woman4 OR Woman5 OR Another 
gender identity6) 
 
A3. Cisgender female 
compared to:  
Cisgender male 
Cisgender Female 




SAAB (Male1) AND GENDERID 
(Man2) 
 
B1. TGNB organs born female 
compared to:  
Cisgender female 
 
GENDERID (Genderqueer1 OR 
Transgender man3 OR Transgender 
woman4 OR Man2 OR Another 
gender identity6) AND 
ORGANS_BORN (cervix1 OR 
ovaries2 OR uterus OR vagina7) 
 
GENDERID (Woman5) AND 
ORGANS_BORN (cervix1 OR 
ovaries2 OR uterus6 OR vagina7) 
B2. TGNB organs born male 
compared to: 
Cisgender male 
GENDERID (Genderqueer1 OR 
Transgender man3 OR Transgender 
woman4 OR Woman5 OR Another 
gender identity6) AND 
ORGANS_BORN (penis3 OR 
prostate4 OR testicles5) 
 
GENDERID (Man2) AND 
ORGANS_BORN (penis3 OR 
prostate4 OR testicles5) 
 
C1. Organs born male + organs 
now female compared to: 
Organs born male + organs now 
male 
ORGANS_BORN  
(penis3 OR prostate4 OR testicles5) 




(cervix1 OR ovaries2 OR uterus6 OR 
vagina7) AND ORGANS_NOW 
(cervix2 OR ovaries3 OR uterus7, 
vagina8) 
   
C2. Organs born female + 
organs now male compared to: 
Organs born male + organs now 
male 
ORGANS_BORN 
(cervix1 OR ovaries2 OR uterus6 OR 
vagina7) AND ORGANS_NOW 
(penis4 OR testicles6) 
 
ORGANS_BORN  
(penis3 OR prostate4 OR testicles5) 
AND ORGANS_NOW  
(penis4 OR prostate5 OR testicles6) 
 
   
D1. TGNB + Organs Now 
Female + AFAB compared to: 
Cisgender + Organs now 
female +AFAB 
GENDERID (Genderqueer1 OR 
Transgender Man3 OR Transgender 
Woman4 OR Another gender 
identity6) AND ORGANS_NOW  
(cervix2 OR ovaries3 OR uterus7 OR 
vagina8) AND SAAB (Female2) 
 
GENDERID (Woman5) AND 
ORGANSNOW (cervix2 OR ovaries3 
OR uterus7 OR vagina8) AND SAAB 
(Female2) 
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Comparison Group Reference 
   
D2. TGNB + Organs Now + 
Assigned Male at Birth 
(AMAB) compared to: 
 
 
GENDERID (Genderqueer1 OR 
Transgender Man3 OR Transgender 
Woman4 OR Another gender 
identity6) AND ORGANS_NOW 
(vagina8) AND SAAB (Male1) 
 
GENDERID (Man2) AND 
ORGANS_NOW (penis4 OR 
prostate5 OR testicles6) AND SAAB 
(Male1) 
E1. Binary Identity 
Transmasculine ALL compared 
to: 
Transfeminine ALL 
GENDERID (Genderqueer1 OR 
Transgender Man3 OR Another 





GENDERID (Man3) AND SAAB 
(Female2) AND LIVEGEN (Man1) 
 
GENDERID (Genderqueer1 OR 
Transgender Man3 OR Another 





GENDERID (Woman5) AND SAAB 
(Male1) AND LIVEGEN (Woman2) 
 
F1. Nonbinary Identity 
Nonbinary + AFAB compared 
to: 
Nonbinary + AMAB 
GENDERID (Genderqueer1 OR 
Another Gender Identity6) OR 
LIVEGEN (Sometimes man / 
sometimes woman3 OR Third gender 
other than man or woman4) AND 
SAAB (Female2) 
 
GENDERID (Genderqueer1 OR 
Another Gender Identity6) OR 
LIVEGEN (Sometimes man / 
sometimes woman3 OR Third gender 




F2. Transgender Nonbinary 
ALL compared to: 
Transgender Binary ALL 
(F1 ALL) (E1 ALL) 
   
AFAB (Assigned Female at Birth) 
AMAB (Assigned Male at Birth) 
SAAB (Sex Assigned at Birth) 
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Characteristic n (%) n (%) n (%) Χ2 p-value 
DEMOGRAPHIC         
Sexual Orientation         
Asexual 353 (10.8) 225 (19.2) 128 (6.1) 132.5 <.0001 
Bisexual 941 (28.9) 382 (32.6) 559 (26.8) 12.3 <.0005 
Gay 1,117 (34.2) 186 (15.9) 931 (44.6) 25.5 <.0001 
Lesbian 698 (21.4) 173 (14.8) 525 (25.2) 48.3 <.0001 
Pansexual 454 (13.9) 256 (21.8) 198 (9.5) 95.5 <.0001 
Queer 1,289 (39.6) 672 (57.3) 617 (29.6) 241.8 <.0001 
Questioning 67 (2.1) 37 (3.2) 30 (1.4) - .0005* 
Same-gender loving 150 (4.6) 71 (6.1) 79 (3.8) 8.8 .0030 
Straight/Heterosexual 60 (1.8) 47 (4.0) 13 (0.6) - <.0001* 
Two-spirit 18 (0.6) 13 (1.1) 5 (0.2) - .0022* 
Another sexual orientation 87 (2.7) 57 (4.9) 30 (1.4) 33.9 <.0001 
Gender Identity         
Genderqueer 599 (18.4) 487 (41.6) 112 (5.4) 654.8 <.0001 
Man 1,091 (33.5) 175 (14.9) 916 (43.9) 283.0 <.0001 
Transgender man 410 (12.6) 407 (34.7) 3 (0.1) 815.8 <.0001 
Transgender woman 165 (5.1) 164 (14.0) 1 (0.1) 303.5 <.0001 
Woman 1,247 (38.3) 75 (6.4) 1,172 (56.2) 787.2 <.0001 
Another gender identity 408 (12.5) 361 (30.8) 47 (2.3) 558.3 <.0001 
Lived gender day-to-day (missing=4)         
Man 1329 (40.8) 415 (35.5) 914 (43.8) 818.1 <.0001 
Woman 1491 (45.8) 335 (28.7) 1156 (55.4)   
Sometimes man/woman* 66 (2) 62 (5.3) 4 (0.2)   
Third gender or something other than man or 
woman 
368 (11.3) 356 (30.5) 12 (0.6)   
Assigned sex at birth         
Male 1,156 (35.5) 241 (20.6) 915 (43.9) 178.0 <.0001 
Female 2,102 (64.5) 931 (79.4) 1,171 (56.1)   
Organs born with         
Cervix 2,104 (64.6) 936 (79.9) 1,168 (56.0) 186.9 <.0001 
Ovaries 1,933 (59.3) 812 (69.3) 1,121 (53.7) 75.1 <.0001 
Penis/Phallus (not prosthetic) 1,942 (59.6) 826 (70.5) 1,116 (53.5) 89.8 <.0001 
Prostate 1,135 (34.8) 223 (19.0) 912 (43.7) 201.6 <.0001 
Testicles 1,090 (33.5) 215 (18.3) 875 (42.0) 187.8 <.0001 










Characteristic n (%) n (%) n (%) Χ2 p-value 
Uterus/Womb 1,086 (33.3) 185 (15.8) 901 (43.2) 253.7 <.0001 
Vagina/Frontal genital opening 1,911 (58.7) 802 (68.4) 1,109 (53.2) 72.1 <.0001 
Organs now         
Breasts or breast tissue 1,945 (59.7) 771 (65.8) 1,174 56.3 28.2 <.0001 
Cervix 1,933 (59.3) 812 (69.3) 1,121 (53.7) 75.1 <.0001 
Penis/Phallus (not prosthetic) 1,952 (59.6) 826 (70.5) 1,116 (53.5) 89.8 <.0001 
Prostate 1,135 (34.8) 223 (19.0) 912 (43.7) 201.6 <.0001 
Testicles 1,090 (33.5) 215 (18.3) 875 (42.0) 187.8 <.0001 
Uterus/Womb 1,086 (33.3) 185 (15.8) 901 (43.2) 253.7 <.0001 
Vagina/Frontal genital opening 1,911 (58.7) 802 (68.4) 1,109 (53.2) 72.1 <.0001 
Race/ethnicity 
(missing=1) 
        
American Indian/Alaska Native 11 (0.3) 6 (0.5) 5 (0.2) 29.2 .0001 
Asian 75 (2.3) 24 (2.1) 51 (2.4)   
Black, African American, African 60 (1.8) 12 (1.0) 48 (2.3)   
Hispanic, Latino, Spanish 73 (2.2) 15 (1.3) 58 (2.8)   
Middle Eastern, North African 9 (0.3) 2 (0.2) 7 (0.3)   
Native Hawaiian, Pacific Islander 0 (0) 0 0 0    
White 2,676 (82.1) 955 (81.6) 1,721 (82.5)   
Other (None fully describe me) 41 (1.3) 21 (1.8) 20 (1.0)   
Mixed (>1 race/ethnicity selected) 312 (9.6) 136 (11.6) 176 (8.4)   
In a Relationship (missing=5)         
Yes 2.,066 (63.5) 732 (62.6) 1,334 (64.0) 0.6 .4281 
No 1,187 (36.5) 437 (37.4) 750 (36.0)   
Legal marital status (missing=5)         
Married 913 (28.1) 261 (22.3) 652 (31.3) 42.2 <.0001 
Legally recognized civil union 4 (0.1) 1 (0.1) 3 (0.1)   
Registered domestic partnership 52 (1.6) 11 (0.9) 41 (2.0)   
Widowed 27 (0.8) 6 (0.5) 21 (1.0)   
Divorced 241 (7.4) 99 (8.5) 142 (6.8)   
Separated 31 (1.0) 15 (1.3) 16 (0.8)   
Single, never married 1,985 (61.0) 776 (66.4) 1,209 (58.0)   
Work in one or more paid jobs?         
Yes 2,430 (74.7) 824 (70.4) 1,606 (77.1) 17.7 <.0001 
No 823 (25.3) 346 (29.6) 477 (22.9)   
Occupation         
Employed >=40 hr/wk 1,558 (47.8) 468 (40.0) 1,090 (52.3) 121.0 <.0001 










Characteristic n (%) n (%) n (%) Χ2 p-value 
Employed 1-39 hr/wk 448 (13.8) 198 (16.9) 250 (12.0)   
Temporarily employed 26 (0.8) 9 (0.8) 17 (0.8)   
Self-employed 148 (4.5) 46 (3.9) 102 (4.9)   
Not employed, looking 122 (3.8) 63 (5.4) 59 (2.8)   
Not employed, not looking 41 (1.3) 22 (1.9) 19 (0.9)   
Homemaker 40 (1.2) 20 (1.7) 20 (1.0)   
Student full time  500 (15.4) 212 (18.1) 288 (13.8)   
Student part time 60 (1.8) 32 (2.7) 28 (1.3)   
Disabled, not able to work 151 (4.6) 76 (6.5) 75 (3.6)   
Retired 163 5.0) 25 (2.1) 138 (6.6)   
Income 2019 tax year (missing=71)         
$0 158 (5.0) 83 (7.3) 75 (3.7) 195.4 <.0001 
$1 – 10,000 511 (16.0) 266 (23.3) 245 (12.0)   
$10,001 – 20,000 348 (10.9) 157 (13.7) 191 (9.4)   
$20,001 – 30,000 341 (10.7) 141 (12.3) 200 (9.8)   
$30,001 – 40,000 376 (11.8) 138 (12.1) 238 (11.7)   
$40,001 – 50,000 265 (8.3) 92 (8.0) 173 (8.5)   
$50,001 – 60,000 238 (7.5) 67 (5.9) 171 (8.4)   
$60,001 – 70,000 171 (5.4) 40 (3.5) 131 (6.4)   
$70,001 – 80,000 149 (4.7) 38 (3.3) 111 (5.4)   
$80,001 – 90,000 113 (3.6) 26 (2.3) 87 (4.3)   
$90,001 – 100,000 97 (3.0) 21 (1.8) 76 (3.7)   
$100,000+ 420 (13.2) 75 (6.6) 345 (16.9)   
Education attainment         
High school or less 145 (4.5) 74 (6.3) 71 (3.4) 14.9 .0001 
More than high school 3113 (95.5) 1,098 (93.7) 2,015 (96.6)   
         
SITUATION – BARRIERS TO CARE         
Less than 50% health care providers aware of 
your sexual orientation 
942 (28.1) 373 (31.8) 569 (27.3) 7.6 .0060 
Less than 50% health care providers aware of 
your gender identity 
584 (39.4) 378 (32.5) 206 (64.6) 107.6 <.0001 
Delayed medical care in past year (missing=1) 1,019 (31.3) 508 (43.3) 511 (24.5) 123.8 <.0001 
Did not see provider because thought would be 
disrespected / mistreated in past year 
574 (17.6) 367 (31.3) 207 (9.9) 236.6 <.0001 
         
SITUATION – ACCESS TO CARE         










Characteristic n (%) n (%) n (%) Χ2 p-value 
Have PCP (missing=45) 2,709 (84.3) 944 (82.0) 1,765 (85.6) 7.2 .0074 
Saw PCP in past year (missing=571) 2,397 (89.2) 848 (91.1) 1,549 (88.2) 5.2 .0224 
Went to provider/clinic for transgender care in 
past year (missing=17) 
693 (21.4) 679 (58.4) 14 (0.7) 1477.3 <.0001 
Have health insurance (missing=13) 3,103 (95.6) 1,096 (94.2) 2,007 (96.4) 8.3 .0039 
Type of health insurance          
Medicaid/Medicare 437 (13.4) 173 (14.8) 264 (12.7) 3.2 .1983 
Private Insurance 2,637 (80.9) 930 (79.4) 1,707 (81.8)   
Other 184 (5.7) 69 (5.9) 115 (5.5)   
Ever used hormones or medication for gender 
affirmation (missing=2) 
703 (21.6) 691 (98.3) 12 (0.6) - <.0001* 
Currently using hormones or medications for 
gender affirmation (missing=2,555) 
642 (91.3) 639 (92.5) 3 (25) - <.0001* 
         
SITUATION – PREVENTIVE CARE         
Health in general (PROMIS-1)         
Excellent 342 (10.5) 80 (6.8) 262 (12.6) 93.0 <.0001 
Very good 1,271 (39.0) 394 (33.6) 877 (42.0)   
Good 1,084 (33.3) 414 (35.3) 670 (32.1)   
Fair 460 (14.1) 228 (19.5) 232 (11.1)   
Poor 101 (3.1) 56 (4.8) 45 (2.2)   
Had HIV test in past year (missing=50) 1,219 (38.0) 438 (38.2) 781 (37.9) 0.04 .8474 
HIV status         
Seronegative 2,923 (89.7) 1,077 (91.9) 1,846 (88.5) - <.0001* 
Seropositive 129 (4.0) 8 (0.7) 121 (5.8)   
Don’t know status 206 (6.3) 87 (7.4) 119 (5.7)   
Ever had a vaccine other than HPV?         
Yes 3,136 (96.3) 1,114 (95.1) 2,022 (96.9) - .0072* 
No 90 (2.8) 39 (3.3) 51 (2.4)   
Don’t know 32 (1.0) 19 (1.6) 13 (0.6)   
Preventive vaccines since 18-years old 
(missing=122) 
        
None 82 (2.6) 32 (2.9) 50 (2.5) 25.9 <.0001 
1-2 vaccines 287 (9.2) 125 (11.2) 162 (8.0)   
3 or more vaccines 2,531 (80.7) 847 (76.0) 1,684 (83.3)   
Don’t know         
         










Characteristic n (%) n (%) n (%) Χ2 p-value 
Ever had a cervical Pap?         
Yes 1,675 (51.6) 679 (58.2) 996 (47.9) 154.3 <.0001 
No 613 (18.9) 293 (25.1) 320 (15.4)   
NA – don’t have a cervix 959 (29.5) 195 (16.7) 764 (36.7)   
HPV test with recent Pap (missing 2,156)         
Yes 909 (82.5) 360 (83.5) 549 (81.8) 0.5 .4665 
No 193 (17.5) 71 (16.5) 122 (18.2)   
Ever had anal/rectal cancer screening (DRE, 
anal Pap, etc.) (missing=99) 
        
Yes 907 (28.7) 214 (19.0) 693 (34.1) 81.3 <.0001 
No 2,252 (71.3) 914 (81.0) 1,338 (65.9)   
INTERNET USE         
See Table 5.3 Health Information Seeking          
         
HEALTH LITERACY         
How confident are you filling out medical 
forms by yourself? (missing=17) 
        
Not at all 14 (0.4) 9 (0.8) 5 (0.2) 86.5 <.0001 
A little bit 47 (1.5) 31 (2.7) 16 (0.8)   
Somewhat 260 (8.0) 117 (10.0) 143 (6.9)   
Quite a bit 965 (29.8) 421 (46.1) 544 (26.2)   
Extremely 1,955 (60.3) 588 (50.4) 1,367 (65.9)   
How often have problems difficulty 
understanding written communication? 
(missing=15) 
        
Never 2,330 (71.9) 753 (64.5) 1,577 (76.0) - <.0001* 
Occasionally 660 (20.4) 285 (24.4) 375 (18.1)   
Sometimes 215 (6.6) 103 (8.8) 112 (5.4)   
Often 34 (1.1) 23 (2.0) 11 (2.0)   
Always 4 (0.1) 4 (0.3) 0 0   
How often need help to read written material 
from doctor/pharmacy? 
        
Never 2,840 (87.4) 971 (83.3) 1,869 (89.8) - <.0001 
Occasionally 311 (9.6) 138 (11.8) 173 (8.3)   
Sometimes 74 (2.3) 39 (3.3) 35 (1.7)   
Often 16 (0.5) 12 (1.0) 4 (0.2)   
Always 7 (0.2) 6 (0.5) 1 (0.1)   









 Range Mean (SD) Mean (SD) Mean (SD) t-test  p-value 
eHEALTH LITERACY          
eHEALS Score 8 – 40 33.5 4.8 32.9 4.8 33.9 4.8 3256 <.0001 
          
Age+ 18 – 98 35.9 14.2 31.7 11.6 38.2 14.9 3256 <.0001 
*Fishers Exact Test for cells <30 
+Age Median = 31 (interquartile range [IQR 25-43]) 
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Table 5. 3 Health Information Seeking 







Characteristic n (%)  n (%) n (%) Χ2 p-value 
INFORMATION SEEKING          
Ever looked for health info or medical 
topics from any source? 
         
Yes 3,134 (96.2)  1,126 (96.1) 2,008 (96.3) 0.1 .7903 
No          
          
The most recent time looked for health 
info or medical topics where did you 
go first? 
         
Books 17 (0.5)  6 (0.5) 11 (0.6) 8.9 .6315 
Brochures 16 (0.5)  5 (0.4) 11 0.6)   
Medical organization 172 (5.5)  6 (5.4) 111 (5.5)   
Family 70 (2.2)  22 (2.0) 48 (2.4)   
Friend/Co-worker 35 (1.1)  18 (1.6) 17 (0.9)   
Doctor or health care provider 305 (9.7)  103 (9.2) 202 (10.1)   
Internet 2,447 (78.1)  891 (79.1) 1,556 (77.5)   
Library 20 (0.6)  7 (0.6) 13 (0.7)   
Magazines 13 (0.4)  3 (0.3) 10 (0.5)   
Newspapers 13 (0.1)  2 (0.2) 11 (0.6)   
Telephone info number 4 (0.1)  1 (0.1) 3 (0.2)   
Complementary, alternative of 
unconventional practitioner 
21 (0.7)  7 (0.6) 14 (0.7)   
          
The most recent time you look for 
health info or medical topics, who was 
it for? 
         
Myself 1 2323 (74.2)  888 (79.0) 1,435 (71.6) 23.0 <.0001 
Someone else 2 383 (12.2)  102 (9.1) 281 (14.0)   
Both myself and someone else 3 423 (13.5)  134 (11.9) 289 (14.4)   
          
Based on results of your most recent 
search… 
         
Took a lot of effort to get info needed          
Strongly agree 1 205 (6.6)  118 (10.5) 87 (4.3) 81.6 <.0001 
Somewhat agree 2 1,048 (33.5)  419 (37.2) 629 (31.4)   
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Characteristic n (%)  n (%) n (%) Χ2 p-value 
Somewhat disagree 3 1,232 (39.4)  424 (37.7) 808 (40.3)   
Strongly disagree 4 646 (20.6)  164 (14.6) 482 (24.0)   
Felt frustrated during your search for 
info 
         
Strongly agree 1 309 (9.9)  166 (14.8) 143 (7.1) 103.2 <.0001 
Somewhat agree 2 1,025 (32.7)  430 (38.2) 595 (29.7)   
Somewhat disagree 3 1,026 (32.8)  336 (29.9) 690 (34.4)   
Strongly disagree 4 772 (24.7)  193 (17.2) 579 (28.9)   
          
How confident that could get advice or 
info about health topics if needed it 
         
Completely confident 1 1,010 (31.0)  263 (22.4) 747 (35.8) 85.8 <.0001 
Very confident 2 1,244 (38.2)  452 (38.6) 792 (38.0)   
Somewhat confident 3 853 (26.2)  380 (32.4) 473 (22.7)   
A little confident 4 117 (3.6)  58 (5.0) 59 (2.8)   
Not confident at all 5 34 (1.0)  19 (1.6) 15 (0.7)   
          
In general, how much would you trust 
info about health or medical topics 
such as info about vaccines from each 
of the following… 
         
          
Doctor or medical provider          
A lot 1 2,569 (78.9)  853 (72.8) 1,716 (82.3) - <.0001* 
Some 2 614 (18.9)  280 (23.9) 334 (16.0)   
A little 3 68 (2.1)  37 (3.2) 31 (1.5)   
Not at all 4 7 (0.2)  2 (0.2) 5 (0.2)   
          
Family or friends          
A lot 1 155 (4.8)  52 (4.4) 103 (4.9) 4.2 .2413 
Some 2 1,635 (50.2)  566 (48.3) 1,069 (51.3)   
A little 3 1,270 (39.0)  476 (40.6) 794 (38.1)   
Not at all 4 196 (6.0)  78 (6.7) 118 (5.7)   
          
Government health agencies          
A lot 1 1,271 (39.1)  388 (33.2) 883 (42.4) 34.7 <.0001 
Some 2 1,516 (46.6)  577 (49.3) 939 (45.0)   
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Characteristic n (%)  n (%) n (%) Χ2 p-value 
A little 3 394 (12.1)  166 (14.2) 228 (10.9)   
Not at all 4 74 (2.3)  39 (3.3) 35 (1.7)   
          
          
Charitable organizations (missing=5)          
A lot 1 248 (7.6)  85 (7.3) 163 (7.8) 27.1 <.0001 
Some 2 1,656 (50.9)  530 (45.3) 1,126 (54.0)   
A little 3 1,052 (32.3)  436 (37.3) 616 (29.6)   
Not at all 4 297 (9.1)  118 (10.1) 179 (8.6)   
          
Religious organizations and leaders 
(missing=3) 
         
A lot 1 12 (0.4)  5 (0.4) 7 (0.3) 21.7 <.0001 
Some 2 159 (4.9)  33 (2.8) 126 (6.0)   
A little 3 580 (17.8)  190 (16.2) 390 (18.7)   
Not at all 4 2,504 (76.9)  942 (80.5) 1,562 (74.9)   
          
The Internet          
A lot 1 191 (5.9)  60 (5.1) 131 (6.3) 4.3 .2307 
Some 2 1,744 (53.6)  614 (52.4) 1,130 (54.2)   
A little 3 1,202 (36.9)  456 (38.9) 746 (35.8)   
Not at all 4 119 (3.7)  41 (3.5) 78 (3.7)   
          
If had a strong need for info about 
health or medical topics like vaccines, 
where would go first? 
         
Books 13 (0.4)  5 (0.4) 8 (0.4) 11.1 .3468* 
Brochures 6 (0.2)  1 (0.1) 5 (0.2)   
Medical organization 320 (9.8)  125 (10.7) 195 (9.4)   
Family 49 (1.5)  12 (1.0) 37 (1.8)   
Friend/Co-worker 22 (0.7)  8 (0.7) 14 (0.7)   
Doctor or health care provider 815 (25.0)  269 (23.0) 546 (26.2)   
Internet 1,854 (56.9)  688 (58.7) 1,166 (55.9)   
Library 21 (0.6)  10 (0.9) 11 (0.5)   
Magazines - -        
Newspapers 2 (0.1)  1 (0.1) 1 (0.1)   
Telephone info number -         
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Characteristic n (%)  n (%) n (%) Χ2 p-value 
Complementary, alternative or 
unconventional practitioner 
10 (0.3)  4 (0.3) 6 (0.3)   
Other 146 (4.5)  49 (4.2) 97 (4.7)   
          
          
          
          
Looked for info about vaccines from 
any source 
2,265 (69.5)  816 (69.6) 1,449 (69.5) .0092 .9234 
          
Gone online to access the Internet, 
WWW or send & receive email 
3,249 (99.7)  1,167 (99.6) 2,082 (99.8) 1.5 .2203 
          
When using the Internet, access 
through… 
         
Regular dial-up telephone line 
(missing=13) 
15 (0.5)  8 (0.7) 7 (0.3) 2.0 .1592 
          
Broadband such as DSL, cable or 
FiOS (missing=23) 
1,959 (60.6)  637 (55.0) 1,322 (63.7) 23.7 <.0001 
          
Cellular network (i.e., phone, 
3G/4G) (missing=20) 
3,089 (95.4)  1,127 (96.8) 1,962 (94.6) 8.4 .0038 
          
Wireless network (Wi-Fi) 
(missing=11) 
         
          
Used the Internet to look for info 
about vaccines for yourself in past 12-
months (missing=9) 
1,068 (32.9)  366 (31.4) 702 (33.7) 1.9 .1704 
          
How often access the Internet through 
each… 
         
Computer at home (missing=10)          
Daily 1 2,313 (71.2)  820 (70.3) 1,493 (71.7) 6.6 .0841 
Sometimes 2    299 (25.6) 506 (24.3)   
Never 3    11 (0.9) 36 (1.7)   
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Characteristic n (%)  n (%) n (%) Χ2 p-value 
Not Applicable 4    37 (3.2) 46 (2.2)   
          
Computer at work (missing=15)          
Daily 1 1,894 (58.4)  585 (50.3) 1,309 (63.0) 50.9 <.0001 
Sometimes 2 342 (10.6)  139 (11.9) 203 (9.8)   
Never 3 151 (4.7)  63 (5.4) 88 (4.2)   
Not Applicable 4 856 (26.4)  377 (32.4) 479 (23.0)   
          
Computer in a public place (library, 
community center, other) 
(missing=13) 
         
Daily 1 53   21 (1.8) 32 (1.5) 28.1 <.0001 
Sometimes 2 1,008   428 (36.7) 580 (27.9)   
Never 3 1,892   620 (53.2) 1,272 (61.2)   
Not Applicable 4 292   97 (8.3) 195 (9.4)   
          
On a mobile device (cell phone / 
smartphone / tablet) (missing=10) 
         
Daily 1 3,031 (93.3)  1,098 (94.1) 1,933 (92.9) 6.6 <.0826 
Sometimes 2 175 (5.4)  58 (5.0) 117 (5.6)   
Never 3 27 (0.8)  4 (0.3) 23 (1.1)   
Not Applicable 4 15 (0.5)  7 (0.6) 8 (0.4)   
          
Used a computer, smartphone, or other 
electronic means in past 12 months 
to… 
         
Look for health or medical info for 
yourself 
3,170 (97.3)  1,153 (98.4) 2,017 (96.7) 8.1 .0044 
          
Bought medicine or vitamins online 
(missing=2) 
1,448 (44.5)  492 (42.0) 956 (45.9) 4.6 .0319 
          
Used e-mail or Internet to 
communicate with a doctor or 
doctor’s office (missing=4) 
2,701 (83.0)  1,009 (86.2) 1,692 (81.2) 13.0 .0003 
          
Tracked healthcare charges and costs 2,303 (70.8)  859 (73.5) 1,444 (69.3) 6.6 .0105 
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Characteristic n (%)  n (%) n (%) Χ2 p-value 
(missing=6) 
          
Looked up medical test results 
(missing=4) 
2,560 (78.7)  927 (79.2) 1,633 (78.4) .3395 .5601 
          
Made appointment with a healthcare 
provider (missing=3) 
2,555 (78.5)  931 (79.6) 1,624 (77.9) 1.4 .2335 
          
Looked for info about the side-
effects of medicines or vaccines 
(missing=1) 
2,570 (78.9)  966 (82.4) 1,604 (76.9) 13.6 .0002 
          
Please indicate if you have each of the 
following… 
         
Tablet computer (e.g., Apple iPad, 
Samsung Galaxy, Motorola Xoom, 
or Kindle Fire) 
1,696 (52.1)  511 (43.6) 1,185 (56.8) 52.4 <.0001 
          
Smartphone (e.g., Apple iPhone, 
Android phone, Blackberry, or 
Windows phone) 
3,206 (98.4)  1,155 (98.6) 2,051 (98.3) 0.2 .6192 
          
Basic cell phone only 50 (1.5)  19 (1.6) 31 (1.5) - .7679* 
          
Do not have any of the above 10 (0.3)  4 (0.3) 6 (0.3) - .2426 
          
Have apps related to health or wellness 
on tablet/smartphone (missing=26) 
         
Yes 1 2,640 (81.7)  935 (80.5) 1,705 (82.4) 1.8 .4049 
No 2 568 (17.6)  218 (18.8) 350 (16.9)   
Don’t Know 3 24 (0.7)  9 (0.8) 15 (0.7)   
          
Has tablet or smartphone…          
Helped track progress on health-
related goal like quitting smoking, 
losing weight, or increasing physical 
activity? (missing=27) 
2,093 (64.8)  718 (61.8) 1,375 (66.4) 6.8 .0089 
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Characteristic n (%)  n (%) n (%) Χ2 p-value 
          
Helped you make a decision about 
how to treat an illness or condition? 
(missing=28) 
1,340 (41.5)  468 (40.3) 872 (42.2) 1.0 .3096 
          
Helped you in discussions with your 
health care provider? (missing=30) 
1,906 (59.1)  709 (61.2) 1,197 (57.9) 3.4 .0658 
          
Used an electronic wearable device to 
monitor/track your health or activity 
(e.g. FitBit, Apple iWatch, or Garmin 
Vivofit) (missing=1) 
1,293 (39.7)  382 (32.6) 911 (43.7) 38.3 <.0001 
          
How often did you use wearable 
device to track your health in past 
month? 
         
Every day 1 718 (55.5)  200 (52.4) 518 (56.9) 10.7 .0307 
Almost every day 2 280 (21.7)  77 (20.2) 203 (22.3)   
1-2 times per week 3 76 (5.9)  30 (7.9) 46 (5.1)   
Less than once per week 4 72 (5.6)  19 (5.0) 53 (5.8)   
Did not use device past month 5 147 (11.4)  56 (14.7) 91 (10.0)   
          
Would you be willing to share health 
data from your wearable device 
with… 
         
Healthcare provider (missing=1,965) 1,111 (85.9)  321 (84.0) 789 (86.7) 1.5 .2252 
          
Family and friends (missing=1,965) 770 (59.6)  215 (56.2) 555 (60.9) 2.4 .1210 
          
Used an electronic monitoring device 
to monitor or track your health (e.g., 
glucometer, or digital BP device) 
(missing=2) 
2,654 (81.5)  209 (17.9) 393 (18.9) 0.5 .4802 
          
Shared health info from either 
electronic monitoring device or 
smartphone with a health professional 
692 (21.2)  253 (21.6) 439 (21.1) 0.1 .7268 
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Characteristic n (%)  n (%) n (%) Χ2 p-value 
in past 12-months (missing=2) 
          
Used Internet for any of the 
following reasons in past 12-
months… 
         
To visit a social networking site, 
such as Facebook or Linked In 
3,141 (96.4)  1,128 (96.3) 2,013 (96.5) .1407 .7076 
          
To share health info on social 
networking sites such as Facebook, 
Twitter, or Instagram (missing=1) 
1,082 (33.2)  448 (38.2) 634 (30.4) 20.9 <.0001 
          
To write in an online diary or blog 
(i.e. Web log) (missing=1) 
561 (17.2)  288 (24.6) 273 (13.1) 69.3 <.0001 
          
To participate in an online forum or 
support group for people with a 
similar health or medical issue 
(missing=2) 
983 (30.2)  537 (45.8) 446 (21.4) 212.2 <.0001 
          
To watch a health-related video on 
YouTube or other online video 
streaming service (missing=1) 
1,722 (52.9)  704 (60.1) 1,018 (48.8) 38.6 <.0001 
          
Sent or received a text message from a 
doctor or other health care 
professional in the past 12-months 
         
Yes 1 1,801 (55.3)  679 (57.9) 1,122 (53.8) 11.6 .0030 
No 2 1,381 (42.4)  457 (39.0) 924 (44.3)   
Don’t know 3 76 (2.3)  36 (3.1) 40 (1.9)   
          
How useful do you feel the Internet is 
in helping you make decisions about 
your health? (missing=1) 
         
Very useful 5 733 (22.5)  287 (24.5) 446 (21.4) 48 .3066 
Useful 4 2,033 (62.4)  707 (60.4) 1,326 (63.6)   
Unsure 3 394 (12.1)  140 (12.0) 254 (12.2)   
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Characteristic n (%)  n (%) n (%) Χ2 p-value 
Not useful 88 (2.7)  34 (2.9) 54 (2.6)   
Not Useful at all 9 (0.3)  3 (0.3) 6 (0.3)   
          
          
How important is it for you to be able 
to access health resources on the 
Internet? (missing=1) 
         
Very important 5          
Important 4 1,771 (54.4)  673 (57.5) 1,098 (52.7) 8.0 .0928 
Unsure 3 1,264 (38.9)  430 (36.7) 831 (40.0)   
Not important 2 153 (4.7)  46 (3.9) 107 (5.1)   
No important at all 1 62 (1.9)  20 (1.7) 42 (2.0)   
 6 (0.2)  2 (0.2) 4 (0.2)   
          
*Fishers exact test for cell size <30 
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Table 5. 4 HPV Vaccine & Number of Doses 







Item n (%) n (%) n (%) Χ2 p-value 
         
Ever received HPV vaccine?         
Yes 1,528 (46.9) 654 (55.8) 874 (41.9) 70.3 <.0001 
No 1,446 (44.4) 412 (35.2) 1,034 (49.6)   
Doctor refused when asked 109 (3.4) 33 (2.8) 76 (3.7)   
I don’t know 174 (5.3) 73 (6.2) 101 (4.8)   
         
Reported doses ever received 
HPV vaccine (missing=1) 
        
HPV Vaccine [1-dose] 121 (7.9) 56 (8.6) 65 (7.5) 18.8 .0009 
HPV Vaccine [2-doses] 197 (12.9) 87 (13.3) 110 (12.6)   
HPV Vaccine [3-doses] 1,004 (65.8) 401 (61.3) 603 (69.1)   
Don’t know / cannot recall 201 (13.2) 110 (16.9) 91 (10.4)   
         
 
Table 5. 5 HPV Knowledge  







Item n (%) n (%) n (%) Χ2 p-value 
         
Ever heard of HPV? (missing=1)         
Yes 3,053 (93.7) 1,107 (94.5) 1,946 (93.3) 3.3 .1913 
No 176 (5.4) 53 (4.5) 123 (5.9)   
I don’t know 28 (0.9) 12 (1.0) 16 (0.8)   
         
 
        
128 
 
Table 5. 6 Receipt of HPV Vaccine 
 Total Group Ref   
Group / Receipt of Vaccine n (%) n (%) n (%) PR 95% CI 
A1. Transgender ALL vs Cisgender ALL   TGNB Cisgender   
Received HPV vaccine (ever) 1,528 (49.6) 654 (59.5) 874 (44.1) 1.3 1.3-1.4 
         
Initiated/Completed (n=1,322)         
  Initiated (1-dose) 121 (7.9) 56 (8.6) 65 (7.5) 1.2 0.8-1.6 
  Completed (3-doses) 1,004 (76.0) 401 (73.7) 603 (77.5) 0.9 0.8-1.0 
         





Received HPV vaccine (ever) 1,239 (38.1) 656 (65.7) 81 (33.8) 2.0 1.6-2.3 
         
Initiated/Completed (n=611)         
  Initiated (1-dose) 64 (10.5) 51 (9.4) 13 (19.7) 0.5 0.3-0.9 
 Completed (3-doses)  453 (74.1) 409 (75.1) 44 (66.7) 1.1 0.9-1.4 
         





Received HPV vaccine (ever) 1,984 (61.0) 647 (57.5) 227 (26.4) 2.2 1.9-2.5 
Initiated/Completed (n=778)         
  Initiated (1-dose) 65 (8.4) 21 (10.2) 44 (7.7) 0.7 0.5-1.2 
  Completed (3-doses) 603 (77.5) 144 (69.9) 459 (80.2) 1.1 1.0-1.2 
1.4         
B1. Gender Identity + Organs Born With   TGNB 
Organs Born Female 
Cisgender Female 
Organs Born Female 
  
Received HPV vaccine (ever) 2,014 (61.8) 586 (66.1) 647 (57.4) 1.2 1.1-1.2 
         
Initiated/Completed (n=1,060)         
  Initiated (1-dose) 88 (8.3) 44 (9.0) 44 (7.7) 1.1 0.7-1.7 
  Completed (3-doses) 822 (77.6) 363 (74.4) 459 (80.2) 0.9 0.8-0.9 
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 Total Group Ref   
Group / Receipt of Vaccine n (%) n (%) n (%) PR 95% CI 
B2. Gender Identity + Organs Born With 
 
  TGNB 
Organs Born Male 
Cisgender Male 
Organs Born Male 
  
Received HPV vaccine (ever) 1,079 (33.1) 70 (32.0) 227 (26.4) 1.2 1.0-1.5 
         
Initiated/Completed (n=264)         
  Initiated (1-dose) 33 (12.5) 12 (20.7) 21 (10.2) 1.9 1.0-3.6 
  Completed (3-doses) 183 (69.3) 39 (67.2) 144 (69.9) 0.9 0.7-1.1 
         
C1. Organs Born With 
 
  Organs Born Female 
Organs Now Male 
Organs Born Female 
Organs Now Female 
  
Received HPV vaccine (ever)  2,003 (61.5) 7 (36.8) 1,220 (61.5) 0.6 0.3-1.1 
         
Initiated/Completed (n=1,055)         
  Initiated (1-dose) 88 (8.3) 0 (0) 88 (8.4)   
  Completed (3-doses) 817 (77.4) 4 (80.0) 813 (77.4) 0.9 0.5-1.6 
         
C2. Organs Born With   Organs Born Male 
Organs Now Female 
Organs Born Male 
Organs Now Male 
  
Received HPV vaccine (ever) 1,076 (33.0) 2 (11.8) 294 (27.8) 0.4 0.1-1.6 
         
Initiated/Completed (n=263)         
  Initiated (1-dose) 33 (12.6) 1 (50.0) 32 (12.3) 4.6 1.1-19.1 
  Completed (3-doses) 182 (69.2) 1 (50.0) 181 (69.4) 0.8 0.2-3.2 
         
D1. Gender Identity + Organs Now + SAAB   TGNB 
Organs Now Female 
AFAB 
Cisgender 
Organs Now Female 
AFAB 
  
Received HPV vaccine (ever) 1,964 (60.3) 562 (66.9) 646 (57.5) 1.2 1.1-1.3 
         
Initiated/Completed (n=1,039)         
  Initiated (1-dose) 88 (8.5) 44 (9.4) 44 (7.7) 1.2 0.8-1.7 
  Completed (3-doses) 803 (77.3) 345 (73.7) 458 (80.2) 0.9 0.8-0.9 
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 Total Group Ref   
Group / Receipt of Vaccine n (%) n (%) n (%) PR 95% CI 
D2. Gender Identity + Organs Now + SAAB   TGNB 
Organs Now Male 
AMAB 
Cisgender 
Organs Now Male 
AMAB 
  
Received HPV vaccine (ever) 898 (27.6) 10 (25.6) 227 (26.4) 1.0 0.6-1.7 
         
Initiated/Completed (n=215)         
  Initiated (1-dose) 24 (11.2) 3 (33.3) 21 (10.2) 3.2 1.2-9.1 
  Completed (3-doses) 148 (68.8) 4 (44.4) 144 (69.9) 0.6 0.3-1.4 
         
E1. Transgender Binary Identity 
 
  Transmasculine Transfeminine   
Received HPV vaccine (ever) 732 (22.5) 232 (60.4) 197 (56.6) 1.1 0.9-1.2 
         
Initiated/Completed (n=357)         
Initiated (1-dose) 39 (10.9) 16 (8.4) 23 (13.9) 0.6 0.3-1.1 
Completed (3-doses) 257 (72.0) 137 (71.7) 120 (72.3) 1.0 0.8-1.1 
         





Received HPV vaccine (ever) 826 (25.4) 483 (67.5) 47 (42.7) 1.6 1.3-2.0 
         
Initiated/Completed (n=440)         
Initiated (1-dose) 41 (9.3) 36 (8.9) 5 (13.5) 0.7 0.3-1.7 
Completed (3-doses) 331 (75.2) 304 (75.4) 27 (73.0) 1.1 0.9-1.4 
         
F2. Trans Nonbinary Identity ALL vs Trans 
Binary Identity ALL 





Received HPV vaccine (ever) 1,558 (47.8) 530 (64.1) 429 (51.9) 1.2 1.1-1.3 
         
Initiated/Completed (n=797)         
Initiated (1-dose) 80 (10.0) 41 (9.3) 39 (10.9) 0.8 0.5-1.3 
Completed (3-doses) 588 (73.8) 331 (75.2) 257 (72.0) 1.1 1.0-1.2 
AFAB (Assigned Female at Birth), AMAB (Assigned Male at Birth), SM (Sexual Minority) 
Robust Poisson method used to calculate PR (Prevalence Ratio) 
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Table 5. 7 Bivariate Analysis 








Item n (%) n (%) Χ2 p-value 
       
GENDER IDENTITY (missing=93)       
TGNB 654 (59.5) 445 (40.5) 67.6 <.0001 
CISGENDER 874 (44.1) 1,110 (56.0)   
(GROUP_A1)       
       
HEALTH INFORMATION SEEKING        
Used computer, smartphone, other electronic 
means to look for health or medical info in 
past year (HINTS_B5a_N) (missing=175) 
1,504 (50.1) 1,499 (49.9) 12.6 .0004 
       
Used Internet to look for info about vaccines 
in past year (HINTS_B3_N) (missing=183) 
484 (47.0) 546 (53.0) 4.2 .0405 
       
KNOWLEDGE/BELIEFS       
Heard of HPV 1,466 (50.6) 1,431 (49.4) 17.0 <.0001 
       
INTERNET USE (past year)       
Visited a social networking site such as 
Facebook or LinkedIn in (HINTS_B14a_N) 
(missing=175) 
1,500 (50.5) 1,472 (49.5) 27.3 <.0001 
       
Shared health info on social networking sites 
(e.g. Facebook, Twitter, or Instagram) 
(HINTSB14b_N) (missing=176) 
520 (50.9) 502 (49.1) 1.1 .2965 
       
Wrote in online diary or BLOG (i.e., Web 
log) (HINTS_B14c_N) (missing=176) 
279 (53.9) 239 (46.1) 4.6 .0326 
       
Participated in an online forum or support 
group for people with a similar health or 
medical issue (HINTS_B14d_N) 
(missing=177) 
466 (50.6) 455 (49.4) 0.5 .4672 
       
Watched a health-related video on YouTube 
or other online video streaming service 
(HINTS_B14e) (missing=176) 
842 (51.9) 779 (48.1) 7.7 .0057 
       
Used computer, smartphone, other electronic 
means to…(HINTS_B5) 
      
Purchase medications online (HINTS_B5b) 
(missing=176) 
619 (45.0) 757 (55.0) 20.7 <.0001 
       
Email doctor’s office (HINTS_B5c) 
(missing=179) 
1,294 (50.5) 1,269 (49.5) 4.9 .0271 
       
Track healthcare charges/costs (HINTS_B5d) 
(missing=180) 
1,147 (52.4) 1,043 (47.6) 23.2 <.0001 










Item n (%) n (%) Χ2 p-value 
       
       
Look up test results (HINTS_B5e) 
(missing=177) 
1,189 (48.5) 1,262 (51.5) 5.6 .0177 
       
Make appointments with healthcare 
providers (HINTS_B5f) (missing=178) 
1,269 (52.5) 1,150 (47.5) 39.2 <.0001 
       
Look-up info on side-effects of 
medications/vaccines (HINTS_B5g) 
(missing=176) 
1,225 (50.4) 1,208 49.7) 2.7 .0973 
       
SITUATION – BARRIERS TO CARE 
(past year) 
      
       
Were delayed in getting medical care, tests or 
treatments you or health care provider 
believed necessary (DELAYCARE) 
(missing=176) 
546 (56.5) 421 (43.5) 26.7 <.0001 
       
Needed to see a health care provider but did 
not because thought would be disrespected or 
mistreated (ANTMEDDISC) (missing=175) 
332 (61.1) 211 (38.9) 35.4 <.0001 
       
Less than 50% health care providers aware of 
Sexual Orientation (NOS_SM6_N) 
(missing=175) 
509 (58.1) 1,019 (46.2) 35.7 <.0001 
       
Less than 50% health care providers aware of 
Gender Identity (NOS_GM6_N) 
(Exclude=1,777 not gender minority) 
322 (59.0) 450 (53.4) 4.1 .0428 
       
SITUATION – ACCESS TO CARE       
Have a Primary Care Provider (PCP_N) 
(missing=214) 
1,224 (47.4) 1,361 (52.7) 26.3 <.0001 
       
Saw PCP in past 12-months 
(PCP_LASTYEAR_N) (missing=693) 
1,082 (47.4) 1,203 (52.7) 0.03 .8731 
       
Have Health Insurance (Any Type) 
(INSURANCE_N) (missing=175) 
1,452 49.4 1,488 50.6 0.2 .6313 
       
Medicaid (missing=175) 22 (11.1) 177 (88.9)  <.0001 
       
SITUATION – PREVENTIVE CARE       
Had HIV test in past year 
(HIVTEST_YEAR_N) (missing=223) 
625 (53.6) 541 (46.4) 12.6 .0004 
       
Had anal/rectal cancer screening 233 (26.9) 1,246 (58.6) 248.5 <.0001 
       
Received vaccines other than HPV ever 
(VAX_EVER_N)  
1,503 (50.5) 1,472 (49.5) 33.2 <.0001 










Item n (%) n (%) Χ2 p-value 
       
Number of vaccines received since 18-years 
old (missing=483) (VAX_NUM_N) 
      
0 vaccines (ref) 40 (57.1) 30 (42.9) 4.1 .1293 
1-2 vaccines 145 (54.7) 120 (45.3)   
3 or more vaccines 1,206 (49.4) 1.234 (50.6)   
       
DEMOGRAPHICS       
Age ≤ 27 (AGE_YOUNG) (missing=175) 889 (83.8) 171 (16.1) 760.5 <.0001 
       
Race (RACE_N) (missing=175)       
American Indian/Alaska Native 2 (20.0) 8 (.80) 13.2 .0678 
Asian 45 (63.4) 26 (36.6)   
Black, African American, or African 36 (58.1) 26 (41.9)   
Hispanic, Latino or Spanish 40 (51.3) 38 (48.7)   
Middle Eastern, or North African 7 (70.0) 3 (30.0)   
Native Hawaiian or other Pacific Islander 2 (66.7) 1 (33.3)   
White (ref) 1,376 (49.0) 1,432 (51.0)   
Other 20 (50.0) 20 (50.0)   
       
Education Attainment (ED_LEVEL_N) 
(missing=175) 
      
High school or less 72 (59.0) 50 41.0) 4.5 .0331 
Greater than High school 1,456 (49.2) 1,505 (50.8)   
       
       
*Fishers statistic for cell size <30, Entry criteria for preliminary main effects model p < .25
        
134 
 
Table 5. 8 Multivariable Logistic Regression 
HPV Vaccine EVER  






Independent Variables p-value p-value aOR (95% CI) 
GENDER IDENTITY    
TGNB ALL ref: CISGENDER ALL <.0001 .0607+ aOR=1.5 (1.1-2.2) 
ONLINE HEALTH INFORMATION SEEKING    
Looked for health info past year .0004 .1958  
Look for vaccine info past year .0405 .0193 aOR=0.7 (0.5-0.9) 
KNOWLEDGE/BELIEFS    
Heard of HPV <.0001 .0091 aOR=2.1 (1.1-4.1) 
INTERNET USE    
Visited social networking site e.g. Facebook <.0001 .0456 aOR=2.4 (1.1-5.6) 
Shared health info online .2965   
Wrote in Blog .0326 .9159  
Participated in online support group .4672   
Watched health video online e.g. YouTube .0057 .2306  
Purchased meds online <.0001 .7303  
Emailed doctor’s office .0271 .2555  
Tracked healthcare charges/costs .0001 .0058 aOR=0.6 (0.5-0.9) 
Looked up test results .0177 .5708  
Made appointments with health care providers online  <.0001 .0046 aOR=0.5 (0.4-0.9) 
Looked up info on side-effects of meds/vaccines  .9751  
SITUATION – BARRIERS TO CARE    
Delayed medical care/tests/treatments in past year <.0001 .0355 aOR=1.5 (1.1-2.0) 
Anticipated disrespect/mistreatment, avoided provider <.0001 .2207  
Less than 50% providers aware of Sexual Orientation <.0001 .0304+ aOR=0.7 (0.5-1.0)  
Less than 50% of providers aware of Gender Identity .0428 .0555+ aOR=1.5 (1.0-2.1) 
SITUATION – ACCESS TO CARE    
Have a Primary Care Provider (PCP) <.0001 .1289  
Saw PCP last year .8731   
Health Insurance (any) .6313   
Medicaid <.0001 .0035 aOR=0.3 (0.1-0.7) 
SITUATION – PREVENTIVE CARE    
HIV test past year .0004 <.0001 aOR=2.0 (1.5-2.8) 
Received vaccines other than HPV (ever) <.0001 --  
Number of vaccines received since 18-years old .1293   
0 (ref)  ref  
1-2  .1491 aOR=1.8 (0.7-4.4) 
3+  .0015 aOR=3.5 (1.5-8.2) 
Had anorectal cancer screening <.0001 .0006 aOR=0.6 (0.4-0.8) 
DEMOGRAPHICS    
Age ≤ 27 <.0001 <.0001 aOR=0.08 (0.05-0.11) 
Race/Ethnicity ref: White .0678 .0098 aOR=1.0 (0.9-1.1) 
Education High school or less .0331 .7283 aOR=1.0 (0.5-2.0) 
χ2  274.1 df=32,  
p < .0001 
276.6, df=17, 
p < .0001 
Nagelkerke R2  34.3% 32.8% 
Hosmer and Lemeshow test  p = .7162 p = .2835 
AIC score  1,528.2 1,546.8 
+Independent variable of interest retained, --Removed due to collinearity,   
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Table 5. 9 Multivariable Logistic Regression 
HPV Vaccine Initiated (1-dose) 






Independent Variables p-value p-value aOR (95% CI) 
GENDER IDENTITY    
TGNB ALL ref: CISGENDER ALL .4201 .9923+ aOR=1.3 (0.9-2.0) 
ONLINE HEALTH INFORMATION SEEKING    
Looked for health info past year .4022 .0152  
Look for vaccine info past year <.0001 <.0001 aOR=2.7 (1.8-4.1) 
KNOWLEDGE/BELIEFS    
Heard of HPV .4950   
INTERNET USE    
Visited social networking site e.g. Facebook .0493 .1783  
Shared health info online .0083 .2982  
Wrote in Blog .7886   
Participated in online support group  .5504   
Watched health video online e.g. YouTube .1631 .0895  
Purchased meds online .2430 .6677  
Emailed doctor’s office .0024 .9532  
Tracked healthcare charges/costs .5267   
Looked up test results .0206 .0951  
Made appointments with health care providers online  .9707   
Looked up info on side-effects of meds/vaccines .4751   
SITUATION – BARRIERS TO CARE    
Delayed medical care/tests/treatments in past year .8068   
Anticipated disrespect/mistreatment, avoided provider .0257 .3255  
Less than 50% providers aware of Sexual Orientation .0016 .0359 * 
Less than 50% of providers aware of Gender Identity .1465 .7946  
SITUATION – ACCESS TO CARE    
Have a Primary Care Provider (PCP) .1634 .0296 * 
Saw PCP last year .5250   
Health Insurance (any) .0271 .8312  
Medicaid .8375   
SITUATION – PREVENTIVE CARE    
HIV test past year .3240   
Received vaccines other than HPV (ever) .0005 --removed  
Number of vaccines received since 18-years old .0112 .0065  
0 (ref)   ref 
1-2   aOR=0.9 (0.3-2.6) 
3+   aOR=0.3 (0.1-0.9) 
Had anorectal cancer screening .7807   
DEMOGRAPHICS    
Age ≤ 27 .0548 .0064 aOR=1.8 (1.2-2.8) 
Race/Ethnicity ref: White .9821 .1945  
Education High school or less .7538 .5640  
χ2  50.6, df=17,  
p <.0001 
37.4, df=5,  
p < .0001 
Nagelkerke R2  8.6% 2.7% 
Hosmer and Lemeshow test  p = .3853 p = .7774 
AIC score  351.2 718.2 
+Independent variable of interest retained, --Removed due to collinearity, *Removed from reduced model alpha .05  
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Table 5. 10 Multivariable Logistic Regression 
HPV Vaccine Completed (3-doses) 






Independent Variables p-value p-value aOR (95% CI) 
GENDER IDENTITY    
TGNB ALL ref: CISGENDER ALL .0018 .7156+ aOR=0.7 (0.5-0.9) 
ONLINE HEALTH INFORMATION SEEKING    
Looked for health info past year .0124 .1706+ aOR=3.8 (1.4-10.5) 
Look for vaccine info past year .2963 .3336+ aOR=0.7 (0.6-1.0) 
KNOWLEDGE/BELIEFS    
Heard of HPV .9630   
INTERNET USE    
Visited social networking site e.g. Facebook .0101 .1463  
Shared health info online .1086 .8811  
Wrote in Blog .0007 .0734  
Participated in online support group .7973   
Watched health video online e.g. YouTube .6451   
Purchased meds online .0008 .4955  
Emailed doctor’s office <.0001 .4795  
Tracked healthcare charges/costs <.0001 .8529  
Looked up test results <.0001 .0625  
Made appointments with health care providers online .0012 .7622  
Looked up info on side-effects of meds/vaccines .0209 .2145  
SITUATION – BARRIERS TO CARE    
Delayed medical care/tests/treatments in past year .5925   
Anticipated disrespect/mistreatment, avoided provider .0645 .9743  
Less than 50% providers aware of Sexual Orientation <.0001 .1294  
Less than 50% of providers aware of Gender Identity .0568 .5430  
SITUATION – ACCESS TO CARE    
Have a Primary Care Provider (PCP) .0544 --  
Saw PCP last year .0114 .0133 aOR=0.5 (0.3-0.8) 
Health Insurance (any) .0327 .3205  
Medicaid .5102   
SITUATION – PREVENTIVE CARE    
HIV test past year .4189   
Received vaccines other than HPV (ever) .0035 --  
Number of vaccines received since 18-years old  .0049  
0 (ref)    
1-2  .0533 aOR= 4.8 (1.9-12.2) 
3+  .0061 aOR= 6.7 (2.8-16.1) 
Had anorectal cancer screening .1228 .4114  
DEMOGRAPHICS    
Age ≤ 27 .1225 .2204 aOR=0.9 (0.7-1.1) 
Race/Ethnicity ref: White .1115 .5229 aOR=1.1 (1.0-1.2) 
Education High school or less <.0001 .0217 aOR=1.8 (1.0-3.4) 
χ2  561.7, df=5,  
p < .0001 
48.8, df=9,  
p < .0001 
Nagelkerke R2  11.3% 4.8% 
Hosmer and Lemeshow test  p = .4067 p = .6760 
AIC score  1,300.5 1,378.9 
+Independent variable of interest retained, --Removed due to collinearity 
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Chapter 6: Conclusions 
The goal of this dissertation is to compare human papilloma virus (HPV) vaccination 
rates among transgender and gender nonbinary (TGNB) people and cisgender sexual minority 
people; and explore how online health information seeking, electronic health (eHealth) literacy, 
general health literacy and other factors may be associated with receipt of HPV vaccine among 
these communities. The dissertation is comprised of three studies; the first, an integrative review 
of the literature that explores barriers to and facilitators for HPV vaccination among TGNB 
people; the second, a cross-sectional secondary analysis of responses to the PRIDE Study 2018-
19 Annual Questionnaire; and the third, a cross-sectional analysis of responses from a novel 
online survey that recruited active participants from the PRIDE Study cohort. This chapter 
summarizes the studies included in the dissertation, reviews key findings, and discusses 
implications of the findings for clinical practice, health policy and future avenues of research. 
Summary of Results and Key Findings 
The first dissertation study involved an integrative review of the literature to explore 
barriers to and facilitators for HPV vaccination among TGNB people. The review found that 
TGNB people are under-represented in HPV vaccination research and the studies retained in the 
review included both sexual minority people and gender minority people and rarely distinguished 
TGNB people in the reporting of results. The review identified key barriers to vaccination at the 
individual-level; lack of HPV knowledge and misconceptions that vaccine is only for individuals 
who were assigned female sex assigned at birth, or that the vaccine may not necessary depending 
on gender affirmation surgery status. Provider recommendation is a key facilitator for 
vaccination but lack of cultural competence in caring for gender minority people is a barrier to 
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vaccination. At the systems-level cost of vaccine and lack of insurance are barriers to 
vaccination, and limited national recommendations for gender minority people, and omission of 
gender minority people in national vaccine surveillance are potential barriers to vaccination. 
The second study consisted of cross-sectional secondary analysis of participant responses 
from The PRIDE Study Annual Questionnaire 2018-19, a large-scale long-term U.S.-based 
national health study of adult SGM people. A total of (N = 5,500) responses were analyzed to 
compare rates of HPV vaccination among TGNB participants and cisgender sexual minority 
participants. The Integrative Model of eHealth Use (IMeHU) guided this study and focused on 
factors that may be associated with HPV vaccination like HPV knowledge, situation factors (e.g., 
barriers to care, access to care, preventive care), Internet use, and demographics. TGNB 
participants in The PRIDE Study cohort reported increased prevalence of ever receiving HPV 
vaccine compared to cisgender sexual minority people but no differences in vaccine initiation 
(e.g., 1-dose) and vaccine completion (e.g., 3-doses). Transgender men who were assigned 
female at birth were more likely to receive the vaccine than transgender women who were 
assigned male sex at birth and this was also reflected among cisgender sexual minority females 
who were more likely to receive the vaccine than cisgender sexual minority males. These 
findings suggest that independent of gender identity, HPV vaccine disparities based on assigned 
sex at birth continue to exist among SGM communities. Additionally, TGNB participants who 
were born with female organs were more likely to receive the vaccine than cisgender sexual 
minority females, suggesting that TGNB people who are born with female organs may engage 
differently in preventative services like HPV vaccination than sexual minority women. 
The third study was a cross-sectional analysis of a novel online survey of participants 
recruited from The PRIDE Study cohort. The objective of this study was to explore the 
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association of online health information seeking and the possible moderating effect of health 
literacy on receipt of HPV vaccine among TGNB people compared to cisgender sexual minority 
people. We used the IMeHU to guide this study and developed the novel survey using items 
drawn from validated instruments (e.g., Health Information National Trends Survey 5 Cycle 3, 
Electronic Health Literacy Scale) and The PRIDE Study Annual Questionnaire. We sent an 
invitation to participate in the online survey to 17,547 current PRIDE Study participants and had 
a response rate of 19.2%. Of the total sample (N=3,258), 46.9% (n=1,528) reported having ever 
received the HPV vaccine (any doses) with a greater proportion (55.8%) of TGNB participants 
reporting receipt compared to cisgender participants (41.9%) (p < .0001). Of the participants who 
reported ever receiving HPV vaccine, a greater proportion (8.6%) of TGNB people reported 
vaccine initiation compared to (7.5%) cisgender participants (p = .0009). However, a lower 
proportion (61.3%) of TGNB participants reported vaccine completion compared to cisgender 
participants (69.1%) (p = .0009). TGNB participants had higher prevalence of receipt of HPV 
vaccine ever compared with cisgender participants. TGNB participants who were born with 
female organs, assigned female sex at birth, or female sex organs now had higher prevalence of 
ever receiving vaccine and vaccine completion but not vaccine initiation compared to cisgender 
participants. In multivariable logistic regression, we found that online health information 
seeking, especially when participants searched online for information about vaccines in the past 
year, was associated with an decrease in ever receiving HPV vaccine and but an increase in 
vaccine initiation among TGNB participants whereas seeking general health information was 
only associated with an increased vaccine completion among TGNB participants compared to 
cisgender participants. Factors most associated with HPV receipt were having received three-or-
more vaccines other than HPV since 18-years age, receipt of HIV testing in the past year, having 
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heard of HPV, and having visited social networking sites like Facebook. We found no 
moderating effects from eHealth literacy or general literacy on the relationship between online 
health information seeking and receipt of vaccine ever, vaccine initiation/completion. Our 
findings suggest disparities in HPV vaccine receipt among SGM that mirror the general 
population with a bias towards people born with female sex organs. The findings also suggest 
that online health information seeking and social media use may be associated with health 
behaviors like HPV vaccination, and engagement in other preventative health behaviors like 
receiving multiple vaccines and getting tested for HIV may also be facilitators for HPV 
vaccination. 
Major Contributions 
These dissertation studies offer considerable contributions to what is known about HPV 
vaccination among TGNB people. The IMeHU is a theoretical model that has never been 
adapted to examine a specific health behavior outcome (e.g., HPV vaccination) among TGNB 
communities. Moreover, the inclusion of eHealth literacy and general health literacy as 
moderators is an innovative adaptation of the theoretical model has also never been 
operationalized to explore health promoting behavior among TGNB communities. 
The construction of meaningful TGNB and cisgender sexual minority comparison groups 
is a methodological contribution to SGM research. Standardized health terminology in gender 
and sexual orientation is an evolving field in health informatics (Kronk & Dexheimer, 2020). 
The cross-sectional studies in this dissertation provide specific heuristics including the 
underlying Boolean logic to distinguish TGNB sub-groups (e.g., transmen vs. transwomen, 
transgender nonbinary vs transgender binary individuals) and cisgender sexual minority sub-
groups (e.g., sexual minority females vs. sexual minority males). These heuristics offer 
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exemplars for other researchers that may work with datasets that collect extensive sexual 
orientation and gender identity information; or who wish to design new instruments with inter- 
and intra-group comparisons in mind. Intra-group comparisons, especially among TGNB 
communities are lacking in the literature. 
Finally, these dissertation studies fill gaps in knowledge about HPV vaccination, online 
health information seeking, and health literacy among TGNB people. Prior research has 
described lower rates of HPV vaccination in cisgender sexual minority people compared to the 
general population but few studies that included any TGNB people (Bednarczyk et al., 2017; 
Reiter et al., 2015). The HINTS instrument includes demographic questions about sexual 
orientation but completely omits any questions about gender identity (National Cancer Institute, 
2018). Moreover, eHealth literacy has been assessed in sexual minority groups but never in 
TGNB communities (Horvath & Bauermeister, 2017). These dissertation studies address these 
gaps in knowledge about TGNB. They leverage a large-scale, national cohort study to describe 
HPV vaccination in a large sample of TGNB people. The studies adopt items from HINTS 5 
Cycle 3 to assess health information seeking in TGNB people for the first time. Likewise, the 
studies leverage a validated instrument eHEALS to assess eHealth literacy in TGNB people. The 
results of these studies offer new knowledge about factors associated with HPV vaccination in 
TGNB people and how these may be different from cisgender sexual minority people. 
Implications for Clinical Practice 
Educating health care providers and nurses about the need for HPV vaccination in TGNB 
people is a first step to promoting vaccination in these communities. Because a lack of 
knowledge about HPV and misperceptions about the need for HPV vaccination may exist in 
TGNB communities, it is critical that health care providers to be well-informed of the need for 
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HPV vaccination for all genders and gender expressions. Studies have shown that health care 
providers may be misinformed about the need for vaccination in both women and men 
(Blackwell, 2016). Our finding that TGNB people are more likely to only initiate HPV vaccine 
but less like to complete HPV vaccine compared to cisgender sexual minority people highlights 
the need for healthcare providers to educate TGNB patients regarding vaccine dosing schedules, 
and provider reminders to ensure vaccine completion. To address the issue of incomplete 
vaccination, the efficacy of a single-dose HPV regimen has been studied and preliminary 
findings in a study of cisgender women showed no differences in predicted probability of HPV 
infection in individuals who received one, two, three doses of HPV vaccine (Sonawane et al., 
2019). Yet, the current national recommendation remains for adults to complete three ‘catch-up’ 
doses if they have not received any doses by age 15-year (Meites, 2019). Additionally, studies 
have shown that HPV vaccination decreases HPV infection even when vaccination is not 
initiated in adolescence (Kang et al., 2018). 
To reduce barriers care and delay in receiving care due to perceived stigma and 
discrimination in TGNB people, health care providers should be trained in culturally competent 
care of TGNB people. Unfortunately, studies have shown that undergraduate medical training 
spends little time on SGM health topics (Obedin-Maliver et al., 2011). There is limited literature 
that examines nurse and nurse practitioner training in culturally competent SGM care despite 
studies that have shown that negative attitudes exist when nurses care for LGBT patients 
(Dorsen, 2012; Dorsen & Van Devanter, 2016). Culturally competent care of TGNB should at a 
minimum train clinicians about how to sensitively discuss gender identity with their patients 
(Maragh-Bass et al., 2017). Providing a health care environment that affirms gender diversity has 
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been associated with increased rates of vaccination in TGNB communities (Apaydin, Fontenot, 
Shtasel, et al., 2018). 
Our finding that greater proportions of TGNB than cisgender sexual minority participants 
reported delaying health care or putting off care because of concern that they would be 
disrespected or mistreated further highlights the need for culturally competent TGNB care. 
Studies have shown that a lack of SGM competence among providers is a barrier to vaccination 
in SGM communities (Blackwell, 2016; Wheldon, Sutton, et al., 2018). For example, studies of 
rural-residing sexual minority women found that health care providers routine did not ask about 
sexual orientation and patients avoided or delayed preventive care due to fear of discrimination 
based on their sexual orientation (Barefoot et al., 2017).  
We did not find an association between the proportion of health care providers aware of a 
participant’s sexual orientation or gender identity and the HPV vaccination outcomes. Yet, 
research has shown that that SGM people who are less ‘out’ to their medical providers and others 
in general are also less likely to engage in primary care services including preventive vaccination 
(Whitehead et al., 2016). Health care providers should be reminded that asking about a patient’s 
sexual orientation and gender identity is an important practice in the care of both TGNB and 
sexual minority people. Lastly, our findings that receipt of other vaccines and/or HIV testing 
increases receipt of HPV vaccine in TGNB people is consistent with the literature that has shown that 
‘bundled’ preventative services may promote vaccine uptake in sexual minority communities, and 
this should be explored further for TGNB people (Apaydin, Fontenot, Borba, et al., 2018; Fontenot et 
al., 2016). 
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Implications for Health Policy 
Transgender people were explicitly added to the recommendation for HPV vaccination in 
December 2016, but there has been little done to describe vaccine uptake in TGNB people since 
the policy was updated (Meites, 2016). Although there have been calls for the collection of 
gender identity information in the electronic health record and survey instruments by the Office 
of the National Coordinator and the NIH SGM Research Office, TGNB people are still missing 
from national surveys (Cahill & Makadon, 2014; National Institutes of Health, 2019). The 
Behavioral Risk Factor Surveillance System (BRFSS) has collected sexual orientation and 
gender identity information (SOGI) and includes items that assess receipt of HPV vaccine, 
however both the SOGI module and adult HPV vaccination module are considered optional, and 
to-date 30 states have implemented the SOGI module and only nine states have implemented the 
adult HPV vaccination module (Baker, 2018; Centers for Disease Control and Prevention, 2018). 
Given the dearth of research that describes HPV vaccination in TGNB people, this 
dissertation research highlights the need for data collection at the national level to inform health 
policy. It is unknown whether disparities exist in HPV vaccination rates in adult TGNB using 
national probability sampling because these data are not yet being collected for TGNB 
communities. Furthermore, given the recent ACIP update that expanded the recommended age 
range from 9 through 26 years to 9 through 45 years for both women and men, the collection of 
adult HPV vaccination information is now critical for vaccine surveillance across all 
communities.  
Finally, our finding of a bias for receipt of HPV vaccine for people who were assigned 
female sex assigned at birth and confusion among TGNB people regarding the need for HPV 
vaccine highlights the need for an update to the ACIP recommendation to do more than just 
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recommend HPV vaccination for transgender people and instead, include HPV information that 
is targeted for TGNB communities that specifically addresses misconceptions that may exist 
regarding assigned sex at birth and gender affirmation surgery. 
During the writing of this dissertation, the SARS-CoV-2 (COVID-19) pandemic is 
unfolding globally. The rapidly evolving spread of COVID-19 has spurred the rapid 
development of vaccines to prevent further spread of the disease. It is unclear how the roll-out of 
new vaccines for COVID-19 will affect existing vaccines like HPV vaccine once they are made 
available. However, CDC surveillance suggests that the COVID-19 pandemic has already 
decreased pediatric vaccination, including adolescent dosing of HPV vaccine (Santoli et al., 
2020). This may have population implications, thereby increasing the number of adults who have 
not received any doses of HPV vaccine and further compounding the lag in gender-based 
vaccination that originated when HPV vaccine was introduced in 2006 and was only 
recommended for girls (Daley et al., 2017). Moreover, there exists the phenomenon of vaccine 
hesitancy whereby fear of vaccine-preventable diseases is shifted from the infectious pathogens 
to the vaccines that would prevent infection (Siddiqui et al., 2013). It is unclear how new 
vaccines for COVID-19 may affect vaccine hesitancy for existing vaccines like HPV, and how 
TGNB and other SGM communities may perceive COVID-19 vaccine in relationship HPV 
vaccine. The data that would inform health policies for vaccine-preventable diseases is 
dynamically evolving. What is certain is that COVID-19 will have long-term implications for 
vaccine uptake, including HPV vaccination among adolescents and adults. 
Implications for Future Research 
Several implications for future research arise from these dissertation studies. An 
association may exist between health information seeking and the health-promoting behavior; 
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HPV vaccine receipt. However, neither eHealth literacy nor general health literacy were found to 
moderate this relationship. The adapted Integrative Model of eHealth Use (IMeHU) theoretical 
framework that informed this dissertation deserves further investigation, especially the constructs 
relating to health information seeking and Internet use (Bodie & Dutta, 2008). The finding in 
Study Number Three that use of social networking sites like Facebook increased the receipt of 
HPV vaccine in TGNB participants also warrants further study. It remains unclear how TGNB 
communities are using social media and how this may influence personal health decision-making 
and health behavior. It is possible that TGNB people who seek health information online may be 
exposed to health information through social media. Incident exposure to health information has 
been found to be associated with seeking health information for oneself and for someone else 
among cisgender sexual minority people (Jabson et al., 2017). Social media platforms like 
Instagram and Facebook may increase incident exposure to health information as users scroll-
through content feeds which might then prompt more directed health information seeking. 
Although these dissertation studies found a general association between social media use and 
HPV vaccine receipt, there was no association observed with sharing health information on 
social media and the vaccine outcome. A future direction of research would be to explore health 
information seeking further in TGNB people using qualitative methods such as in-depth 
interviews or focus groups to better understand how TGNB people use social media, seek health 
information online and what types of information are used for personal health decision-making, 
like whether or not to receive a vaccine. 
The results of these dissertation studies could inform interventions to improve HPV 
vaccine receipt among TGNB communities. At the individual patient-level, social media 
interventions that combine information seeking and culturally appropriate content for TGNB 
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people can deliver health information to encourage HPV vaccine uptake. A social media 
intervention that uses recognizable queer or TGNB people or even social media influencers from 
the community to deliver health promotion messages through video or chat may foster trust and 
reassurance among TGNB communities.  
Interventions in the clinical setting may also be important. For example, interventions 
that bundle HPV vaccine with other vaccines and/or HIV testing for TGNB people is another 
potential avenue for research. Because clinicians may have misconceptions about HPV 
vaccination and the appropriateness for TGNB people, interventions that target knowledge 
deficits in primary care providers who order HPV vaccine are a priority area of focus. 
Professional clinical organizations like the American Academy of Nurse Practitioners could be 
leveraged to send their members targeted electronic infographic campaigns that highlight the 
need for HPV vaccination among all TGNB and sexual minority people. Such campaigns could 
be combined with links to brief clinical briefs on working TGNB patients and updates on the 
latest 2019 ACIP HPV vaccine recommendations. Regardless of the intervention, future HPV 
vaccine research must consider recruiting TGNB people as the primary community of interest. 
This would provide a better understanding of the unique perspective of TGNB people and 
distinguish them from cisgender sexual minority people. Although these studies did not observe 
profound differences between HPV vaccination among transgender nonbinary participants and 
transgender binary participants, TGNB sub-groups should be distinguished from one another in 
future studies to better characterize whether intra-group disparities exist. 
Strengths and Limitations 
These dissertation studies have both strengths and limitations. To our knowledge, this is 
the first study of online health information seeking among TGNB people and the first evaluation 
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of eHealth literacy among these communities. The studies include large samples of TGNB 
people that are drawn from a unique national cohort of SGM people, The PRIDE Study. 
Moreover, the novel survey developed from the HINTS 5 Cycle 3 survey items, PRIDE Study 
Annual Questionnaire, and the eHEALS instrument, enabled the exploration of novel scientific 
questions among a TGNB sample. 
A limitation of the literature review was that it included only U.S.-based, English-
language studies and may have omitted studies that describe more dedicated samples of TGNB 
people. The PRIDE Study cohort is a convenience sample which limits the value of probability 
sampling when performing secondary analysis. The sample populations in both cross-sectional 
analyses were predominantly White and had attained greater than high school education and this 
lack of demographic diversity limits the generalizability of the findings. The cross-sectional 
design of the quantitative studies limits any causal conclusions. 
Conclusion 
These dissertation studies aimed to compare the rate of HPV vaccination among TGNB 
communities and explore the association of factors like online health information seeking and 
eHealth literacy with vaccine receipt. Although higher rates of ever receiving HPV vaccine were 
observed in TGNB people compared to cisgender sexual minority people, there is still room to 
improve vaccine receipt in both TGNB and cisgender communities as the rates for each are still 
far below the previous Healthy People 2020 goal of 80% vaccine uptake overall. When 
individuals who are at increased risk of HPV infection are left unvaccinated, there may be dire 
consequences for those who develop HPV-associated cancer. The incidence of HPV-associated 
throat cancer has now exceeded that of cervical cancer and the incidence of anal cancer has 
doubled over that past two decades (D'Souza et al., 2017; Machalek et al., 2012; Sonawane et al., 
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2017; Stier et al., 2016). Yet, TGNB people remain missing from studies of cancer prevalence. 
The National Cancer Institute surveillance programs neglect to collect information on gender 
identity, and in doing so, neglect to consider TGNB people in their population data. Studies that 
incorporate large representative samples of TGNB people are clearly a priority for future HPV 
research. Moreover, given that nearly all HPV-associated cancer can be prevented by 
vaccination, innovative solutions are needed to promote vaccine uptake among TGNB and 
cisgender sexual minority communities. The findings from these studies illuminate a potential 
path for future research into interventions that consider the association of online health 
information seeking, social media use, and the receipt of HPV vaccine. 
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Appendix A: Database Search Queries 
 
PubMed/MEDLINE 
bisexual[tiab] OR bisexuality[MeSH Terms] OR bisexuality[tiab] OR bisexuals[tiab] OR 
gay[tiab] OR gays[tiab] OR GLB[tiab] OR GLBT[tiab] OR homosexual[tiab] OR 
homosexualities[tiab] OR homosexuality[MeSH Terms] OR homosexuality[tiab] OR 
homosexuals[tiab] OR intersex[tiab] OR lesbian[tiab] OR lesbianism[tiab] OR 
lesbians[tiab] OR LGB[tiab] OR LGBT[tiab] OR "men who have sex with men"[tiab] OR 
msm[tiab] OR queer [tiab] OR "sexual minorities"[tiab] OR "sexual minority"[tiab] OR 
"sexual orientation"[tiab] OR transgender[tiab] OR transgendered[tiab] OR 
transgenders[tiab] OR transsexual[tiab] OR transsexualism[MeSH Terms] OR 
transsexualism[tiab] OR transsexuality[tiab] OR transsexuals[tiab] OR "women loving 
women"[tiab] OR "women who have sex with women"[tiab] OR WSW[tiab] NOT gay[au] 
OR "laparoscopic gastric bypass"[tiab] OR "markov state model" OR "multiple source 
method"[tiab] 
AND 
HPV[tiab] OR human papillomavirus[tiab] OR "papillomavirus vaccines"[MeSH] OR 
human papilloma virus* OR HPV*[tiab] OR papillomavirus*[tiab] OR immunis*[tiab] OR 
immuniz*[tiab] OR vaccin*[MeSH] OR vaccine*[tiab] OR vaccination*[tiab] 
AND 
accept*[tiab] OR attitud*[tiab] OR attitud*[tiab] OR aware*[tiab] OR barrier*[tiab] OR 
behavior*[tiab] OR behavior*[tiab] OR choice*[tiab] OR cognitive*[tiab] OR decision*[tiab] 
OR educat*[tiab] OR "eHealth literacy"[tiab] OR "electronic health literacy"[tiab] OR 
facilitat*[tiab] OR health information[tiab] OR "health literacy"[tiab] OR information*[tiab] 
OR intent*[tiab] OR knowledg*[tiab] OR knowledg*[tiab] OR literacy[tiab] OR literate[tiab] 
OR motivat*[tiab] OR participat*[tiab] OR percept*[tiab] OR predict*[tiab] OR primary 
prevention[tiab] OR refus*[tiab] OR seek*[tiab] OR social norm*[tiab] OR uncertain*[tiab] 
OR uptak*[tiab] OR value*[tiab] 
 
  





bisexual OR bisexuality OR bisexuality OR bisexuals OR gay OR gays OR GLB OR 
GLBT OR homosexual OR homosexualities OR homosexuality OR homosexuality OR 
homosexuals OR intersex OR lesbian OR lesbianism OR lesbians OR LGB OR LGBT 
OR "men who have sex with men" OR msm OR queer OR "sexual minorities" OR 
"sexual minority" OR "sexual orientation" OR transgender OR transgendered OR 
transgenders OR transsexual OR transsexualism OR transsexualism OR transsexuality 
OR transsexuals OR "women loving women" OR "women who have sex with women" 
OR WSW NOT gay OR "laparoscopic gastric bypass" OR "markov state model" OR 
"multiple source method" 
AND 
HPV OR human papillomavirus OR "papillomavirus vaccines" OR human papilloma 
virus* OR HPV* OR papillomavirus* OR immunis* OR immuniz* OR vaccin* OR 
vaccine* OR vaccination* 
AND 
accept* OR attitud* OR attitud* OR aware* OR barrier* OR behavior* OR behavior* OR 
choice* OR cognitive* OR decision* OR educat* OR "eHealth literacy" OR "electronic 
health literacy" OR facilitat* OR health information OR "health literacy" OR information* 
OR intent* OR knowledg* OR knowledg* OR literacy OR literate OR motivat* OR 
participat* OR percept* OR predict* OR primary prevention OR refus* OR seek* OR 
social norm* OR uncertain* OR uptak* OR value* 
  





bisexuality OR 'LGBT people' OR homosexuality OR intersex OR 'homosexual female' 
OR 'men who have sex with men' OR 'homosexual male' OR 'sexual and gender 
minority' OR 'sexual orientation' OR transgender OR transgenderism OR transsexualism 
OR transsexuality OR 'women who have sex with women' OR 'women who have sex 
with women and men' OR 'men who have sex with men and women' 
AND 
'Wart virus vaccine' OR immunization OR vaccination 
AND 
acceptance OR 'attitude to health' OR attitude OR awareness OR barriers OR behavior 
OR 'decision making' OR cognition OR education OR 'medical information' OR 'health 
literacy' OR behavior OR literacy OR motivation OR participation OR perception OR 
prediction OR 'primary prevention' OR prevention OR knowledge OR refuse OR 'social 
norm' OR uncertainty OR uptake OR value 
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Appendix B: eHealth Literacy Scale 
1. How useful do you feel the Internet is in helping you in making decisions about your health? 
  
1 2 3 4 5 
Not useful at all Not useful Unsure Useful Very Useful 
 
2. How important is it for you to be able to access health resources on the Internet? 
  
1 2 3 4 5 
Not important at 
all Not important Unsure Important Very important 
 
3. I know what health resources are available on the Internet 
1)  Strongly Disagree 
2)  Disagree    
3)  Undecided  
4)  Agree 
5)  Strongly Agree 
 
4. I know where to find helpful health resources on the Internet 
1)  Strongly Disagree 
2)  Disagree    
3)  Undecided  
4)  Agree 
5)  Strongly Agree 




5. I know how to find helpful health resources on the Internet 
1)  Strongly Disagree 
2)  Disagree    
3)  Undecided  
4)  Agree 
5)  Strongly Agree 
 
6. I know how to use the Internet to answer my questions about health 
1)  Strongly Disagree 
2)  Disagree    
3)  Undecided  
4)  Agree 
5)  Strongly Agree 
 
7. I know how to use the health information I find on the Internet to help me 
1)  Strongly Disagree 
2)  Disagree    
3)  Undecided  
4)  Agree 
5)  Strongly Agree 
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8. I have the skills I need to evaluate the health resources I find on the Internet 
1)  Strongly Disagree 
2)  Disagree    
3)  Undecided  
4)  Agree 
5)  Strongly Agree 
 
9. I can tell high quality health resources from low quality health resources on the Internet 
1)  Strongly Disagree 
2)  Disagree    
3)  Undecided  
4)  Agree 
5)  Strongly Agree 
 
10. I feel confident in using information from the Internet to make health decisions 
1)  Strongly Disagree 
2)  Disagree    
3)  Undecided  
4)  Agree 
5)  Strongly Agree 
Thank you! 
 
* Note: Questions #1 and #2 are recommended as supplementary items for use with the eHEALS to 
understand consumer’s interest in using eHealth in general. These items are not a formal part of the 
eHealth Literacy scale, which comprises questions #3-10. 
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Appendix C: General Health Literacy Items 
 
How confident are you filling out medical forms by yourself? 
Not at all 
A little bit 
Somewhat 
Quite a bit 
Extremely 
 













Note: Items not intended to be used as as a scale. 
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Appendix E: HPV and Health Information Seeking Survey 
 
Start of Block: WELCOME 
 
WELCOME_INTRO  
HPV and Health Information Seeking Survey      
 
 
PLEASE READ THIS  
 
 Welcome to the HPV and Health Information Seeking Survey of The PRIDE Study. This 
survey asks about human papillomavirus (also known as HPV) and how you seek health 




WELCOME_INTRO1 Depending on the browser you are using, you may need to scroll up to the 
top of each survey screen to see all the questions. 
  
 Some browsers will auto-scroll to the top of each survey screen, while others do not. We 
recommend using Chrome. We apologize for the inconvenience. 
  
 Please advance to the next screen to start this survey. 
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End of Block: WELCOME 
 
Start of Block: HOW TO SAVE & SURVEY INFO 
 
SAVE_INTRO HOW TO SAVE YOUR SURVEY TO FINISH LATER 
 
 While we recommend that you complete the survey in one sitting, you can start the survey and 
finish it later by selecting “Save and Exit” in the upper-right corner of the screen. You will return 















We anticipate this study will take 20-30 minutes to complete. You will not be paid for taking part 
in this study. We will, however, hold a raffle for multiple $50 gift cards as a thank you to 
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interested individuals. If you complete this survey you will automatically be entered into a raffle 
to be conducted no later than May 1, 2020 (after the survey is closed) for a $50 gift card. The 
drawing will be conducted by The PRIDE Study of Stanford University in Palo Alto, California. 
 
 
Participation in the study is not required in order to participate in the raffle. You can enter the 




The chance of winning a prize will vary depending on the number of people who express 
interest, and we estimate that it will never be worse than 1 in 1000. The winner will be notified 
immediately by email and provided with information on how to receive the prize. To participate 
in this study please click the right arrow to continue. 
 
End of Block: HOW TO SAVE & SURVEY INFO 
 
Start of Block: HEALTH BEHAVIOR OUTCOMES / HPV KNOWLEDGE 
 
HPVKNOW_INTRO  
The following questions are related to whether you received a vaccine (shots) to prevent human 
papillomavirus, also known as HPV. 
 
 






 Have you EVER heard of HPV? HPV stands for human papillomavirus. Some types of HPV 
increase your risk for cervical or anal cancer while others do not. 
o Yes  (1)  
o No  (0)  





HPV_SHOT Have you EVER received an HPV shot or vaccine? HPV stands for human 
papillomavirus. The vaccines are sometimes called CERVARIX® or GARDASIL®. The HPV 
vaccine is given as a three-dose series routinely to people from age 9-45. It was released in 2006. 
o Yes  (1)  
o No  (0)  
o Health care provider refused when asked  (2)  
o I don't know  (88)  
 
 
Display This Question: 
If HPV_SHOT = Yes 
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HPVQUANT How many HPV vaccine shots did you have? 
o None  (0)  
o One  (1)  
o Two  (2)  
o Three or more  (3)  
o I don't know  (88)  
 
End of Block: HEALTH BEHAVIOR OUTCOMES / HPV KNOWLEDGE 
 
Start of Block: HISB - LOOKING FOR HEALTH INFORMATION 
 
HISB_INTRO  
The following questions are related to how you look for health information to make personal 
health decisions. For example, information to help you decide whether or not to get a 






Have you EVER looked for information about health or medical topics from any source? 
o Yes  (1)  
o No  (2)  
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Display This Question: 
If SEEKHEALTHINFO = Yes 
  
 
HINTSA2 The most recent time you looked for information about health or medical topics, 
where did you go first? (Mark only one.) 
o Books  (1)  
o Brochures, pamphlets, etc.  (2)  
o Medical organization  (3)  
o Family  (4)  
o Friend/Co-worker  (5)  
o Doctor or health care provider  (6)  
o Internet  (7)  
o Library  (8)  
o Magazines  (9)  
o Newspapers  (10)  
o Telephone information number  (11)  
o Complimentary, alternative, or unconventional practitioner  (12)  
 
 
Display This Question: 
If SEEKHEALTHINFO = Yes 
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HINTSA3 The most recent time you looked for information about health or medical topics, who 
was it for? 
o Myself  (1)  
o Someone else  (2)  
o Both myself and someone else  (3)  
 
 
Page Break  
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Display This Question: 
If SEEKHEALTHINFO = Yes 
 
HINTS_A4 Based on the results of your most recent search for information about health or 
medical topics, how much do you agree or disagree with each of the following statements? 
 
 
Display This Question: 
If SEEKHEALTHINFO = Yes 
  
 
HINTS_A4a It took a lot of effort to get the information you needed. 
o Strongly agree  (1)  
o Somewhat agree  (2)  
o Somewhat disagree  (3)  
o Strongly disagree  (4)  
 
 
Display This Question: 
If SEEKHEALTHINFO = Yes 
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HINTS_A4b You felt frustrated during your search for the information. 
o Strongly agree  (1)  
o Somewhat agree  (2)  
o Somewhat disagree  (3)  
o Strongly disagree  (4)  
 
 
Page Break  
  





HINTS_A5 Overall, how confident are you that you could get advice or information about health 
or medical topics if you needed it? 
o Completely confident  (1)  
o Very confident  (2)  
o Somewhat confident  (3)  
o A little confident  (4)  
o Not confident at all  (5)  
 
 
Page Break  
  




HINTS_A6 In general, how much would you trust information about health or medical topics, 





HINTS_A6a A doctor or medical provider. 
o Not at all  (4)  
o A little  (3)  
o Some  (2)  





HINTS_A6b Family or friends. 
o Not at all  (4)  
o A little  (3)  
o Some  (2)  
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HINTS_A6c Government health agencies. 
o Not at all  (4)  
o A little  (3)  
o Some  (2)  





HINTS_A6d Charitable organizations. 
o Not at all  (4)  
o A little  (3)  
o Some  (2)  





HINTS_A6e Religious organizations and leaders. 
o Not at all  (4)  
o A little  (3)  
o Some  (2)  
o A lot  (1)  
 






HINTS_A6f The Internet. 
o Not at all  (4)  
o A little  (3)  
o Some  (2)  
o A lot  (1)  
 
 
Page Break  
  





HINTS_A7 Imagine you had a strong need to get information about health or medical topics, 
such as information on vaccines. Where would you go first? (Mark only one.) 
o Books  (1)  
o Brochures, pamphlets, etc.  (2)  
o Medical organization  (3)  
o Family  (4)  
o Friend/Co-worker  (5)  
o Doctor or health care provider  (6)  
o Internet  (7)  
o Library  (8)  
o Magazines  (9)  
o Newspapers  (10)  
o Telephone information number  (11)  
o Complimentary, alternative, or unconventional practitioner  (12)  
o Other (please specify)  (91) ________________________________________________ 
 
 
Page Break  
  





HINTS_A8 Have you ever looked for information about vaccines from any source? 
o Yes  (1)  
o No  (2)  
 
End of Block: HISB - LOOKING FOR HEALTH INFORMATION 
 
Start of Block: HISB - USING THE INTERNET TO FIND INFORMATION 
  
 
HINTS_B1 Do you EVER go online to access the Internet or World Wide Web, or to send and 
receive e-mail? 
o Yes  (1)  
o No  (2)  
 
 
Page Break  
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Display This Question: 
If HINTS_B1 = Yes 
 
HINTS_B2 When you use the Internet, do you access it through... 
 
 
Display This Question: 
If HINTS_B1 = Yes 
  
 
HINTS_B2a A regular dial-up telephone line. 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If HINTS_B1 = Yes 
  
 
HNTS_B2b Broadband such as DSL, cable, or FiOS. 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If HINTS_B1 = Yes 
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HINTS_B2c A cellular network (i.e., phone, 3G/4G). 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If HINTS_B1 = Yes 
  
 
HINTS_B2d A wireless network (Wi-Fi). 
o Yes  (1)  
o No  (2)  
 
 
Page Break  
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Display This Question: 
If HINTS_B1 = Yes 
  
 
HINTS_B3 In the PAST 12 MONTHS, have you used the Internet to look for information about 
vaccines for yourself? 
o Yes  (1)  
o No  (2)  
 
 
Page Break  
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Display This Question: 
If HINTS_B1 = Yes 
 
HINTS_B4 How often do you access the Internet through each of the following? 
 
 
Display This Question: 
If HINTS_B1 = Yes 
  
 
HINTS_B4a Computer at home. 
o Daily  (1)  
o Sometimes  (2)  
o Never  (3)  
o Not Applicable  (4)  
 
 
Display This Question: 
If HINTS_B1 = Yes 
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HINTS_B4b Computer at work. 
o Daily  (1)  
o Sometimes  (2)  
o Never  (3)  
o Not Applicable  (4)  
 
 
Display This Question: 
If HINTS_B1 = Yes 
  
 
HINTS_B4c Computer in a public place (library, community center, other). 
o Daily  (1)  
o Sometimes  (2)  
o Never  (3)  
o Not Applicable  (4)  
 
 
Display This Question: 
If HINTS_B1 = Yes 
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HINTS_B4d On a mobile device (cell phone/smartphone/tablet). 
o Daily  (1)  
o Sometimes  (2)  
o Never  (3)  
o Not Applicable  (4)  
 
 
Page Break  
  




HINTS_B5 In the PAST 12 MONTHS, have you used a computer, smartphone, or other 






Looked for health or medical information for yourself. 
o Yes  (1)  





HINTS_B5b Bought medicine or vitamins online. 
o Yes  (1)  
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HINTS_B5c Used e-mail or the Internet to communicate with a doctor or doctor's office. 
o Yes  (1)  





HINTS_B5d Tracked healthcare charges and costs. 
o Yes  (1)  





HINTS_B5e Looked up medical test results. 
o Yes  (1)  





HINTS_B5f Made appointments with a health care provider. 
o Yes  (1)  
o No  (2)  
 






HINTS_B5g Looked for information about the side-effects of medicines or vaccines. 
o Yes  (1)  
o No  (2)  
 
 
Page Break  
  





HINTS_B6 Please indicate if you have each of the following. (Check all that apply.) 
▢ Tablet computer (for example, an Apple iPad, Samsung Galaxy, Motorola Xoom, 
or Kindle Fire)  (2)  
▢ Smartphone (for example, an Apple iPhone, Android phone, Blackberry, or 
Windows phone)  (3)  
▢ Basic cell phone only  (4)  
▢ ⊗I do not have any of the above  (5)  
 
 
Page Break  
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Display This Question: 
If HINTS_B6 = Tablet computer (for example, an Apple iPad, Samsung Galaxy, Motorola Xoom, or Kindle Fire) 
Or HINTS_B6 = Smartphone (for example, an Apple iPhone, Android phone, Blackberry, or Windows phone) 
  
 
HINTS_B7 On your tablet or smartphone, do you have any applications (also known as 'apps') 
related to health and wellness? 
o Yes  (1)  
o No  (2)  
o Don't know  (3)  
 
 
Display This Question: 
If HINTS_B6 = Tablet computer (for example, an Apple iPad, Samsung Galaxy, Motorola Xoom, or Kindle Fire) 
Or HINTS_B6 = Smartphone (for example, an Apple iPhone, Android phone, Blackberry, or Windows phone) 
 
HINTS_B8 Has your tablet or smartphone... 
 
 
Display This Question: 
If HINTS_B6 = Tablet computer (for example, an Apple iPad, Samsung Galaxy, Motorola Xoom, or Kindle Fire) 
Or HINTS_B6 = Smartphone (for example, an Apple iPhone, Android phone, Blackberry, or Windows phone) 
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HINTS_B8a Helped you track progress on a health-related goal such as quitting smoking, losing 
weight, or increasing physical activity? 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If HINTS_B6 = Tablet computer (for example, an Apple iPad, Samsung Galaxy, Motorola Xoom, or Kindle Fire) 
Or HINTS_B6 = Smartphone (for example, an Apple iPhone, Android phone, Blackberry, or Windows phone) 
  
 
HINTS_B8b Helped you make a decision about how to treat an illness or condition? 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If HINTS_B6 = Tablet computer (for example, an Apple iPad, Samsung Galaxy, Motorola Xoom, or Kindle Fire) 
Or HINTS_B6 = Smartphone (for example, an Apple iPhone, Android phone, Blackberry, or Windows phone) 
  
 
HINTS_B8c Helped you in dicussions with your health care provider? 
o Yes  (1)  
o No  (2)  
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Page Break  
  





HINTS_B9 In the PAST 12 MONTHS, have you used an electronic wearable device to monitor 
or track your health or activity? For example, a FitBit, Apple iWatch, or Garmin Vivofit. 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If HINTS_B9 = Yes 
  
 
HINTS_B10 In the past month, how often did you use a wearable device to track your health? 
o Every day  (1)  
o Almost every day  (2)  
o 1-2 times per week  (3)  
o Less than once per week  (4)  
o I did not use a wearable device in the past month  (5)  
 
 
Display This Question: 
If HINTS_B9 = Yes 
 
HINTS_B11 Would you be willing to share health data from your wearable device with... 
 




Display This Question: 
If HINTS_B9 = Yes 
  
 
HINTS_B11a Your health care provider. 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If HINTS_B9 = Yes 
  
 
HINTS_B11b Your family and friends. 
o Yes  (1)  
o No  (2)  
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HINTS_B12 In the PAST 12 MONTHS, have you used an electronic monitoring device to 
monitor or track your health? For example, a glucometer or digital blood pressure device. 
o Yes  (1)  






Have you shared health information from either an electronic monitoring device or smartphone 
with a health professional within the PAST 12 MONTHS? 
 
 
o Yes  (1)  
o No  (2)  
 
 
Page Break  
  





Sometimes people use the Internet to connect with other people online through social networks 
like Facebook, Twitter, and Instagram. This is often called "social media".  
 
 






To visit a social networking site, such as Facebook or LinkedIn. 
o Yes  (1)  






To share health information on social networking sites, such as Facebook, Twitter, or Instagram. 
o Yes  (1)  
o No  (2)  
 







To write in an online diary or blog (i.e., Web log). 
o Yes  (1)  






To participate in an online forum or support group for people with a similar health or medical 
issue. 
o Yes  (1)  






To watch a health-related video on YouTube or other online video streaming service. 
o Yes  (1)  
o No  (2)  
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Q145 Have you sent or received a text message from a doctor or other health care professional 
within the PAST 12 MONTHS? 
o Yes  (1)  
o No  (2)  
o Don't know  (3)  
 
End of Block: HISB - USING THE INTERNET TO FIND INFORMATION 
 
Start of Block: HEALTH LITERACY - GENERAL (CHEW ITEMS) 
 
HEALTHLIT  
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CHEW1 How confident are you filling out medical forms by yourself? 
o Not at all  (5)  
o A little bit  (4)  
o Somewhat  (3)  
o Quite a bit  (2)  
o Extremely  (1)  





CHEW2 How often do you have problems learning about your medical condition because of 
difficulty understanding written information? 
o Never  (5)  
o Occasionally  (4)  
o Sometimes  (3)  
o Often  (2)  
o Always  (1)  
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CHEW3 How often do you need to have someone help you when you read, pamphlets, or other 
written material from your doctor or pharmacy? 
o Never  (1)  
o Occasionally  (2)  
o Sometimes  (3)  
o Often  (4)  
o Always  (5)  
o I don't know  (88)  
 
End of Block: HEALTH LITERACY - GENERAL (CHEW ITEMS) 
 
Start of Block: HEALTH LITERACY - eHEALS 
 
EHEALS  
The following questions related to how you feel about your ability to use health information that 
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EHEALS1 I know what health resources are available on the Internet. 
o Strongly Disagree  (1)  
o Disagree  (2)  
o Undecided  (3)  
o Agree  (4)  





EHEALS2 I know where to find helpful health resources on the Internet. 
o Strongly Disagree  (1)  
o Disagree  (2)  
o Undecided  (3)  
o Agree  (4)  
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EHEALS3 I know how to find helpful health resources on the Internet. 
o Strongly Disagree  (1)  
o Disagree  (2)  
o Undecided  (3)  
o Agree  (4)  





EHEALS4 I know how to use the Internet to answer my questions about health. 
o Strongly Disagree  (1)  
o Disagree  (2)  
o Undecided  (3)  
o Agree  (4)  
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EHEALS5 I know how to use the health information I find on the Internet to help me. 
o Strongly Disagree  (1)  
o Disagree  (2)  
o Undecided  (3)  
o Agree  (4)  





EHEALS6 I have the skills I need to evaluate the health resources I find on the Internet. 
o Strongly Disagree  (1)  
o Disagree  (2)  
o Undecided  (3)  
o Agree  (4)  
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EHEALS7 I can tell high quality health resources from low quality health resources on the 
Internet. 
o Strongly Disagree  (1)  
o Disagree  (2)  
o Undecided  (3)  
o Agree  (4)  





EHEALS8 I feel confident in using information from the Internet to make health decisions. 
o Strongly Disagree  (1)  
o Disagree  (2)  
o Undecided  (3)  
o Agree  (4)  
o Strongly Agree  (5)  
 
 
Page Break  
  





EHOPT1 How useful do you feel the Internet is in helping you in making decisions about your 
health? 
o Not useful at all  (1)  
o Not useful  (2)  
o Unsure  (3)  
o Useful  (4)  





EHOPT2 How important is it for you to be able to access health resources on the Internet? 
o Not important at all  (1)  
o Not important  (2)  
o Unsure  (3)  
o Important  (4)  
o Very important  (5)  
 
End of Block: HEALTH LITERACY - eHEALS 
 
Start of Block: SITUATION - BARRIERS TO CARE 
 











What percent of your doctors or other health care providers do you think are aware of your 
sexual orientation (meaning they are aware of whether you consider yourself bisexual, gay, 
straight, etc.)? 
o 0%  (0)  
o 10%  (1)  
o 20%  (2)  
o 30%  (3)  
o 40%  (4)  
o 50%  (5)  
o 60%  (6)  
o 70%  (7)  
o 80%  (8)  
o 90%  (9)  
o 100%  (19)  
 







What percent of your doctors or other health care providers do you think are aware that you are a 
gender minority person (for example: genderqueer, non-binary, questioning one's gender 
identity, transgender, etc.)? 
o 0%  (0)  
o 10%  (1)  
o 20%  (2)  
o 30%  (3)  
o 40%  (4)  
o 50%  (5)  
o 60%  (6)  
o 70%  (7)  
o 80%  (8)  
o 90%  (9)  
o 100%  (19)  
o Not applicable (I do not identify as a gender minority person)  (20)  
 
 
Page Break  
  





DELAYCARE In the PAST 12 MONTHS, were you delayed in getting medical care, tests, or 
treatments that you or a healthcare provider believed necessary? 
o Yes  (1)  






Was there a time in the PAST 12 MONTHS when you needed to see a health care provider but 
did not because you thought you would be disrespected or mistreated? 
o Yes  (1)  
o No  (0)  
 
 
Display This Question: 
If ANTMEDDISC = Yes 
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ANTMEDDISCY When you put off seeing a health care provider in the PAST 12 MONTHS 
because you thought you were going to be disrespected, were you concerned you would be 
disrespected or mistreated because of your ... (Check all that apply.) 
▢ Ability/disability status  (1)  
▢ Age  (2)  
▢ Body size, weight, or shape  (3)  
▢ Gender expression  (4)  
▢ Gender identity  (5)  
▢ Race and/or ethnicity  (6)  
▢ Sexual orientation  (7)  
▢ Something else (please specify)  (8) 
________________________________________________ 
▢ ⊗None of the above  (0)  
 
End of Block: SITUATION - BARRIERS TO CARE 
 
Start of Block: SITUATION - ACCESS TO CARE 
 
SITUATION_ACCESS  
The following questions help us to understand your access to health care. 
 
 





PCP A primary care provider is a health care provider who takes care of your overall general 
health and may coordinate your care with other medical specialists. Do you have a primary care 
provider (PCP)? 
o Yes  (1)  
o No  (0)  
o I don't know  (88)  
 
 
Display This Question: 
If PCP = Yes 
  
 
PCP_LASTYEAR Have you seen your primary care provider (PCP) in the PAST 12 
MONTHS? 
o Yes  (1)  
o No  (0)  
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TRANSDOC In the PAST 12 MONTHS have you gone to a doctor, health care provider or 
clinic for transgender-related health care, such as hormone treatment? 
o Yes  (1)  
o No  (0)  





GAHORMONE_EVER Have you EVER taken hormones or medication for the purposes of 
gender affirmation (also called gender transition)? 
o Yes  (1)  
o No  (0)  
 
 
Display This Question: 
If GAHORMONE_EVER = Yes 
  
 
GAHORMONE_AN Are you CURRENTLY taking hormones or medications for the purposes 
of gender affirmation (also called gender transition)? 
o Yes  (1)  
o No  (0)  
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Page Break  
  





INSURANCE Are you CURRENTLY covered by any health insurance or health coverage plan? 
o Yes  (1)  
o No  (0)  
o I don't know  (88)  
 
 
Display This Question: 
If INSURANCE = Yes 
  
 
        
228 
 
INSURANCE_TYPE Are you CURRENTLY covered by any of the following types of health 
insurance or health coverage plans? (If you have more than one insurance/coverage plans, please 
select your primary/coverage plan.) 
o Insurance through my current or former employer or union  (1)  
o Insurance through someone else's current of former employer or union  (2)  
o Insurance purchased through Healthcare.gov or another health insurance marketplace 
(sometimes called "Obamacare" or the Affordable Care Act")  (3)  
o Insurance purchased directly through an insurance company  (4)  
o Medicare (for people 65 and older or people with certain disabilities)  (5)  
o Medicaid (government-assistance plan for those with low incomes or a disability)  (6)  
o TRICARE or other military healthcare  (7)  
o Veteran's Affairs (VA)  (8)  
o Indian Health Service  (9)  
o Other (please specify)  (10) ________________________________________________ 
 
End of Block: SITUATION - ACCESS TO CARE 
 
Start of Block: SITUATION - PREVENTIVE CARE 
 
SITUATION_PREVENTIVE  
The following questions help us to understand what sorts of preventive care you may have 
received in the past. 
 
 





PROMIS1 In general, would you say your health is… 
o Excellent  (5)  
o Very good  (4)  
o Good  (3)  
o Fair  (2)  
o Poor  (1)  
 
 
Page Break  
  





HIVTEST_YEAR Have    you been tested for HIV in the PAST 12 MONTHS? 
o Yes  (1)  
o No  (0)  





HIVSTATUS What is your HIV status? 
o Positive  (1)  
o Negative  (0)  
o I don't know  (I don't know whether or not I have HIV.)  (88)  
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VAX_EVER Other than the human papillomavirus (HPV) vaccine, have you received any other 
vaccines? For example, a vaccine for the flu, pneumonia (pneumococcal), hepatitis A/B, or 
shingles? 
o Yes  (1)  
o No  (0)  
o I don't know  (88)  
 
 
Display This Question: 




 How many preventive vaccines have you received since you were 18 years old? 
o 0  (0)  
o 1-2  (1)  
o 3 or more  (2)  
o I don't know  (88)  
 
 
Page Break  
  






Have you EVER had a Pap smear or Pap test? (A Pap smear or Pap test is a routine test in which 
a health care provider places an instrument inside the vagina, examines the cervix, and takes a 
few cells from the cervix with a small stick or brush to look for abnormal or cancer cells.) 
o Yes  (1)  
o No  (0)  
o I don't have a cervix  (2)  
o I don't know  (88)  
 
 
Display This Question: 
If PAP_EVER_V = Yes 
  
 
HPV_EVER An HPV test is sometimes added to the Pap test for cervical cancer screening. Have 
you EVER had an HPV test with along with your cervical Pap test? 
o Yes  (1)  
o No  (0)  
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ANORECTCA_SCREEN) Have you EVER had any of the following tests as an evaluation for 
anal or rectal cancer? (Check all that apply) 
▢ Digital anal rectal exam (an examination where a doctor or health care provider 
inserts their finger into your anus (butt)  (1)  
▢ Anal HPV test (a routine test with a swab that tests for human papillomavirus, 
HPV)  (2)  
▢ Anal Pap smear (a routine test in which a healthcare provider takes a few cells 
from the anus (butt) using a swab for abnormal or cancer cells)  (3)  
▢ High-Resolution Anoscopy (HRA) (an exam with a microscope of the rectum and 
anus/butt)  (4)  
▢ ⊗None of these  (5)  
▢ ⊗I don't know  (88)  
 
End of Block: SITUATION - PREVENTIVE CARE 
 
Start of Block: DEMOGRAPHICS - SOGI 
 
DEMO_SOGI  
The following questions help us to have the most updated demographic information about you. 
You may have answered these questions in the The PRIDE Study Annual Questionnaire. We 
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ORIENTATION What is your current sexual orientation? (Check all that apply.) 
▢ Asexual  (1)  
▢ Bisexual  (2)  
▢ Gay  (3)  
▢ Lesbian  (4)  
▢ Pansexual  (5)  
▢ Queer  (6)  
▢ Questioning  (7)  
▢ Same-gender loving  (8)  
▢ Straight/Heterosexual  (9)  
▢ Two-spirit  (10)  
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GENDERID What is your current gender identity? (Check all that apply.) 
▢ Genderqueer  (1)  
▢ Man  (2)  
▢ Transgender man  (3)  
▢ Transgender woman  (4)  
▢ Woman  (5)  






LIVEGEN What gender do you live as your day-to-day life? 
o Man  (1)  
o Woman  (2)  
o Sometimes man, sometimes woman  (3)  
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SAAB What was your sex assigned at birth, for example on your original birth certificate? 
o Male  (1)  





INTERSEX_DEF Do    you identify as intersex? 
o Yes  (1)  
o No  (0)  
 
End of Block: DEMOGRAPHICS - SOGI 
 
Start of Block: DEMOGRAPHICS - ORGANS 
 
DEMO_ORGANS  
To understand your health, we need to know what organs you were born with. 
 
 
Note: People may have a wide range of language or terms for their physical anatomy. Some 
people are not comfortable with the term ‘vagina’ and may prefer the term ‘frontal genital 
opening.’ The PRIDE Study chooses to include both the terms ‘vagina’ and ‘frontal genital 
opening’ for all relevant questions to honor the preferences and comfort of our participants. 









ORGANS_BORN Which of the following organs were you born with? (Check all that apply.) 
▢ Cervix (you likely have/had this if you were assigned female sex at birth)  (1)  
▢ Ovaries  (2)  
▢ Penis/Phallus (not including a prosthetic)  (3)  
▢ Prostate (you likely have this if you were assigned male sex at birth)  (4)  
▢ Testicles  (5)  
▢ Uterus/Womb  (6)  
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ORGANS_NOW Which of the following organs do you have now? (Check all that apply.) 
▢ Breasts or breast tissue  (1)  
▢ Cervix (you likely have this if you have a uterus or womb)  (2)  
▢ Ovaries  (3)  
▢ Penis/Phallus (not including a prosthetic)  (4)  
▢ Prostate (you likely have this if you were assigned male sex at birth)  (5)  
▢ Testicles  (6)  
▢ Uterus/Womb  (7)  
▢ Vagina/Frontal genital opening  (8)  
 
End of Block: DEMOGRAPHICS - ORGANS 
 
Start of Block: DEMOGRAPHICS - RACE/MARITAL/AGE/WORK/INCOME/EDUC 
 
DEMO_FINAL  
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RACE_ETHN Which categories describe you? (Check all that apply.) 
▢ American Indian or Alaska Native (For example: Aztec, Blackfeet Tribe, Mayan, 
Navajo Nation, Native Village of Barrow Inupiat Traditional Government, Nome Eskimo 
Community, etc.)  (1)  
▢ Asian (For example: Asian Indian, Chinese, Filipino, Japanese, Korean, 
Vietnamese, etc.)  (2)  
▢ Black, African American or African (For example: African American, Ethiopian, 
Haitian, Jamaican, Nigerian, Somali, etc.)  (3)  
▢ Hispanic, Latino or Spanish (For example: Columbian, Cuban, Dominican, 
Mexican or Mexican American, Puerto Rican, Salvadoran, etc.)  (4)  
▢ Middle Eastern or North African (For example: Algerian, Egyptian, Iranian, 
Lebanese, Moroccan, Syrian, etc.)  (5)  
▢ Native Hawaiian or other Pacific Islander (For example: Chamorro, Fijian, 
Marshallese, Native Hawaiian, Tongan, etc.)  (6)  
▢ White (For example: English, European, French, German, Irish, Italian, Polish, 
etc.)  (7)  




Page Break  
  





RELATIONSHIP Are you CURRENTLY in a relationship? 
o Yes  (1)  





MARITALSTATUS What is your CURRENT legal marital status? 
o Married  (1)  
o Legally recognized civil union  (2)  
o Registered domestic partnership  (3)  
o Widowed  (4)  
o Divorced  (5)  
o Separated  (6)  





AGE Enter your age in years (using whole numbers). 
________________________________________________________________ 
 






WORK Do you CURRENTLY work one or more paid jobs? 
o Yes  (1)  





OCC Which of the following describes your current occupation? 
o Employed, working 40 or more hours per week  (1)  
o Employed, working 1-39 hours per week  (2)  
o Temporarily employed  (3)  
o Self-employed  (4)  
o Not employed, looking for work  (5)  
o Not employed, not looking for work  (6)  
o Homemaker  (7)  
o Student (Full time)  (8)  
o Student (Part time)  (9)  
o Disabled, not able to work  (10)  
o Retired  (11)  
 
 





INCOME What were your individual earnings (in US Dollars) before taxes and deductions from 
ALL sources (including jobs, businesses, welfare, child support, disability, social security, etc.) 
in the 2019 tax year? 
o $0  (1)  
o $1 - 10,000  (2)  
o $10,001 - 20,000  (3)  
o $20,001 - 30,000  (4)  
o $30,001 - 40,000  (5)  
o $40,001 - 50,000  (6)  
o $50,001 - 60,000  (7)  
o $60,001 - 70,000  (8)  
o $70,001 - 80,000  (9)  
o $80,001 - 90,000  (10)  
o $90,001 - 100,000  (11)  
o $100,001+  (12)  
 
 
Page Break  
  





ED_LEVEL What is your highest education level completed? 
o No schooling  (1)  
o Nursery school to high school, no diploma  (2)  
o High school graduate or equivalent  (3)  
o Trade/Technical/Vocational training  (4)  
o Some college  (5)  
o 2-year college degree  (6)  
o 4-year college degree  (7)  
o Master's degree  (8)  
o Doctoral degree  (9)  
o Professional degree (e.g., M.D., J.D., M.B.A.)  (10)  
 
 
Page Break  
  





YOU ARE ALMOST DONE WITH THIS SURVEY - PLEASE READ BELOW AND 
THEN CLICK NEXT 
 This is required in order for the system to mark your survey as "Complete."   
    
Thank you for completing the HPV and Health Information Seeking Survey.    
 
 We deeply appreciate for your time, your interest in The PRIDE Study, and your investment in 
research that will help our communities understand how the experience of being LGBTQ+ is 
related to all aspects of health and life. 
     
TO LOG YOUR SURVEY AS COMPLETE, PLEASE ADVANCE TO THE NEXT 
SCREEN 
 and then select "Back to Dashboard" 
 
End of Block: DEMOGRAPHICS - RACE/MARITAL/AGE/WORK/INCOME/EDUC 
 
 
 
